U.S. patent application number 15/801432 was filed with the patent office on 2018-10-25 for use of melanocortins to treat insulin sensitivity.
This patent application is currently assigned to Ipsen Pharma S.A.S.. The applicant listed for this patent is Ipsen Pharma S.A.S.. Invention is credited to Andrew A. BUTLER, Michael DeWitt CULLER, Heather A. HALEM.
Application Number | 20180303899 15/801432 |
Document ID | / |
Family ID | 40626385 |
Filed Date | 2018-10-25 |
United States Patent
Application |
20180303899 |
Kind Code |
A1 |
HALEM; Heather A. ; et
al. |
October 25, 2018 |
Use of Melanocortins to Treat Insulin Sensitivity
Abstract
The present invention relates to peptide ligands of the
melanocortin receptors, in particular the melancortin-4 receptor,
and as such, are useful in the treatment of disorders responsive to
the activation of this receptor, such as insulin resistance.
Inventors: |
HALEM; Heather A.;
(Westborough, MA) ; CULLER; Michael DeWitt;
(Hopkinton, MA) ; BUTLER; Andrew A.; (Kirkwood,
MO) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ipsen Pharma S.A.S. |
Boulogne-Billancourt |
|
FR |
|
|
Assignee: |
Ipsen Pharma S.A.S.
Boulogne-Billancourt
LA
Board of Supervisors of Louisiana State University and
Agricultural and Mechanical College
Baton Rouge
|
Family ID: |
40626385 |
Appl. No.: |
15/801432 |
Filed: |
November 2, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15242866 |
Aug 22, 2016 |
9827286 |
|
|
15801432 |
|
|
|
|
14844128 |
Sep 3, 2015 |
9439943 |
|
|
15242866 |
|
|
|
|
12740917 |
May 17, 2010 |
9155777 |
|
|
PCT/US2008/012490 |
Nov 5, 2008 |
|
|
|
14844128 |
|
|
|
|
61001933 |
Nov 5, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 43/00 20180101;
C07K 7/64 20130101; A61P 3/04 20180101; A61K 38/33 20130101; A61P
3/00 20180101; A61K 38/04 20130101; A61P 3/10 20180101; A61K 38/12
20130101; A61P 5/50 20180101 |
International
Class: |
A61K 38/12 20060101
A61K038/12; A61K 38/33 20060101 A61K038/33; C07K 7/64 20060101
C07K007/64; A61K 38/04 20060101 A61K038/04 |
Claims
1-35. (canceled)
36. A method of treating insulin resistance in a subject in need
thereof, comprising administration of an effective amount of
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2
(SEQ ID NO:26) or a pharmaceutically acceptable salt thereof.
37. The method of claim 36, wherein said subject is a child.
38. The method of claim 37, wherein the child is obese.
39. The method of claim 37, wherein the child is normal weight or
lean.
40. The method of claim 37, wherein the child suffers from Type II
diabetes.
41. The method of claim 36, wherein said subject is an adult.
42. The method of claim 36, wherein said subject is an elderly
adult.
43. The method of claim 36, wherein the
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2
(SEQ ID NO:26) or a pharmaceutically acceptable salt thereof is
formulated as a pharmaceutical composition.
44. The method of claim 43, wherein said pharmaceutical composition
is a sustained release composition.
45. The method of claim 36, wherein said administration is oral,
subcutaneous, intraperitoneal, intramuscular, intravenous, rectal,
transdermal or intranasal.
46. The method according to claim 36, wherein said administration
is continuous.
47. A method of treating insulin resistance in a subject in need
thereof, comprising administration of an effective amount of a
compound selected from the group consisting of:
c[Hydantoin(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH.sub.2 (SEQ ID NO:
274) c[Hydantoin(C(O)-(Asp-A.sup.3c))-D-Phe-Arg-Trp-Lys]-NH.sub.2;
(SEQ ID NO: 274)
c[Hydantoin(C(O)-(Asp-A.sup.5c))-D-Phe-Arg-Trp-Lys]-NH.sub.2; (SEQ
ID NO: 274)
c[Hydantoin(C(O)-(Asp-A.sup.6c))-D-Phe-Arg-Trp-Lys]-NH.sub.2; (SEQ
ID NO: 274) or a pharmaceutically acceptable salt thereof.
48. The method of claim 47, wherein said subject is a child.
49. The method of claim 47, wherein said subject is an adult.
50. The method of claim 48, wherein the child is obese.
51. The method of claim 48, wherein the child suffers from Type II
diabetes.
52. The method of claim 47, wherein the compound or a
pharmaceutically acceptable salt thereof is formulated as a
pharmaceutical composition.
53. The method of claim 52, wherein said pharmaceutical composition
is a sustained release composition.
54. The method of claim 47, wherein said administration is oral,
subcutaneous, intraperitoneal, intramuscular, intravenous, rectal,
transdermal or intranasal.
55. The method according to claim 47, wherein said administration
is continuous.
Description
[0001] This application is a continuation application of pending
U.S. Ser. No. 15/242,866, filed Aug. 22, 2016, which is a
continuation application of U.S. Ser. No. 14/844,128, filed Sep. 3,
2015, now U.S. Pat. No. 9,439,943, which is a continuation
application of U.S. Ser. No. 14/740,917, filed May 17, 2010, now
U.S. Pat. No. 9,155,777, which is a United States national filing
under 35 U.S.C. .sctn. 371 of international (PCT) application No.
PCT/US2008/012490, filed Nov. 5, 2008 and designating the US, which
claims priority to U.S. provisional application No. 61/001,933,
filed Nov. 5, 2007, each of which is hereby incorporated by
reference in its entirety.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web, and is hereby
incorporated by reference in its entirety. The ASCII copy is named
"183P_PCT2_US-A_SeqListing_01_05May_2015_ST25.txt", created on May
1, 2015, and has the file size of 234,000 bytes.
BACKGROUND OF THE INVENTION
[0003] Melanocortins are a family of regulatory peptides which are
formed by post-translational processing of pro-hormone
pro-opiomelanocortin (POMC; 131 amino acids in length). POMC is
processed into three classes of hormones; the melanocortins,
adrenocorticotropin hormone, and various endorphins (e.g.
lipotropin) (Cone et al., Recent Prog. Horm. Res., 51:287-317,
(1996); Cone et al., Ann. N.Y. Acad. Sci., 31:342-363, (1993)).
[0004] Five melanocortin receptors (MC-R) have been characterized
to date. These include melanocyte-specific receptor (MC1-R),
corticoadrenal-specific ACTH receptor (MC2-R), melacortin-3
(MC3-R), melanocortin-4 (MC4-R) and melanocortin-5 receptor
(MC5-R). All of the melanocortin receptors respond to the peptide
hormone class of melanocyte stimulating hormones (MSH) (Cone et
al., Ann. N.Y. Acad. Sci., 680:342-363 (1993); Cone et al., Recent
Prog. Horm. Res., 51:287-318 (1996)).
[0005] There has been great interest in melanocortin (MC-R)
receptors as targets for the design of novel therapeutics to treat
disorders of body weight such as obesity and cachexia. One of the
receptors, MC4-R, is a 332 amino acid transmembrane protein
expressed in brain as well as placental and gut tissues (Cone et
al., Ann. N.Y. Acad. Sci., 680:342-363 (1993); Cone et al., Recent
Prog. Horm. Res., 51:287-318 (1996)). Recent pharmacological
confirmation has established that central MC4-R receptors are the
prime mediators of the anorexic and orexigenic effects reported for
melanocortin agonists and antagonists, respectively (Giraudo et
al., Brain Res., 809:302-306 (1998); Farooqi et al., NE J Med.,
348:1085-1095 (2003); MacNeil et al., Eu. J. Pharm., 44:141-157
(2002); MacNeil et al., Eu. J. Pharm., 450:93-109 (2002); Kask et
al., NeuroReport, 10:707-711 (1999); Chen et al., Transgenic Res.,
9:145-54, (2000); Marsh et al., Nat Genet., 21:119-22, (1999);
Balthasar et al., Cell, 123:493-505 (2005)).
[0006] Complications of body weight disorders commonly include an
inability to produce and utilize insulin, often resulting in faulty
glucose regulation. The consequence of failure to properly control
glucose metabolism affects many aspects of overall health including
energy metabolism, neuropathy and heart disease. Current progress
with receptor-selective melanocortin receptor ligands evidences the
therapeutic potential of melanocortin receptor activation,
particularly MC4-R, in the treatment of glucose regulation,
including insulin metabolism.
SUMMARY OF THE INVENTION
[0007] The present invention is directed to the use of peptides
which are ligands of one or more of the melanocortin receptors
(MC-R), or the pharmaceutically-acceptable salts thereof, to treat
mammals suffering from insulin resistance. In one embodiment, the
ligands are agonists to the melanocortin 4 receptor. In a preferred
embodiment, the melanocortin receptor ligands are according to the
formulae described herein or are selected from particular peptides
described herein.
[0008] The insulin resistant subject mammals may be obese or
overweight and may lose weight as a result of the administration of
the peptides of the invention. The insulin resistant subject
mammals may also be normal weight or lean. The insulin resistant
condition of the subject mammals may be treated independent of
weight loss. In addition, the subject mammals may be human subjects
of any age, such as an infant, a child, an adult or an elderly
adult.
[0009] In the first embodiment, the invention provides a method to
treat insulin resistance in a mammalian subject, with or without
weight loss, by the administration of a therapeutically effective
amount of a melanocortin receptor 4 ligand according to Formula (I)
and pharmaceutically acceptable salts, hydrates, solvates or
prodrugs thereof (see International Patent Application Publication
Number WO 2007/008704, incorporated herein by reference in its
entirety):
(R.sup.2R.sup.3)-A.sup.1-c(A.sup.2-A.sup.3-A.sup.4-A.sup.5-A.sup.6-A.sup-
.7-A.sup.8-A.sup.9)-A.sup.10-R.sup.1 (I)
wherein:
[0010] A1 is Acc, HN--(CH.sub.2).sub.m--(C(O), L- or D-amino acid,
or deleted;
[0011] A.sup.2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or
Glu;
[0012] A.sup.3 is Gly, Ala, .beta.-Ala, Gaba, Aib, D-amino acid, or
deleted;
[0013] A.sup.4 is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi, or
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe;
[0014] A.sup.5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal,
D-(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, L-Phe or
D-(Et)Tyr;
[0015] A.sup.6 is Arg, hArg, Dab, Dap, Lys, Orn, or
HN--CH((CH.sub.2).sub.n--N(R.sup.4R.sup.5))--(C(O);
[0016] A.sup.7 is Trp, 1-Nal, 2-Nal, Bal, Bip, D-Trp, D-1-Nal,
D-2-Nal, D-Bal or D-Bip;
[0017] A.sup.8 is Gly, D-Ala, Acc, Ala, .beta.-Ala, Gaba, Apn, Ahx,
Aha, HN--(CH.sub.2).sub.s--(C(O), or deleted;
[0018] A.sup.9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap,
Orn, or Lys;
[0019] A.sup.10 is Acc, HN--(CH.sub.2).sub.t--(C(O), L- or D-amino
acid, or deleted;
[0020] R.sup.1 is OH or NH.sub.2;
[0021] each of R.sup.2 and R.sup.3 is, independently for each
occurrence, selected from the group consisting of H,
(C.sub.1-C.sub.30)alkyl, (C.sub.1-C.sub.30)heteroalkyl,
(C.sub.1-C.sub.30)acyl, (C.sub.2-C.sub.30)alkenyl,
(C.sub.2-C.sub.30)alkynyl, aryl(C.sub.1-C.sub.30)alkyl,
aryl(C.sub.1-C.sub.30)acyl, substituted (C.sub.1-C.sub.30)alkyl,
substituted (C.sub.1-C.sub.30)heteroalkyl, substituted
(C.sub.1-C.sub.30)acyl, substituted (C.sub.2-C.sub.30)alkenyl,
substituted (C.sub.2-C.sub.30)alkynyl, substituted
aryl(C.sub.1-C.sub.30)alkyl, and substituted
aryl(C.sub.1-C.sub.30)acyl;
[0022] each of R.sup.4 and R.sup.5 is, independently for each
occurrence, H, (C.sub.1-C.sub.40)alkyl,
(C.sub.1-C.sub.40)heteroalkyl, (C.sub.1-C.sub.40)acyl,
(C.sub.2-C.sub.40)alkenyl, (C.sub.2-C.sub.40)alkynyl,
aryl(C.sub.1-C.sub.40)alkyl, aryl(C.sub.1-C.sub.40)acyl,
substituted (C.sub.1-C.sub.40)alkyl, substituted
(C.sub.1-C.sub.40)heteroalkyl, substituted (C.sub.1-C.sub.40)acyl,
substituted (C.sub.2-C.sub.40)alkenyl, substituted
(C.sub.2-C.sub.40)alkynyl, substituted aryl(C.sub.1-C.sub.40)alkyl,
substituted aryl(C.sub.1-C.sub.40)acyl,
(C.sub.1-C.sub.40)alkylsulfonyl, or --C(NH)--NH.sub.2;
[0023] m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or
7;
[0024] n is, independently for each occurrence, 1, 2, 3, 4 or
5;
[0025] s is, independently for each occurrence, 1, 2, 3, 4, 5, 6,
or 7;
[0026] t is, independently for each occurrence, 1, 2, 3, 4, 5, 6,
or 7;
[0027] X.sup.1, X.sup.2, X.sup.3, X.sup.4, and X.sup.5 each is,
independently for each occurrence, H, F, Cl, Br, I,
(C.sub.1-10)alkyl, substituted (C.sub.1-10)alkyl,
(C.sub.2-10)alkenyl, substituted (C.sub.2-10)alkenyl,
(C.sub.2-10)alkynyl, substituted (C.sub.2-10)alkynyl, aryl,
substituted aryl, OH, NH.sub.2, NO.sub.2, or CN; provided that
[0028] (I). when R.sup.4 is (C.sub.1-C.sub.40)acyl,
aryl(C.sub.1-C.sub.40)acyl, substituted (C.sub.1-C.sub.40)acyl,
substituted aryl(C.sub.1-C.sub.40)acyl,
(C.sub.1-C.sub.40)alkylsulfonyl, or --C(NH)--NH.sub.2, then R.sup.5
is H or (C.sub.1-C.sub.40)alkyl, (C.sub.1-C.sub.40)heteroalkyl,
(C.sub.2-C.sub.40)alkenyl, (C.sub.2-C.sub.40)alkynyl,
aryl(C.sub.1-C.sub.40)alkyl, substituted (C.sub.1-C.sub.40)alkyl,
substituted (C.sub.1-C.sub.40)heteroalkyl, substituted
(C.sub.2-C.sub.40)alkenyl, substituted (C.sub.2-C.sub.40)alkynyl,
or substituted aryl(C.sub.1-C.sub.40)alkyl; [0029] (II). when
R.sup.2 is (C.sub.1-C.sub.30)acyl, aryl(C.sub.1-C.sub.30)acyl,
substituted (C.sub.1-C.sub.30)acyl, or substituted
aryl(C.sub.1-C.sub.30)acyl, then R.sup.3 is H,
(C.sub.1-C.sub.30)alkyl, (C.sub.1-C.sub.30)heteroalkyl,
(C.sub.2-C.sub.30)alkenyl, (C.sub.2-C.sub.30)alkynyl,
aryl(C.sub.1-C.sub.30)alkyl, substituted (C.sub.1-C.sub.30)alkyl,
substituted (C.sub.1-C.sub.30)heteroalkyl, substituted
(C.sub.2-C.sub.30)alkenyl, substituted (C.sub.2-C.sub.30)alkynyl,
or substituted aryl(C.sub.1-C.sub.30)alkyl; [0030] (III). either
A.sup.3 or A.sup.8 or both must be present in said compound; [0031]
(IV). when A.sup.2 is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen, then
A.sup.9 is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen; [0032] (V).
when A.sup.2 is Asp or Glu, then A.sup.9 is Dab, Dap, Orn, or Lys;
[0033] (VI). when A.sup.8 is Ala or Gly, then A.sup.1 is not Nle;
and [0034] (VII). when A.sup.1 is deleted, then R.sup.2 and R.sup.3
cannot both be H; or pharmaceutically acceptable salts thereof.
[0035] In one aspect of the first embodiment, the invention
provides a method to treat insulin resistance in a mammalian
subject, with or without weight loss, by the administration of a
therapeutically effective amount of a subgroup of melanocortin
receptor ligands of the immediate foregoing Formula I, wherein':
[0036] A.sup.1 is A.sup.6c, Arg, D-Arg, Cha, D-Cha, hCha, Chg,
D-Chg, Gaba, Ile, Leu, hLeu, Met, .beta.-hMet, 2-Nal, D-2-Nal, Nip,
Nle, Oic, Phe, D-Phe, hPhe, hPro, Val, or deleted; [0037] A.sup.2
is Asp, Cys, D-Cys, hCys, D-hCys, Glu, Pen, or D-Pen; [0038]
A.sup.3 is D-Abu, Aib, Ala, .beta.-Ala, D-Ala, D-Cha, Gaba, D-Glu,
Gly, D-Ile, D-Leu, D-Tle, D-Val, or deleted; [0039] A.sup.4 is His
or 3-Pal; [0040] A.sup.5 is D-Bal, D-1-Nal, D-2-Nal, D-Phe, D-Trp,
or D-(Et)Tyr; [0041] A.sup.6 is Arg, or hArg; [0042] A.sup.7 is
Bal, Bip, 1-Nal, 2-Nal, Trp, D-Trp; [0043] A.sup.8 is A.sup.6c,
D-Ala, Aha, Ahx, Ala, .beta.-Ala, Apn, Gaba, Gly or deleted; [0044]
A.sup.9 is Cys, D-Cys, hCys, D-hCys, Lys, Pen, or D-Pen; [0045]
A.sup.10 is Thr, or deleted; [0046] wherein at least one of A.sup.3
or A.sup.8 is deleted, but not both, [0047] or pharmaceutically
acceptable salts thereof.
[0048] More preferred compounds of the immediately foregoing group
of ligands according to Formula (I) useful to treat insulin
resistance in a mammalian subject, with or without weight loss, are
compounds of the formula:
TABLE-US-00001 SEQ ID NO: 1
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ ID NO:
1 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH.sub.2; SEQ ID NO: 2
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH.sub.2; SEQ ID NO: 3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH.sub.2; SEQ ID NO: 3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 3 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 2 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ
ID NO: 4 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH.sub.2; SEQ ID
NO: 5 Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO:
6 Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO:
6 Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-.beta.-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO:
7 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 8
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 8
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 8
Ac-Nle-c(D-Cys-.beta.-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 8 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 8 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 8 Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 9 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2; SEQ ID
NO: 9 Ac-Nle-c(Cys-.beta.-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 9 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 9 Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 9 Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 10 Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 10
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2; SEQ ID NO:
10 Ac-Nle-c(D-Cys-.beta.-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2; SEQ
ID NO: 10 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 10 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 11 Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 12
n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 11 Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 11 Ac-.beta.-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH.sub.2;
SEQ ID NO: 14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ ID
NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH.sub.2; SEQ ID
NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-NH.sub.2;
SEQ ID NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH.sub.2;
SEQ ID NO: 16 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
SEQ ID NO: 16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH.sub.2; SEQ ID NO:
16 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH.sub.2; SEQ ID
NO: 17
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH.sub.2; SEQ
ID NO: 17
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 18 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH.sub.2; SEQ ID
NO: 18 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH.sub.2; SEQ ID
NO: 18 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH.sub.2; SEQ ID
NO: 61 Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 19 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH.sub.2; SEQ ID
NO: 20 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH.sub.2; SEQ ID
NO: 21 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 22 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID
NO: 22 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID
NO: 23
D-Phe-c(Cys-His-D-Phe-hArg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 24
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 25
D-Phe-c(Cys-His-D-Phe-Arg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 24
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 26
D-Phe-c(Cys-His-D-Phe-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 27
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ ID NO: 28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH.sub.2; SEQ ID NO: 28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH.sub.2; SEQ ID NO: 29
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 31
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 32
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 32
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 33
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 34
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 34
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 35
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 36
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO: 37
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH.sub.2; SEQ ID NO: 38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ ID
NO: 39 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 39 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH.sub.2; SEQ ID
NO: 40 Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 40 Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 41 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-OH; SEQ ID
NO: 42 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH; SEQ ID NO: 43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH; SEQ ID NO: 43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-OH; SEQ ID NO:
43 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH; SEQ ID NO: 42
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH; SEQ ID NO: 41
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH; SEQ ID NO: 44
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 29
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO: 44
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH; SEQ ID NO: 47
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO: 29
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO: 48
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH; SEQ ID NO: 49
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 50
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 51
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID NO: 52
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 52
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 51
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID NO: 53
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH.sub.2; SEQ ID NO: 53
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 24
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 27 Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ ID
NO: 32 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID
NO: 34 Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 1
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ ID NO:
2 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH.sub.2; SEQ ID NO: 3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 3 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 2 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ
ID NO: 4 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH.sub.2; SEQ ID
NO: 6 Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO:
6 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 11
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 11
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 11
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 11
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 15
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-NH.sub.2; SEQ ID
NO: 21 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
SEQ ID NO: 22 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2;
SEQ ID NO: 23
D-Phe-c(Cys-His-D-Phe-hArg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 25
D-Phe-c(Cys-His-D-Phe-Arg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 24
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 26
D-Phe-c(Cys-His-D-Phe-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 28 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH.sub.2;
SEQ ID NO: 28 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH.sub.2;
SEQ ID NO: 29 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID
NO: 30 Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 30 Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 30 Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 30 Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 30 Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 30 Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 31 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 32 Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID
NO: 33 Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 33 Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 33 Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 33 Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 33 Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 33 Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 34 Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO:
35 Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO:
36 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO: 37
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH.sub.2; SEQ ID NO:
20 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH.sub.2; SEQ ID NO:
38 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH.sub.2; SEQ ID NO:
38 Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ
ID NO: 39 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ
ID NO: 39 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH.sub.2; SEQ
ID NO: 40 Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ
ID NO: 40 Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH.sub.2; or
SEQ ID NO: 49
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
or pharmaceutically acceptable salts thereof.
[0049] In the second embodiment, the invention provides a method to
treat insulin resistance in a mammalian subject, with or without
weight loss, by the administration of a therapeutically effective
amount of a melanocortin receptor ligand according to Formula (II)
and pharmaceutically acceptable salts, hydrates, solvates or
prodrugs thereof (see International Patent Application Publication
Number WO 2007/008704 incorporated herein by reference in its
entirety):
(R.sup.2R.sup.3)-A.sup.1-c(A.sup.2-A.sup.3-A.sup.4-A.sup.5-A.sup.6-A.sup-
.7-A.sup.8-A.sup.9)-NH.sub.2 (II)
wherein:
[0050] A.sup.1 is Nle or deleted;
[0051] A.sup.2 is Cys or Asp;
[0052] A.sup.3 is Glu or D-Ala;
[0053] A.sup.4 is His;
[0054] A.sup.5 is D-Phe;
[0055] A.sup.6 is Arg;
[0056] A.sup.7 is Trp, 2-Nal or Bal;
[0057] A.sup.8 is Gly, Ala, D-Ala, .beta.-Ala, Gaba or Apn;
[0058] A.sup.9 is Cys or Lys;
[0059] each of R.sup.2 and R.sup.3 is independently selected from
the group consisting of H or (C.sub.1-C.sub.6)acyl;
[0060] provided that [0061] (I). when R.sup.2 is
(C.sub.1-C.sub.6)acyl, then R.sup.3 is H; and [0062] (II). when
A.sup.2 is Cys, then A.sup.9 is Cys, or a pharmaceutically
acceptable salt thereof.
[0063] More preferred of the immediately foregoing group of
compounds which are useful to treat insulin resistance in a
mammalian subject, with or without weight loss, are compounds of
the formula:
TABLE-US-00002 SEQ ID NO: 54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH.sub.2; SEQ ID NO:
54 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)- NH.sub.2; SEQ
ID NO: 54 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-.beta.-Ala-Cys)-
NH.sub.2; SEQ ID NO: 54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)- NH.sub.2; SEQ ID
NO: 54 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ
ID NO: 55 Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH.sub.2; SEQ ID
NO: 55 Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH.sub.2; SEQ ID
NO: 56 Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH.sub.2; SEQ ID
NO: 56 Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH.sub.2; SEQ ID
NO: 57 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH.sub.2; SEQ
ID NO: 57 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-.beta.-Ala-Cys)-
NH.sub.2; SEQ ID NO: 57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)- NH.sub.2; or SEQ ID
NO: 58 Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH.sub.2;
or a pharmaceutically acceptable salt thereof.
[0064] In the third embodiment, the invention provides a method to
treat insulin resistance in a mammalian subject, with or without
weight loss, by the administration of a therapeutically effective
amount of a melanocortin receptor compound according to Formula
(III), and pharmaceutically acceptable salts, hydrates, solvates or
prodrugs thereof (see International Application Publication Number
WO 2007/008684, incorporated herein by reference in its
entirety):
(R.sup.2R.sup.3)--B.sup.1-A.sup.1-c(A.sup.2-A.sup.3-A.sup.4-A.sup.5-A.su-
p.6-A.sup.7-A.sup.8-A.sup.9)-A.sup.10-A.sup.11-A.sup.12-A.sup.13-B.sup.2---
B.sup.3--R.sup.1 (III)
wherein:
[0065] B.sup.1 is a peptide moiety which contains 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, or 15 amino acids, wherein at least 5 amino
acids are independently selected from the group consisting of
L-Arg, D-Arg, L-hArg and D-hArg, or B.sup.1 is optionally
deleted;
[0066] A.sup.1 is Acc, HN--(CH.sub.2).sub.m--(C(O), L- or D-amino
acid or deleted;
[0067] A.sup.2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp or
Glu;
[0068] A.sup.3 is Gly, Glu, Ala, .beta.-Ala, Gaba, Aib, D-amino
acid or deleted;
[0069] A.sup.4 is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi or
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe;
[0070] A.sup.5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal,
D-(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, D-(Et)Tyr, D-Dip,
D-Bip or D-Bpa;
[0071] A.sup.6 is Arg, hArg, Dab, Dap, Lys, Orn or
HN--CH((CH.sub.2).sub.n--N(R.sup.4R.sup.5))--(C(O);
[0072] A.sup.7 is Trp, 1-Nal, 2-Nal, Bal, Bip, Dip, Bpa, D-Trp,
D-1-Nal, D-2-Nal, D-Bal, D-Bip, D-Dip or D-Bpa;
[0073] A.sup.8 is Gly, D-Ala, Acc, Ala, .beta.-Ala, Gaba, Apn, Ahx,
Aha, HN--(CH.sub.2).sub.s--(C(O) or deleted;
[0074] A.sup.9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap,
Orn or Lys;
[0075] A.sup.10 is Acc, HN--(CH.sub.2).sub.t--(C(O), Pro, hPro,
3-Hyp, 4-Hyp, Thr, an L- or D-amino acid or deleted;
[0076] A.sup.11 is Pro, hPro, 3-Hyp, 4-Hyp or deleted;
[0077] A.sup.12 is Lys, Dab, Dap, Arg, hArg or deleted;
[0078] A.sup.13 is Asp, Glu or deleted;
[0079] B.sup.2 is a peptide moiety containing 1, 2, 3, 4, or 5
amino acids or deleted,
[0080] B.sup.3 is a peptide moiety which contains 5, 6, 7, 8, 9,
10, 11, 12, 13, 14 or 15 amino acids wherein at least 5 amino acids
are independently selected from the group consisting of L-Arg,
D-Arg, L-hArg and D-hArg, or is deleted;
[0081] R.sup.1 is OH or NH.sub.2;
[0082] R.sup.2 and R.sup.3 each is, independently for each
occurrence, selected from the group consisting of H,
(C.sub.1-C.sub.30)alkyl, (C.sub.1-C.sub.30)heteroalkyl,
(C.sub.1-C.sub.30)acyl, (C.sub.2-C.sub.30)alkenyl,
(C.sub.2-C.sub.30)alkynyl, aryl(C.sub.1-C.sub.30)alkyl,
aryl(C.sub.1-C.sub.30)acyl, substituted (C.sub.1-C.sub.30)alkyl,
substituted (C.sub.1-C.sub.30)heteroalkyl, substituted
(C.sub.1-C.sub.30)acyl, substituted (C.sub.2-C.sub.30)alkenyl,
substituted (C.sub.2-C.sub.30)alkynyl, substituted
aryl(C.sub.1-C.sub.30)alkyl and substituted
aryl(C.sub.1-C.sub.30)acyl;
[0083] R.sup.4 and R.sup.5 each is, independently for each
occurrence, H, (C.sub.1-C.sub.40)alkyl,
(C.sub.1-C.sub.40)heteroalkyl, (C.sub.1-C.sub.40)acyl,
(C.sub.2-C.sub.40)alkenyl, (C.sub.2-C.sub.40)alkynyl,
aryl(C.sub.1-C.sub.40)alkyl, aryl(C.sub.1-C.sub.40)acyl,
substituted (C.sub.1-C.sub.40)alkyl, substituted
(C.sub.1-C.sub.40)heteroalkyl, substituted (C.sub.1-C.sub.40)acyl,
substituted (C.sub.2-C.sub.40)alkenyl, substituted
(C.sub.2-C.sub.40)alkynyl, substituted aryl(C.sub.1-C.sub.40)alkyl,
substituted aryl(C.sub.1-C.sub.40)acyl,
(C.sub.1-C.sub.40)alkylsulfonyl or C(NH)--NH.sub.2;
[0084] n is, independently for each occurrence, 1, 2, 3, 4 or
5;
[0085] m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or
7;
[0086] s is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or
7;
[0087] t is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or
7;
[0088] X.sup.1, X.sup.2, X.sup.3, X.sup.4 and X.sup.5 each is,
independently for each occurrence, H, F, Cl, Br, I,
(C.sub.1-10)alkyl, substituted (C.sub.1-10)alkyl,
(C.sub.2-10)alkenyl, substituted (C.sub.2-10)alkenyl,
(C.sub.2-10)alkynyl, substituted (C.sub.2-10)alkynyl, aryl,
substituted aryl, OH, NH.sub.2, NO.sub.2 or CN;
provided that:
[0089] (I) when R.sup.4 is (C.sub.1-C.sub.40)acyl,
aryl(C.sub.1-C.sub.40)acyl, substituted (C.sub.1-C.sub.40)acyl,
substituted aryl(C.sub.1-C.sub.40)acyl,
(C.sub.1-C.sub.40)alkylsulfonyl or C(NH)--NH.sub.2, then R.sup.5 is
H, (C.sub.1-C.sub.40)alkyl, (C.sub.1-C.sub.40)heteroalkyl,
(C.sub.2-C.sub.40)alkenyl, (C.sub.2-C.sub.40)alkynyl,
aryl(C.sub.1-C.sub.40)alkyl, substituted (C.sub.1-C.sub.40)alkyl,
substituted (C.sub.1-C.sub.40)heteroalkyl, substituted
(C.sub.2-C.sub.40)alkenyl, substituted (C.sub.2-C.sub.40)alkynyl or
substituted aryl(C.sub.1-C.sub.40)alkyl;
[0090] (II) when R.sup.2 is (C.sub.1-C.sub.30)acyl,
aryl(C.sub.1-C.sub.30)acyl, substituted (C.sub.1-C.sub.30)acyl or
substituted aryl(C.sub.1-C.sub.30)acyl, then R.sup.3 is H,
(C.sub.1-C.sub.30)alkyl, (C.sub.1-C.sub.30)heteroalkyl,
(C.sub.2-C.sub.30)alkenyl, (C.sub.2-C.sub.30)alkynyl,
aryl(C.sub.1-C.sub.30)alkyl, substituted (C.sub.1-C.sub.30)alkyl,
substituted (C.sub.1-C.sub.30)heteroalkyl, substituted
(C.sub.2-C.sub.30)alkenyl, substituted (C.sub.2-C.sub.30)alkynyl or
substituted aryl(C.sub.1-C.sub.30)alkyl;
[0091] (III) neither B.sup.1 nor B.sup.2 contains one or more of
the following amino acid sequences:
Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3,
Tyr-Ala-Arg-Lys-Ala-(Arg).sub.2-Gln-Ala-(Arg).sub.2,
Tyr-Ala-Arg-(Ala).sub.2-(Arg).sub.2-(Ala).sub.2-(Arg).sub.2,
Tyr-Ala-(Arg).sub.9, Tyr-(Ala).sub.3-(Arg).sub.7,
Tyr-Ala-Arg-Ala-Pro-(Arg).sub.2-Ala-(Arg).sub.3 or
Tyr-Ala-Arg-Ala-Pro-(Arg).sub.2-Pro-(Arg).sub.2;
[0092] (IV) either B.sup.1 or B.sup.2 or both must be present in
said compound;
[0093] (V) when A.sup.2 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen,
then A.sup.9 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen; and
[0094] (VI) when A.sup.2 is Asp or Glu, then A.sup.9 is Dab, Dap,
Orn or Lys;
or pharmaceutically acceptable salts thereof.
[0095] In one aspect of the third embodiment, the invention is
directed to the use of compounds of Formula (III) to treat insulin
resistance in a mammalian subject, with or without weight loss,
wherein
[0096] B.sup.1 is Arg-Lys-Gln-Lys-(Arg).sub.5,
Arg-(Lys).sub.2-Arg-Gln-(Arg).sub.4,
Arg-(Lys).sub.2-(Arg).sub.3-Gln-(Arg).sub.2,
Arg-(Lys).sub.2-(Arg).sub.4-Gln-Arg,
Arg-(Lys).sub.2-(Arg).sub.5-Gln, Arg-(Lys).sub.2-Gln-(Arg).sub.5,
Arg-Gln-(Lys).sub.2-(Arg).sub.5, Arg-Gln-(Arg).sub.7,
Arg-Gln-(Arg).sub.8, (Arg).sub.2-Gln-(Arg).sub.6,
(Arg).sub.2-Gln-(Arg).sub.7, (Arg).sub.3-Gln-(Arg).sub.5,
(Arg).sub.3-Gln-(Arg).sub.6, (Arg).sub.4-Gln-(Arg).sub.4,
(Arg).sub.4-Gln-(Arg).sub.5, (Arg).sub.5,
(Arg).sub.5-Gln-(Arg).sub.3, (Arg).sub.5-Gln-(Arg).sub.4,
(Arg).sub.6, (Arg).sub.6-Gln-(Arg).sub.3, (Arg).sub.7,
(Arg).sub.7-Gln-(Arg).sub.2, (Arg).sub.8, (Arg).sub.8-Gln-Arg,
(Arg).sub.9, (Arg).sub.9-Gln, (D-Arg).sub.5, (D-Arg).sub.6,
(D-Arg).sub.7, (D-Arg).sub.8, (D-Arg).sub.9,
Gln-Arg-(Lys).sub.2-(Arg).sub.5, Gln-(Arg).sub.8, Gln-(Arg).sub.9,
Tyr-Gly-Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3,
Tyr-Gly-Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-Doc; or
deleted;
[0097] B.sup.2 is .beta.-Ala, .beta.-Ala-Gly, .beta.-Ala-Tyr,
.beta.-Ala-Tyr-Gly, (.beta.-Ala).sub.2, (.beta.-Ala).sub.2-Gly,
(.beta.-Ala).sub.2-Tyr, (.beta.-Ala).sub.2-Tyr-Gly, Doc, Doc-Gly,
Doc-Tyr, Doc-Tyr-Gly, (Doc).sub.2, (Doc).sub.2-Gly,
(Doc).sub.2-Tyr, Doc).sub.2-Tyr-Gly, or deleted;
[0098] B.sup.3 is Arg-Lys-Gln-Lys-(Arg).sub.5,
Arg-Lys-(Arg).sub.3-Gln-(Arg).sub.3,
Arg-(Lys).sub.2-Arg-Gln-(Arg).sub.4,
Arg-(Lys).sub.2-Gln-(Arg).sub.5,
Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3,
Arg-(Lys).sub.2-(Arg).sub.3-Gln-(Arg).sub.2,
Arg-(Lys).sub.2-(Arg).sub.4-Gln-Arg,
Arg-(Lys).sub.2-(Arg).sub.5-Gln, Arg-Gln-(Lys).sub.2-(Arg).sub.5,
Arg-Gln-(Arg).sub.7, Arg-Gln-(Arg).sub.8,
(Arg).sub.2-Lys-(Arg).sub.2-Gln-(Arg).sub.3,
(Arg).sub.2-Gln-(Arg).sub.6, (Arg).sub.2-Gln-(Arg).sub.7,
(Arg).sub.3-Gln-(Arg).sub.5, (Arg).sub.3-Gln-(Arg).sub.6,
(Arg).sub.4-Gln-(Arg).sub.4, (Arg).sub.4-Gln-(Arg).sub.5,
(Arg).sub.5, (Arg).sub.5-Gln-(Arg).sub.3,
(Arg).sub.5-Gln-(Arg).sub.4, (Arg).sub.6,
(Arg).sub.6-Gln-(Arg).sub.3, (Arg).sub.7,
(Arg).sub.7-Gln-(Arg).sub.2, (Arg).sub.8, (Arg).sub.8-Gln-Arg,
(Arg).sub.9, (Arg).sub.9-Gln, (D-Arg).sub.5, (D-Arg).sub.6,
(D-Arg).sub.7, (D-Arg).sub.8, (D-Arg).sub.9,
Gln-Arg-(Lys).sub.2-(Arg).sub.5, Gln-(Arg).sub.8, Gln-(Arg).sub.9,
or deleted;
[0099] A.sup.1 is A6c, Cha, hCha, Chg, D-Chg, hChg, Gaba, hLeu,
Met, .beta.-hMet, D-2-Nal, Nip, Nle, Oic, Phe, D-Phe, hPhe, hPro,
or deleted;
[0100] A.sup.2 is Cys
[0101] A.sup.3 is D-Abu, Aib, Ala, .beta.-Ala, D-Ala, D-Cha, Gaba,
Glu, Gly, D-Ile, D-Leu, D-Met, D-Nle, D-Phe, D-Tle, D-Trp, D-Tyr,
D-Val, or deleted;
[0102] A.sup.4 is His;
[0103] A.sup.5 is D-Bal, D-1-Nal, D-2-Nal, D-Phe,
D-(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, D-Trp, or
D-(Et)Tyr;
[0104] A.sup.6 is Arg or hArg;
[0105] A.sup.7 is Bal, Bip, 1-Nal, 2-Nal, Trp, or D-Trp;
[0106] A.sup.8 is A.sup.5c, A.sup.6c, Aha, Ahx, Ala, .beta.-Ala,
Apn, Gaba, Gly, or deleted;
[0107] A.sup.9 is Cys, D-Cys, hCys, D-hCys, Lys, Pen, or D-Pen;
[0108] A.sup.10 is Pro, Thr or deleted;
[0109] A.sup.11 is Pro or deleted;
[0110] A.sup.12 is arg, Lys, or deleted;
[0111] A.sup.13 is Asp or deleted; [0112] each of R.sup.2 and
R.sup.3 is, independently, H or acyl; or pharmaceutically
acceptable salts thereof.
[0113] Preferred ligands of the immediately foregoing group of
compounds according to Formula (III), useful to treat insulin
resistance in a mammalian subject, with or without weight loss, are
compounds of the formula:
TABLE-US-00003 (SEQ ID NO: 60)
Tyr-Gly-Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-Nle-c(Asp-His-D-2-Nal--
Arg-Trp-Lys)-NH.sub.2; (SEQ ID NO: 61)
Tyr-Gly-Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-Doc-Nle-c(Asp-His-D-2--
Nal-Arg-Trp-Lys)- NH.sub.2; (SEQ ID NO: 62)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-Arg-(Lys).sub.2-(Arg-
).sub.2-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 62)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-Arg-(Lys).sub.2-(-
Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 63)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-Arg-(Lys).sub.2-(Ar-
g).sub.2-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 64)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro).sub.2-Lys-Asp-Tyr-Gly-Arg-(Lys-
).sub.2-(Arg).sub.2- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 65)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro).sub.2-Lys-Asp-Tyr-Gly-Arg--
(Lys).sub.2- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 66)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-Arg-(Lys)-
.sub.2-(Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 67)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro).sub.2-Lys-Asp-Doc-Tyr-Gly-Arg--
(Lys).sub.2- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 68)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro).sub.2-Lys-Asp-Doc-Tyr-Gly--
Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-Doc-Tyr-Gly--
Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
70)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-Arg-(Lys).sub.2--
(Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 72)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 73)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-G-
ly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 74)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 75)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-Arg-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO:
76)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-Gln-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 77)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- Lys-Gln-Lys-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 78)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.4-Gln-Arg-NH.sub.2; (SEQ ID NO:
79)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Aib-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 84)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 85)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.3-Gln-(Arg).sub.2-NH.sub.2; (SEQ
ID NO: 86)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- Gln-(Lys).sub.2-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 87)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.5-Gln-NH.sub.2; (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
89)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
90)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.2- Lys-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 91)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID
NO: 92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 93)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
94)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 95)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.2- Lys-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 96)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- Lys-(Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
97)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID
NO: 92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 98)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
99)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.2- Lys-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- Lys-(Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID
NO: 103)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
104)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
105)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-A-
rg-Lys-(Arg).sub.3- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.2- Lys-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-G-
ly-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID
NO: 103)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-G-
ly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 106)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-Arg-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO:
107)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-Gln-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 108)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- Lys-Gln-Lys-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 109)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- Gln-(Lys).sub.2-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 110)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.3-Gln-(Arg).sub.2-NH.sub.2; (SEQ
ID NO: 111)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.4-Gln-Arg-NH.sub.2; (SEQ ID NO:
112)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.5-Gln-NH.sub.2; (SEQ ID NO: 113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 117)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 117)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 119)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 119)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5-
Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.6-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 123)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 123)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 124)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 124)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.6-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 129)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 129)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 131)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 131)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 132)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-G-
ly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 133)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 133)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 135)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 135)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-Arg-(Lys).su-
b.2-(Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 137)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-Arg-(Lys).sub-
.2-Arg-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys).sub.2-(Arg-
).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 139)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 140)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.2-L-
ys-(Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-Arg-Lys-(Arg)-
.sub.3-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.2-Lys-(-
Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-Arg-Lys-(Arg).sub-
.3-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 143)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.2-Lys-(Arg)-
.sub.2-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 144)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Arg-Lys-(Arg).sub.3-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 145)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-Arg-(Lys).sub-
.2-Arg-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 146)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys).sub.2-(Arg-
).sub.2-Gln-
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 147)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 147)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Gly-(Arg).sub-
.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).su-
b.4-NH.sub.2; (SEQ ID NO: 156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln--
(Arg).sub.4-NH.sub.2; (SEQ ID NO: 158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 159)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 160)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 161)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 162)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(Ar-
g).sub.3-NH.sub.2; (SEQ ID NO: 163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.3-
-NH.sub.2; (SEQ ID NO: 164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.5-
-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(Ar-
g).sub.3-NH.sub.2; (SEQ ID NO: 166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub.-
3-NH.sub.2; (SEQ ID NO: 166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).sub.3-NH-
.sub.2; (SEQ ID NO: 168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3-NH.sub-
.2; (SEQ ID NO: 167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub.-
3-NH.sub.2; (SEQ ID NO: 170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(Ar-
g).sub.4-NH.sub.2; (SEQ ID NO: 169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(Arg).s-
ub.4-NH.sub.2; (SEQ ID NO: 169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.4-
-NH.sub.2; (SEQ ID NO: 170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.5-
-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Gly-(Arg).sub.5-Gln-
-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(Ar-
g).sub.4-NH.sub.2; (SEQ ID NO: 173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub.-
4-NH.sub.2; (SEQ ID NO: 172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).sub.4-NH-
.sub.2; (SEQ ID NO: 172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4-NH.sub-
.2; (SEQ ID NO: 173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2; (SEQ ID NO: 174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln-(Arg).-
sub.4-NH.sub.2; (SEQ ID NO: 174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub.-
4-NH.sub.2; (SEQ ID NO: 175)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-.beta.-Ala-Tyr-Gly-(Arg).su-
b.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 176)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-.beta.-Ala-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 177)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 178)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 179)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gly-(Ar-
g).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 180)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).sub.5-
-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 181)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 182)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 183)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 184)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 183)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 185)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 186)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 185)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 186)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 187)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 195)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 196)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 197)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 198)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 201)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-.beta.-Ala-Tyr-Gly-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 202)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-.beta.-Ala-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(.beta.-Ala).sub.2-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc).sub.2-Gly-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-Tyr-Gly-(Ar-
g).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 210)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-(Arg).sub.5-
-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-Gly-(Arg).s-
ub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 211)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-(Arg).sub.5-
-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 212)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-Tyr-
-Gly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-(Ar-
g).sub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-Gly-
-(Arg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 267)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-(Ar-
g).sub.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-Tyr-Gly-(Arg).sub.-
5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2; (SEQ ID NO: 215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-Tyr-Gly-(A-
rg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-(Arg).sub.-
5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-Gly-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-(Arg).sub.-
5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-Tyr-Gly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-(Arg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 220)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-Tyr-G-
ly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).-
sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-Tyr-Gly-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-(Arg).sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-Tyr-G-
ly-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 226)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-Tyr-Gly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-(Arg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 229)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 230)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 232)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-Doc-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 231)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-Tyr-G-
ly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 232)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 233)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 234)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.-
3-NH.sub.2; (SEQ ID NO: 235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.-
5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2; (SEQ ID NO: 238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.-
4-NH.sub.2; (SEQ ID NO: 237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.-
5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2; (SEQ ID NO: 239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub-
.3-NH.sub.2; (SEQ ID NO: 240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3-NH.su-
b.2; (SEQ ID NO: 239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub-
.3-NH.sub.2; (SEQ ID NO: 241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub-
.4-NH.sub.2; (SEQ ID NO: 242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4-NH.su-
b.2; (SEQ ID NO: 241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub-
.4-NH.sub.2; (SEQ ID NO: 243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2;
(SEQ ID NO: 244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub-
.3-NH.sub.2; (SEQ ID NO: 259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub-
.4-NH.sub.2; (SEQ ID NO: 261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub-
.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3-NH.s-
ub.2; (SEQ ID NO: 263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).su-
b.4-NH.sub.2; (SEQ ID NO: 266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4-NH.s-
ub.2; (SEQ ID NO: 265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln--
(Arg).sub.4-NH.sub.2; or (SEQ ID NO: 266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).su-
b.4-NH.sub.2;;
or pharmaceutically acceptable salts thereof.
[0114] In a fourth embodiment, the invention provides a method to
treat insulin resistance in a mammalian subject, with or without
weight loss, by the administration of a therapeutically effective
amount of a melanocortin receptor compound according to Formula
(IV), and pharmaceutically acceptable salts, hydrates, solvates and
prodrugs thereof, with a compound having the following formula
(formula (IV)):
Ac-c(Cys-Glu-His-A.sup.1-Arg-A.sup.2-A.sup.3-Cys)-(Pro).sub.2-Lys-Asp-NH-
.sub.2 (IV)
wherein: A.sup.1 is the D-isomer of X-Phe or 2-Nal where X is
halogen;
A.sup.2 is Bal, 1-Nal, 2-Nal, or Trp; and
A.sup.3 is Aib, Ala, .beta.-Ala or Gly,
[0115] or pharmaceutically acceptable salts thereof.
[0116] Preferred compounds of the immediately foregoing formula
discovered to treat insulin resistance in a mammalian subject, with
or without weight loss, include the following:
TABLE-US-00004 (SEQ ID NO: 268)
Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-
(Pro).sub.2-Lys-Asp-NH.sub.2; (SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-
Lys-Asp-NH.sub.2; (SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-
(Pro).sub.2-Lys-Asp-NH.sub.2; (SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-
(Pro).sub.2-Lys-Asp-NH.sub.2; (SEQ ID NO: 2690)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-
Lys-Asp-NH.sub.2; (SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-.beta.-Ala-Cys)-
(Pro).sub.2-Lys-Asp-NH.sub.2; or (SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-
(Pro).sub.2-Lys-Asp-NH.sub.2;
or pharmaceutically acceptable salts thereof.
[0117] The invention additionally provides a method to treat
insulin resistance in a mammalian subject, with or without weight
loss, by the administration of a therapeutically effective amount
of a melanocortin receptor compound modified with a hydantoin
moiety according to Formula (V), (VI) or (VII), and
pharmaceutically acceptable salts, hydrates, solvates or prodrugs
thereof.
[0118] According to a fifth embodiment, the invention provides a
method to treat insulin resistance in a mammalian subject, with or
without weight loss, by the administration of a therapeutically
effective amount of a melanocortin receptor ligand according to the
following formula (Formula (V)), pharmaceutically-acceptable salts,
hydrates, solvates and/or prodrugs thereof (see International
Patent Application Number PCT/US08/06675 incorporated herein by
reference in its entirety):
##STR00001##
wherein
[0119] X is selected from the group consisting of
--CH.sub.2--S--S--CH.sub.2--,
--C(CH.sub.3).sub.2--S--S--CH.sub.2--,
--CH.sub.2--S--S--C(CH.sub.3).sub.2--,
--C(CH.sub.3).sub.2--S--S--C(CH.sub.3).sub.2--,
--(CH.sub.2).sub.2--S--S--CH.sub.2--,
--CH.sub.2--S--S--(CH.sub.2).sub.2--,
--(CH.sub.2).sub.2--S--S--(CH.sub.2).sub.2--,
--C(CH.sub.3).sub.2--S--S--(CH.sub.2).sub.2--,
--(CH.sub.2).sub.2--S--S--C(CH.sub.3).sub.2--, --(CH.sub.2)
t-C(O)--NR.sup.8--(CH.sub.2).sub.r and
--(CH.sub.2).sub.r--NR.sup.8--C(O)--(CH.sub.2).sub.t--;
[0120] R.sup.1 and R.sup.2 each is, independently, H,
(C.sub.1-C.sub.10)alkyl or substituted (C.sub.1-C.sub.10)alkyl;
[0121] R.sup.3 is --OH or --NH.sub.2;
[0122] R.sup.4 and R.sup.5 each is, independently, H,
(C.sub.1-C.sub.10)alkyl or substituted (C.sub.1-C.sub.10)alkyl;
[0123] X.sup.1 is
##STR00002##
[0124] A.sup.1 is His, 2-Pal, 3-Pal, 4-Pal,
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, Taz, 2-Thi, 3-Thi or
is deleted;
[0125] A.sup.2 is D-Bal, D-1-Nal, D-2-Nal, D-Phe or
D-(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe;
[0126] A.sup.3 is Arg, hArg, Dab, Dap, Lys or Orn;
[0127] A.sup.4 is Bal, 1-Nal, 2-Nal,
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe or Trp;
[0128] R.sup.6 and R.sup.7 each is, independently for each
occurrence thereof, H, (C.sub.1-C.sub.10)alkyl,
(C.sub.1-C.sub.10)heteroalkyl, aryl(C.sub.1-C.sub.5)alkyl,
substituted (C.sub.1-C.sub.10)alkyl, substituted
(C.sub.1-C.sub.10)heteroalkyl or substituted
aryl(C.sub.1-C.sub.5)alkyl provided that R.sup.6 and R.sup.7 may be
joined together to form a ring;
[0129] R.sup.8 is H, (C.sub.1-C.sub.10)alkyl or substituted
(C.sub.1-C.sub.10)alkyl;
[0130] r is, independently for each occurrence thereof, 1, 2, 3, 4
or 5; and
[0131] t is, independently for each occurrence thereof, 1 or 2.
[0132] Preferrably, a compound according the foregoing formula
found useful to treat insulin resistance in a mammalian subject,
with or without weight loss, include compounds wherein X.sup.1 is
selected from the group consisting of:
##STR00003##
Representative embodiments of the foregoing class of compounds
useful to treat insulin resistance in a mammalian subject, with or
without weight loss, are as follows:
TABLE-US-00005 (SEQ ID NO: 271)
c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp- Cys]-NH.sub.2;
(SEQ ID NO: 271) c[Hydantoin(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-
Cys]-NH.sub.2; (SEQ ID NO: 272)
c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp- Cys]-NH.sub.2;
or (SEQ ID NO: 272) c[Hydantoin(C(O)-(hCys-D-Ala))-His-D-2-Nal-Arg-
Trp-Cys]-NH.sub.2; (SEQ ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp- Lys]-NH.sub.2;
(SEQ ID NO: 273) c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-
Orn]-NH.sub.2; (SEQ ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp- Dab]-NH.sub.2; or
(SEQ ID NO: 273) c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-
Dap]-NH.sub.2; (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-His))-D-2-Nal-Arg-Trp- Lys]-NH.sub.2; (SEQ ID
NO: 274) c[Hydantoin(C(O)-(Asp-His))-D-Phe-Arg-Trp- Lys]-NH.sub.2
(SEQ ID NO: 274) c[Hydantoin(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-
Lys]-NH.sub.2; (SEQ ID NO: 274)
c[Hydantoin(C(O)-(Asp-A5c))-D-Phe-Arg-Trp- Lys]-NH.sub.2; (SEQ ID
NO: 274) c[Hydantoin(C(O)-(Asp-A6c))-D-Phe-Arg-Trp- Lys]-NH.sub.2;
(SEQ ID NO: 275) c[Hydantoin(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-
Lys]-NH.sub.2; (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp- Lys]-NH.sub.2; (SEQ ID
NO: 275) c[Hydantoin(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-
Lys]-NH.sub.2; (SEQ ID NO: 274)
c[Hydantoin(C(O)-(Asp-Aic))-D-Phe-Arg-Trp- Lys]-NH.sub.2; (SEQ ID
NO: 274) c[Hydantoin(C(O)-(Asp-Apc))-D-Phe-Arg-Trp- Lys]-NH.sub.2;
(SEQ ID NO: 275) c[Hydantoin(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-
Lys]-NH.sub.2; (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp- Lys]-NH.sub.2; (SEQ ID
NO: 275) c[Hydantoin-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-
Lys]-NH.sub.2 (SEQ ID NO: 275)
c[Hydantoin-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp- Lys]-NH.sub.2 (SEQ ID
NO: 276) c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-
Orn]-NH.sub.2; (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp- Dab]-NH.sub.2; or
(SEQ ID NO: 276) c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-
Dap]-NH.sub.2, (SEQ ID NO: 277)
c[Hydantoin(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH.sub.2
[0133] According to a sixth embodiment, the invention provides a
method to treat insulin resistance in a mammalian subject, with or
without weight loss, by the administration of a therapeutically
effective amount of a melanocortin receptor compound according to
Formula (VI), pharmaceutically-acceptable salts, hydrates, solvates
and/or prodrugs thereof (see International Patent Application
Number PCT/US08/06675 which is incorporated herein by reference in
its entirety):
##STR00004##
wherein
[0134] X.sup.1 is
##STR00005##
[0135] X.sup.2 is
##STR00006##
[0136] A.sup.1 is Asp, Cys, D-Cys, Dab, Dap, Glu, Lys, Orn, Pen or
D-Pen;
[0137] A.sup.2 is an L- or D-amino acid;
[0138] A.sup.3 is His, 2-Pal, 3-Pal, 4-Pal,
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, Taz, 2-Thi or
3-Thi;
[0139] A.sup.4 is D-Bal, D-1-Nal, D-2-Nal, D-Phe or
D-(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe;
[0140] A.sup.5 is Arg, hArg, Dab, Dap, Lys or Orn;
[0141] A.sup.6 is Bal, 1-Nal, 2-Nal,
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe or Trp;
[0142] A.sup.7 is Asp, Cys, D-Cys, Dab, Dap, Glu, Lys, Orn, Pen or
D-Pen;
[0143] R.sup.1 is H, (C.sub.1-C.sub.10)alkyl or substituted
(C.sub.1-C.sub.10)alkyl;
[0144] R.sup.2 and R.sup.3 each is, independently, H,
(C.sub.1-C.sub.10)alkyl, (C.sub.1-C.sub.10)heteroalkyl,
aryl(C.sub.1-C.sub.5)alkyl, substituted (C.sub.1-C.sub.10)alkyl,
substituted (C.sub.1-C.sub.10)heteroalkyl or substituted
aryl(C.sub.1-C.sub.5)alkyl or R.sup.2 and R.sup.3 may be fused
together form a cyclic moiety;
[0145] R.sup.4 is CO.sub.2H or C(O)NH.sub.2;
[0146] R.sup.5 and R.sup.6 each is, independently, H,
(C.sub.1-C.sub.10)alkyl, (C.sub.1-C.sub.10)heteroalkyl,
aryl(C.sub.1-C.sub.5)alkyl, substituted (C.sub.1-C.sub.10)alkyl,
substituted (C.sub.1-C.sub.10)heteroalkyl or substituted
aryl(C.sub.1-C.sub.5)alkyl or R.sup.5 and R.sup.6 may be fused
together form a cyclic moiety;
[0147] R.sup.7 and R.sup.8 each is, independently, H,
(C.sub.1-C.sub.10)alkyl, (C.sub.1-C.sub.10)heteroalkyl,
aryl(C.sub.1-C.sub.5)alkyl, substituted (C.sub.1-C.sub.10)alkyl,
substituted (C.sub.1-C.sub.10)heteroalkyl or substituted
aryl(C.sub.1-C.sub.5)alkyl; or R.sup.7 and R.sup.8 may be fused
together form a cyclic moiety;
[0148] R.sup.9 is H, (C.sub.1-C.sub.10)alkyl or substituted
(C.sub.1-C.sub.10)alkyl; and
[0149] n is, independently for each occurrence thereof, 1, 2, 3, 4,
5, 6 or 7;
or a pharmaceutically acceptable salt thereof.
[0150] A preferred class of compounds according to Formula (VI)
useful to treat insulin resistance in a mammalian subject, with or
without weight loss, are those compounds wherein:
[0151] A.sup.1 is Cys;
[0152] A.sup.2 is D-Ala, Asn, Asp, Gln, Glu or D-Phe;
[0153] A.sup.3 is His;
[0154] A.sup.4 is D-2-Nal or D-Phe;
[0155] A.sup.5 is Arg;
[0156] A.sup.6 is Trp; and
[0157] A.sup.7 is Cys or Pen;
[0158] each of R.sup.1, R.sup.2, R.sup.3, and R.sup.9 is,
independently, H;
[0159] R.sup.4 is C(O)NH.sub.2;
[0160] each of R.sup.5 and R.sup.6 is, independently, H,
(C.sub.1-C.sub.10)alkyl, (C.sub.1-C.sub.10)heteroalkyl, substituted
(C.sub.1-C.sub.10)alkyl or substituted
(C.sub.1-C.sub.10)heteroalkyl or R.sup.5 and R.sup.6 may be fused
together form a cyclic moiety; and
[0161] each of R.sup.7 and R.sup.8 is, independently, H,
(C.sub.1-C.sub.10)alkyl, (C.sub.1-C.sub.10)heteroalkyl, substituted
(C.sub.1-C.sub.10)alkyl or substituted
(C.sub.1-C.sub.10)heteroalkyl;
or pharmaceutically acceptable salts thereof.
[0162] Preferred compounds of the immediately foregoing formula
(Formula (VI)) useful to treat insulin resistance in a mammalian
subject, with or without weight loss, include:
TABLE-US-00006 (SEQ ID NO: 278)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 280)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2;
(SEQ ID NO: 280)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 281)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 281)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 282)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 282)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 280)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2;
(SEQ ID NO: 280)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
or (SEQ ID NO: 279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 283)
Hydantoin(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 283)
Hydantoin(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 283)
Hydantoin(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
or (SEQ ID NO: 284)
Hydantoin(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 285)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 285)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 286)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 286)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 287)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 287)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 288)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
and (SEQ ID NO: 288)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 289)
Hydantoin(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
or pharmaceutically acceptable salts thereof.
[0163] In a seventh embodiment, the invention provides a method to
treat insulin resistance in a mammalian subject, with or without
weight loss, by the administration of a therapeutically effective
amount of a melanocortin receptor ligand belonging to a class of
cyclic peptide analogs that are ligands for the melanocortin
receptors having a structure according to Formula (VII) as depicted
below (see International Patent Application Number PCT/US08/06675
which is incorporated herein by reference in its entirety):
##STR00007##
wherein
[0164] X is selected from the group consisting of
--CH.sub.2--S--S--CH.sub.2--,
--C(CH.sub.3).sub.2--S--S--CH.sub.2--,
--CH.sub.2--S--S--C(CH.sub.3).sub.2--,
--C(CH.sub.3).sub.2--S--S--C(CH.sub.3).sub.2--,
--(CH.sub.2).sub.2--S--S--CH.sub.2--,
--CH.sub.2--S--S--(CH.sub.2).sub.2,
--(CH.sub.2).sub.2--S--S--(CH.sub.2).sub.2--,
--C(CH.sub.3).sub.2--S--S--(CH.sub.2).sub.2--,
--(CH.sub.2).sub.2--S--S--C (CH.sub.3).sub.2--,
--(CH.sub.2).sub.t--(C(O)--NR.sup.8--(CH.sub.2).sub.r and
--(CH.sub.2).sub.r--NR.sup.8--C(O)--(CH.sub.2).sub.t--;
[0165] each of R.sup.1 and R.sup.5 is, independently, H,
(C.sub.1-C.sub.10)alkyl or substituted (C.sub.1-C.sub.10)alkyl;
[0166] each of R.sup.2 and R.sup.3 is, independently, H,
(C.sub.1-C.sub.10)alkyl, (C.sub.1-C.sub.10)heteroalkyl,
aryl(C.sub.1-C.sub.5)alkyl, substituted (C.sub.1-C.sub.10)alkyl,
substituted (C.sub.1-C.sub.10)heteroalkyl or substituted
aryl(C.sub.1-C.sub.5)alkyl or R.sup.2 and R.sup.3 may be fused
together to form a ring;
[0167] R.sup.4 is OH or NH.sub.2;
[0168] each of R.sup.6 and R.sup.7 is, independently, H,
(C.sub.1-C.sub.10)alkyl or substituted (C.sub.1-C.sub.10)alkyl;
[0169] A.sup.1 is an L- or D-amino acid or deleted;
[0170] A.sup.2 is His, 2-Pal, 3-Pal, 4-Pal,
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, Taz, 2-Thi or
3-Thi;
[0171] A.sup.3 is D-Bal, D-1-Nal, D-2-Nal, D-Phe or
D-(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe;
[0172] A.sup.4 is Arg, hArg, Dab, Dap, Lys or Orn;
[0173] A.sup.5 is Bal, 1-Nal, 2-Nal,
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe or Trp;
[0174] r is, independently for each occurrence thereof, 1, 2, 3, 4
or 5; and
[0175] t is, independently for each occurrence thereof, 1 or 2;
or pharmaceutically acceptable salts thereof.
[0176] In the preferred aspect of the compounds according to
Formula (VII) useful to treat insulin resistance in a mammalian
subject, with or without weight loss,
[0177] A.sup.1 is Ala, D-Ala, Asn, Asp, Gln, Glu or Gly;
or pharmaceutically acceptable salts thereof.
[0178] Preferred compounds according to Formula (VII) useful in the
treatment of insulin resistance in a mammalian subject, include the
following compounds:
TABLE-US-00007 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg- Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290) c[Hydantoin(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2; (SEQ ID NO: 290)
c[Hydantoin(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2; (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg- Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290) c[Hydantoin(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2; (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg- Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290) c[Hydantoin(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2; (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg- Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290) c[Hydantoin(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2; (SEQ ID NO: 290)
c[Hydantoin(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg- Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290) c[Hydantoin(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2; (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg- Trp-Cys]-NH.sub.2;
or (SEQ ID NO: 291) c[Hydantoin(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2; or (SEQ ID NO: 291)
c[Hydantoin(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-
Trp-Cys]-NH.sub.2;
or pharmaceutically acceptable salts thereof.
[0179] In an eighth embodiment, the present invention is directed
to a method to treat insulin resistance in a mammalian subject,
with or without weight loss, by the administration of a
therapeutically effective amount of a melanocortin receptor ligand
according to Formula (VIII) (see International Patent Application
Number PCT/US08/07411, incorporated herein by reference in its
entirety):
(R.sup.2R.sup.3)-A.sup.0-A.sup.1-c(A.sup.2-A.sup.3-A.sup.4-A.sup.5-A.sup-
.6-A.sup.7-A.sup.8-A.sup.9)-A.sup.10-R.sup.1 (VIII)
wherein:
[0180] A.sup.0 is an aromatic amino acid
[0181] A.sup.1 is Acc, HN--(CH.sub.2).sub.m(C(O), an L- or D-amino
acid;
[0182] A.sup.2 is Asp, Cys, D-Cys, hCys, D-hCys, Glu, Pen, or
D-Pen;
[0183] A.sup.3 is Aib, Ala, .beta.-Ala, Gaba, Gly or a D-amino
acid;
[0184] A.sup.4 is His, 2-Pal, 3-Pal, 4-Pal,
(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, Taz, 2-Thi, or
3-Thi;
[0185] A.sup.5 is D-Bal, D-1-Nal, D-2-Nal, D-Phe, L-Phe,
D-(X.sup.1,X.sup.2,X.sup.3,X.sup.4,X.sup.5)Phe, L-Phe, D-Trp or
D-(Et)Tyr;
[0186] A.sup.6 is Arg, hArg, Dab, Dap, Lys, Orn, or
HN--CH((CH.sub.2).sub.n--N(R.sup.4R.sup.5))--(C(O);
[0187] A.sup.7 is Bal, D-Bal, Bip, D-Bip, 1-Nal, D-1-Nal, 2-Nal,
D-2-Nal, or D-Trp;
[0188] A.sup.8 is Acc, Aha, Ahx, Ala, D-Ala, .beta.-Ala, Apn, Gaba,
Gly, HN--(CH.sub.2).sub.s--(C(O), or deleted;
[0189] A.sup.9 is Cys, D-Cys, hCys, D-hCys, Dab, Dap, Lys, Orn,
Pen, or D-Pen;
[0190] A.sup.10 is Acc, HN--(CH.sub.2).sub.t--(C(O), L- or D-amino
acid, or deleted;
[0191] R.sup.1 is OH, or NH.sub.2;
[0192] each of R.sup.2 and R.sup.3 is, independently for each
occurrence selected from the group consisting of H,
(C.sub.1-C.sub.30)alkyl, (C.sub.1-C.sub.30)heteroalkyl,
(C.sub.1-C.sub.30)acyl, (C.sub.2-C.sub.30)alkenyl,
(C.sub.2-C.sub.30)alkynyl, aryl(C.sub.1-C.sub.30)alkyl,
aryl(C.sub.1-C.sub.30)acyl, substituted (C.sub.1-C.sub.30)alkyl,
substituted (C.sub.1-C.sub.30)heteroalkyl, substituted
(C.sub.1-C.sub.30)acyl, substituted (C.sub.2-C.sub.30)alkenyl,
substituted (C.sub.2-C.sub.30)alkynyl, substituted
aryl(C.sub.1-C.sub.30)alkyl, and substituted
aryl(C.sub.1-C.sub.30)acyl;
[0193] each of R.sup.4 and R.sup.5 is, independently for each
occurrence, H, (C.sub.1-C.sub.40)alkyl,
(C.sub.1-C.sub.40)heteroalkyl, (C.sub.1-C.sub.40)acyl,
(C.sub.2-C.sub.40)alkenyl, (C.sub.2-C.sub.40)alkynyl,
aryl(C.sub.1-C.sub.40)alkyl, aryl(C.sub.1-C.sub.40)acyl,
substituted (C.sub.1-C.sub.40)alkyl, substituted
(C.sub.1-C.sub.40)heteroalkyl, substituted (C.sub.1-C.sub.40)acyl,
substituted (C.sub.2-C.sub.40)alkenyl, substituted
(C.sub.2-C.sub.40)alkynyl, substituted aryl(C.sub.1-C.sub.40)alkyl,
substituted aryl(C.sub.1-C.sub.40)acyl,
(C.sub.1-C.sub.40)alkylsulfonyl, or --C(NH)--NH.sub.2;
[0194] m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or
7;
[0195] n is, independently for each occurrence, 1, 2, 3, 4 or
5;
[0196] s is, independently for each occurrence, 1, 2, 3, 4, 5, 6,
or 7;
[0197] t is, independently for each occurrence, 1, 2, 3, 4, 5, 6,
or 7;
[0198] X.sup.1, X.sup.2, X.sup.3, X.sup.4, and X.sup.5 each is,
independently for each occurrence, H, F, Cl, Br, I,
(C.sub.1-10)alkyl, substituted (C.sub.1-10)alkyl,
(C.sub.2-10)alkenyl, substituted (C.sub.2-10)alkenyl,
(C.sub.2-10)alkynyl, substituted (C.sub.2-10)alkynyl, aryl,
substituted aryl, OH, NH.sub.2, NO.sub.2, or CN; provided that
[0199] (I). when R.sup.4 is (C.sub.1-C.sub.40)acyl,
aryl(C.sub.1-C.sub.40)acyl, substituted (C.sub.1-C.sub.40)acyl,
[0200] substituted aryl(C.sub.1-C.sub.40)acyl,
(C.sub.1-C.sub.40)alkylsulfonyl, or --C(NH)--NH.sub.2, then R.sup.5
is H or (C.sub.1-C.sub.40)alkyl, (C.sub.1-C.sub.40)heteroalkyl,
(C.sub.2-C.sub.40)alkenyl, (C.sub.2-C.sub.40)alkynyl,
aryl(C.sub.1-C.sub.40)alkyl, substituted (C.sub.1-C.sub.40)alkyl,
substituted (C.sub.1-C.sub.40)heteroalkyl, substituted
(C.sub.2-C.sub.40)alkenyl, substituted (C.sub.2-C.sub.40)alkynyl,
or substituted aryl(C.sub.1-C.sub.40)alkyl;
[0201] (II). when R.sup.2 is (C.sub.1-C.sub.30)acyl,
aryl(C.sub.1-C.sub.30)acyl, substituted (C.sub.1-C.sub.30)acyl, or
substituted aryl(C.sub.1-C.sub.30)acyl, then R.sup.3 is H,
(C.sub.1-C.sub.30)alkyl, (C.sub.1-C.sub.30)heteroalkyl,
(C.sub.2-C.sub.30)alkenyl, (C.sub.2-C.sub.30)alkynyl,
aryl(C.sub.1-C.sub.30)alkyl, substituted (C.sub.1-C.sub.30)alkyl,
substituted (C.sub.1-C.sub.30)heteroalkyl, substituted
(C.sub.2-C.sub.30)alkenyl, substituted (C.sub.2-C.sub.30)alkynyl,
or substituted aryl(C.sub.1-C.sub.30)alkyl;
[0202] (III). when A.sup.2 is Cys, D-Cys, hCys, D-hCys, Pen, or
D-Pen, then A.sup.9 is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen;
[0203] (IV). when A.sup.2 is Asp or Glu, then A.sup.9 is Dab, Dap,
Orn, or Lys;
[0204] (V). when A.sup.8 is Ala or Gly, then A.sup.1 is not Nle;
or
pharmaceutically acceptable salts thereof.
[0205] A preferred group of compounds of the immediate foregoing
formula useful to treat insulin resistance in a mammalian subject,
with or without weight loss, is wherein
[0206] A.sup.0 is 1-Nal, 2-Nal, His, Pff, Phe, Trp, or Tyr;
[0207] A.sup.1 is Arg;
[0208] A.sup.2 is Cys;
[0209] A.sup.3 is D-Ala;
[0210] A.sup.4 is His;
[0211] A.sup.5 is D-Phe
[0212] A.sup.6 is Arg;
[0213] A.sup.7 is Trp
[0214] A.sup.8 is deleted;
[0215] A.sup.9 is Cys; and
[0216] A.sup.10 is deleted;
or pharmaceutically acceptable salts thereof.
[0217] Preferred compounds of the immediately foregoing group of
compounds is which are useful to treat insulin resistance in a
mammalian subject, with or without weight loss, of the formula:
TABLE-US-00008 (SEQ ID NO: 292)
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; (SEQ ID NO:
292) Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)- NH.sub.2;
(SEQ ID NO: 292) Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-
NH.sub.2; (SEQ ID NO: 292)
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)- NH.sub.2; (SEQ ID
NO: 292) Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 292)
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; (SEQ ID NO:
293) H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; or (SEQ
ID NO: 292)
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
or pharmaceutically acceptable salts thereof.
[0218] In yet another preferred embodiment, the compound or
compounds of Formula (I), (II), (III), (IV), (V), (VI), (VII) or
(VIII) as defined hereinabove, which are useful to treat insulin
resistance in a mammalian subject, with or without weight loss, or
a pharmaceutically acceptable salt thereof, are provided to said
subject in need in a composition with a pharmaceutically acceptable
carrier or diluent.
[0219] In preferred embodiment, the invention provides a method of
treating insulin resistance in a subject in need thereof,
comprising peripheral administration of an effective amount of a
melanocortin receptor 4 agonist to treat the insulin resistance in
the subject in need thereof.
[0220] In one aspect, the melanocortin receptor 4 agonist useful to
treat insulin resistance with or without an accompanying reduction
in body weight in the subject in need thereof, is selected from the
group consisting of:
TABLE-US-00009 SEQ ID NO: 1
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ ID NO:
1 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH.sub.2; SEQ ID NO: 2
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH.sub.2; SEQ ID NO: 3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH.sub.2; SEQ ID NO: 3
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 3 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 2 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ
ID NO: 4 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH.sub.2; SEQ ID
NO: 5 Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO:
6 Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO:
6 Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 6
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-.beta.-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO:
7 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 7
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 8
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 8
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 8
Ac-Nle-c(D-Cys-.beta.-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 8 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 8 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 8 Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 9 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2; SEQ ID
NO: 9 Ac-Nle-c(Cys-.beta.-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 9 Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 9 Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 9 Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 10 Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 10
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2; SEQ ID NO:
10 Ac-Nle-c(D-Cys-.beta.-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2; SEQ
ID NO: 10 Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 10 Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH.sub.2;
SEQ ID NO: 11 Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 12
n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 11 Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 11 Ac-.beta.-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 11 Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 13 Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH.sub.2;
SEQ ID NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH.sub.2;
SEQ ID NO: 14
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ ID
NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH.sub.2; SEQ ID
NO: 14 Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH.sub.2; SEQ ID
NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-NH.sub.2;
SEQ ID NO: 15 Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH.sub.2;
SEQ ID NO: 16 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
SEQ ID NO: 16
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH.sub.2; SEQ ID NO:
16 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH.sub.2; SEQ ID
NO: 17
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH.sub.2; SEQ
ID NO: 17
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 18 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH.sub.2; SEQ ID
NO: 18 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH.sub.2; SEQ ID
NO: 18 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH.sub.2; SEQ ID
NO: 61 Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 19 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH.sub.2; SEQ ID
NO: 20 Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH.sub.2; SEQ ID
NO: 21 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID
NO: 22 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID
NO: 22 Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID
NO: 23
D-Phe-c(Cys-His-D-Phe-hArg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 24
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 25
D-Phe-c(Cys-His-D-Phe-Arg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 24
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 26
D-Phe-c(Cys-His-D-Phe-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2; SEQ
ID NO: 26
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-NH.sub.2;
SEQ ID NO: 27 Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ ID
NO: 28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH.sub.2; SEQ ID NO: 28
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH.sub.2; SEQ ID NO: 29
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 30
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 31
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 32
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 32
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 33
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 33
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 34
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 34
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 35
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 36
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO: 37
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH.sub.2; SEQ ID NO: 38
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-.beta.-Ala-Lys)-NH.sub.2; SEQ ID
NO: 39 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID
NO: 39 Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH.sub.2; SEQ ID
NO: 40 Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 40 Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH.sub.2; SEQ ID
NO: 41 Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-OH; SEQ ID
NO: 42 Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH; SEQ ID NO: 43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH; SEQ ID NO: 43
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-OH; SEQ ID NO:
43 D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH; SEQ ID NO: 42
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH; SEQ ID NO: 41
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH; SEQ ID NO: 44
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 44
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-OH; SEQ ID NO: 45
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH; SEQ ID NO: 46
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH; SEQ ID NO: 47
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO: 48
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH; SEQ ID NO: 49
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 50
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 50
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; SEQ ID NO: 51
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID NO: 52
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 52
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH.sub.2; SEQ ID NO: 51
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2; SEQ ID NO: 53
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH.sub.2; SEQ ID NO: 53
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH.sub.2; SEQ ID NO: 35
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2; SEQ ID NO: 54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH.sub.2; SEQ ID NO:
54 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH.sub.2; SEQ ID
NO: 54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-.beta.-Ala-Cys)-NH.sub.2; SEQ
ID NO: 54 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH.sub.2;
SEQ ID NO: 54
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH.sub.2; SEQ ID NO:
55 Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH.sub.2; SEQ ID NO: 55
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH.sub.2; SEQ ID NO: 56
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH.sub.2; SEQ ID NO: 56
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH.sub.2; SEQ ID NO: 57
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH.sub.2; SEQ ID NO:
57 Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-.beta.-Ala-Cys)-NH.sub.2;
SEQ ID NO: 58
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH.sub.2; (SEQ ID NO:
60)
Tyr-Gly-Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-Nle-c(Asp-His-D-2-Nal--
Arg-Trp-Lys)-NH.sub.2; (SEQ ID NO: 61)
Tyr-Gly-Arg-(Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-Doc-Nle-c(Asp-His-D-2--
Nal-Arg-Trp-Lys)- NH.sub.2; (SEQ ID NO: 62)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-Arg-(Lys).sub.2-(Arg-
).sub.2-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 62)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-Arg-(Lys).sub.2-(-
Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 63)
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-Arg-(Lys).sub.2-(Ar-
g).sub.2-Gln-(Arg).sub.3- NH.sub.2;
(SEQ ID NO: 64)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro).sub.2-Lys-Asp-Tyr-Gly-Arg-(Lys-
).sub.2-(Arg).sub.2- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 65)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro).sub.2-Lys-Asp-Tyr-Gly-Arg--
(Lys).sub.2- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO 66)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-Arg-(Lys)-
.sub.2-(Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 67)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro).sub.2-Lys-Asp-Doc-Tyr-Gly-Arg--
(Lys).sub.2- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 68)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro).sub.2-Lys-Asp-Doc-Tyr-Gly--
Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-Doc-Tyr-Gly--
Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
70)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-Arg-(Lys).sub.2--
(Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 72)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 73)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-G-
ly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 74)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 75)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-Arg-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO:
76)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-Gln-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 77)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- Lys-Gln-Lys-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 78)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.4-Gln-Arg-NH.sub.2; (SEQ ID NO:
79)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Aib-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 84)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 85)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.3-Gln-(Arg).sub.2-NH.sub.2; (SEQ
ID NO: 86)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- Gln-(Lys).sub.2-(Arg).sub.5-NH.sub.2; (SEQ ID NO: 87)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.5-Gln-NH.sub.2; (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg- (Lys).sub.2-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
89)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
90)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.2- Lys-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 91)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID
NO: 92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 95)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.2- Lys-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 96)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- Lys-(Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
97)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID
NO: 92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Gly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 98)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.2-Lys-
(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 99)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-Arg- Lys-(Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
104)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
105)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-A-
rg-Lys-(Arg).sub.3- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.2- Lys-(Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ
ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO:
102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-G-
ly-(Arg).sub.2-Lys- (Arg).sub.2-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID
NO: 103)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-G-
ly-Arg-Lys- (Arg).sub.3-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 113)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 114)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 115)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 116)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 118)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 119)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 120)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 121)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 122)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.6-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 124)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.6-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 125)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 126)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 127)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.6-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-
-Tyr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 128)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-
-Tyr-Gly- (Arg).sub.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 130)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-(-
Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 133)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 134)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.5- Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 135)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 135)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Arg-Asp-.beta.-Ala-T-
yr-Gly-(Arg).sub.6- Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-Arg-(Lys).su-
b.2-(Arg).sub.2-Gln-
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 137)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-Arg-(Lys).sub-
.2-Arg-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 136)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys).sub.2-(Arg-
).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 139)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 140)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.2-L-
ys-(Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-Arg-Lys-(Arg)-
.sub.3-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-(Arg).sub.2-Lys-(-
Arg).sub.2-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Gly-Arg-Lys-(Arg).sub-
.3-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 143)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.2-Lys-(Arg)-
.sub.2-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 144)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Arg-Lys-(Arg).sub.3-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 148)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3-NH.sub.2;; (SEQ ID NO: 149)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 150)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 151)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 152)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 153)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 154)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Gly-(Arg).sub-
.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 155)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).su-
b.4-NH.sub.2; (SEQ ID NO: 156)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 157)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln--
(Arg).sub.4-NH.sub.2; (SEQ ID NO: 158)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 159)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 160)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 161)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 162)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(Ar-
g).sub.3-NH.sub.2; (SEQ ID NO: 163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 163)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.3-
-NH.sub.2; (SEQ ID NO: 164)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.5-
-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 165)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(Ar-
g).sub.3-NH.sub.2; (SEQ ID NO: 166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub.-
3-NH.sub.2; (SEQ ID NO: 166)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).sub.3-NH-
.sub.2; (SEQ ID NO: 168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3-NH.sub-
.2; (SEQ ID NO: 167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 167)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 168)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub.-
3-NH.sub.2; (SEQ ID NO: 170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(Ar-
g).sub.4-NH.sub.2; (SEQ ID NO: 169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(Arg).s-
ub.4-NH.sub.2; (SEQ ID NO: 169)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.4-
-NH.sub.2; (SEQ ID NO: 170)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.5-
-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-Gly-(Arg).sub.5-Gln-
-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 171)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(Ar-
g).sub.4-NH.sub.2; (SEQ ID NO: 173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub.-
4-NH.sub.2; (SEQ ID NO: 172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg).sub.5-Gln-(Arg).sub.4-NH-
.sub.2; (SEQ ID NO: 172)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4-NH.sub-
.2; (SEQ ID NO: 173)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2; (SEQ ID NO: 174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-Gly-(Arg).sub.5-Gln-(Arg).-
sub.4-NH.sub.2; (SEQ ID NO: 174)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub.-
4-NH.sub.2; (SEQ ID NO: 175)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-.beta.-Ala-Tyr-Gly-(Arg).su-
b.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 176)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-.beta.-Ala-Lys)-.beta.-Ala-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 177)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 178)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 179)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gly-(Ar-
g).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 180)
D-Phe-c(Cys-His-D-Phe-Arg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).sub.5-
-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 181)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-
-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 182)
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).s-
ub.3-NH.sub.2; (SEQ ID NO: 183)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 184)
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 183)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 185)
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 186)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 185)
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).-
sub.3-NH.sub.2; (SEQ ID NO: 186)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 187)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 188)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 189)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 190)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 191)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 192)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 193)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 194)
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 195)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 196)
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 197)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 198)
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 199)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 200)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 201)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-.beta.-Ala-Tyr-Gly-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 202)
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-.beta.-Ala-Cys)-.beta.-Ala-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 203)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-.beta.-Ala-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 204)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(.beta.-Ala).sub.2-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 205)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 206)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 207)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc).sub.2-Gly-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 208)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-Tyr-Gly-(Ar-
g).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 210)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-(Arg).sub.5-
-Gln-(Arg).sub.3-NH.sub.2;
(SEQ ID NO: 209)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-Gly-(Arg).s-
ub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 211)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-.beta.-Ala-(Arg).sub.5-
-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 212)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-Tyr-
-Gly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-(Ar-
g).sub.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 213)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-Gly-
-(Arg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 267)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(.beta.-Ala).sub.2-(Ar-
g).sub.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-Tyr-Gly-(Arg).sub.-
5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 214)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-Gly-(Arg).sub.5-Gl-
n-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-Doc-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2; (SEQ ID NO: 215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-Tyr-Gly-(A-
rg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 216)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-(Arg).sub.-
5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 215)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-Gly-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 217)
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-.beta.-Ala-D-Cys)-(Doc).sub.2-(Arg).sub.-
5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 218)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-Tyr-Gly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 219)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-(Arg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 220)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 221)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-Tyr-G-
ly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).-
sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 222)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-Tyr-Gly-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 223)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-(Arg).sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-Doc-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 224)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-Tyr-G-
ly-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 225)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 226)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-Tyr-Gl-
y-(Arg).sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-.beta.-Ala-(Arg).-
sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 227)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-Tyr-Gly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 228)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(.beta.-Ala).sub.-
2-(Arg).sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 229)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 230)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)-
.sub.5-Gln- (Arg).sub.4-NH.sub.2; (SEQ ID NO: 232)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-Doc-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 231)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-Tyr-G-
ly-(Arg).sub.5-Gln- (Arg).sub.3-NH.sub.2; (SEQ ID NO: 232)
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-.beta.-Ala-D-Cys)-Thr-(Doc).sub.2-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 233)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 234)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.-
3-NH.sub.2; (SEQ ID NO: 235)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.-
5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 236)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(A-
rg).sub.3-NH.sub.2; (SEQ ID NO: 237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2; (SEQ ID NO: 238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub.-
4-NH.sub.2; (SEQ ID NO: 237)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub.-
5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 238)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(A-
rg).sub.4-NH.sub.2;
(SEQ ID NO: 239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub-
.3-NH.sub.2; (SEQ ID NO: 240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3-NH.su-
b.2; (SEQ ID NO: 239)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 240)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub-
.3-NH.sub.2; (SEQ ID NO: 241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).sub-
.4-NH.sub.2; (SEQ ID NO: 242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4-NH.su-
b.2; (SEQ ID NO: 241)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 242)
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).sub-
.4-NH.sub.2; (SEQ ID NO: 243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 243)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 244)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 245)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 246)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 247)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 248)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 249)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 250)
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.3-NH.sub.2; (SEQ ID NO: 251)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 252)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3--
NH.sub.2; (SEQ ID NO: 253)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.3- NH.sub.2; (SEQ ID NO: 254)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.3-NH.sub.2; (SEQ ID NO: 255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg)-
.sub.4-NH.sub.2; (SEQ ID NO: 255)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg)-
.sub.5-Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 256)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-G-
ln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4--
NH.sub.2; (SEQ ID NO: 257)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5--
Gln-(Arg).sub.4- NH.sub.2; (SEQ ID NO: 258)
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg-
).sub.4-NH.sub.2; (SEQ ID NO: 259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub-
.3-NH.sub.2; (SEQ ID NO: 259)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub-
.5-Gln-(Arg).sub.3-NH.sub.2; (SEQ ID NO: 260)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(-
Arg).sub.3-NH.sub.2; (SEQ ID NO: 261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-Tyr-Gly-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-.beta.-Ala-(Arg).sub.5-Gln-(Arg).sub-
.4-NH.sub.2; (SEQ ID NO: 261)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-Tyr-Gly-(Arg).sub-
.5-Gln-(Arg).sub.4-NH.sub.2; (SEQ ID NO: 262)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(.beta.-Ala).sub.2-(Arg).sub.5-Gln-(-
Arg).sub.4-NH.sub.2; (SEQ ID NO: 263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.3-NH.s-
ub.2; (SEQ ID NO: 263)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln--
(Arg).sub.3-NH.sub.2; (SEQ ID NO: 264)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).su-
b.3-NH.sub.2; (SEQ ID NO: 265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg).sub.5-Gln-(Arg).su-
b.4-NH.sub.2; (SEQ ID NO: 266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg).sub.5-Gln-(Arg).sub.4-NH.s-
ub.2; (SEQ ID NO: 265)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-Tyr-Gly-(Arg).sub.5-Gln--
(Arg).sub.4-NH.sub.2; (SEQ ID NO: 266)
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc).sub.2-(Arg).sub.5-Gln-(Arg).su-
b.4-NH.sub.2; (SEQ ID NO: 268)
Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-(Pro).sub.2-Lys-Asp-NH.sub.2;
(SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro).sub.2-Lys-Asp-NH.sub.2;
(SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-NH.sub.2;
(SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro).sub.2-Lys-Asp-NH.sub.2;
(SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro).sub.2-Lys-Asp-NH.sub.2;
(SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-.beta.-Ala-Cys)-(Pro).sub.2-Lys-Asp-NH.-
sub.2; (SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-(Pro).sub.2-Lys-Asp-NH.sub.2;
(SEQ ID NO: 271)
c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH.sub.2; (SEQ
ID NO: 271)
c[Hydantoin(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 272)
c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 272)
c[Hydantoin(C(O)-(hCys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH.sub.2; (SEQ
ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH.sub.2; (SEQ
ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH.sub.2; (SEQ
ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH.sub.2; (SEQ
ID NO: 275)
c[Hydantoin(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 274) c[Hydantoin(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH.sub.2;
(SEQ ID NO: 274)
c[Hydantoin(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 274) c[Hydantoin(C(O)-(Asp-A5c))-D-Phe-Arg-Trp-Lys]-NH.sub.2;
(SEQ ID NO: 274)
c[Hydantoin(C(O)-(Asp-A6c))-D-Phe-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 275) c[Hydantoin(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2;
(SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 275) c[Hydantoin(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2;
(SEQ ID NO: 275) c[Hydantoin
(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2; (SEQ ID NO: 274)
c[Hydantoin(C(O)-(Asp-Aic))-D-Phe-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 274) c[Hydantoin(C(O)-(Asp-Apc))-D-Phe-Arg-Trp-Lys]-NH.sub.2;
(SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 275) c[Hydantoin(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2;
(SEQ ID NO: 275)
c[Hydantoin-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 275)
c[Hydantoin-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH.sub.2; (SEQ ID
NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH.sub.2; (SEQ
ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH.sub.2; (SEQ
ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH.sub.2; (SEQ
ID NO: 277)
c[Hydantoin(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH.sub.2; (SEQ ID
NO: 278)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 280)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2;
(SEQ ID NO: 280)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 281)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 281)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 278)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 279)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 282)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 282)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 283)
Hydantoin(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 283)
Hydantoin(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 283)
Hydantoin(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 284)
Hydantoin(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 285)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 285)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 286)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 286)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 287)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 288)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 288)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 289)
Hydantoin(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2,
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 290)
c[Hydantoin(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 291)
c[Hydantoin(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH.sub.2;
(SEQ ID NO: 292)
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; (SEQ ID NO:
292) Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; (SEQ
ID NO: 292)
Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-NH.sub.2; (SEQ ID
NO: 292) Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
(SEQ ID NO: 292)
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; (SEQ ID NO:
292) Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2; (SEQ
ID NO: 293) H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
and (SEQ ID NO: 292)
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2;
or a pharmaceutically acceptable salt thereof.
[0221] In one preferred aspect, the melanocortin receptor 4 agonist
useful to treat insulin resistance in the subject in need thereof,
is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID
NO:50) or a pharmaceutically acceptable salt thereof. In another
preferred aspect, the melanocortin receptor 4 agonist useful to
treat insulin resistance in the subject in need thereof, is
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH.sub.2
(SEQ ID NO:278) or a pharmaceutically acceptable salt thereof.
[0222] In other aspects of the invention, administration of a
compound or composition comprising a compound or pharmaceutical
salt of a compound of the invention useful to treat insulin
resistance, is continuous, hourly, four times daily, three time
daily, twice daily, once daily, once every other day, twice weekly,
once weekly, once every two weeks, once a month, or once every two
months, or longer.
[0223] The subject in need of treatment may be obese, overweight,
of normal weight or lean. The obese, overweight, normal weight or
lean subject may suffer from type II diabetes. The preferred
administration of a compound or composition comprising a compound
or pharmaceutical salt of a compound of the invention useful to
treat insulin resistance, is peripheral administration. Examples of
peripheral administration include oral, subcutaneous,
intraperitoneal, intramuscular, intravenous, rectal, transdermal or
intranasal forms of administration.
BRIEF DESCRIPTION OF THE DRAWINGS
[0224] FIG. 1: Food consumed in fasted rats 6 hours after
administration of 100 nmole/Kg of selected compounds.
[0225] FIG. 2A. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of Compound A upon body weight in rats.
[0226] FIG. 2B. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of Compound A upon cumulative food intake in
rats.
[0227] FIG. 2C. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of Compound A upon insulin levels in rats.
[0228] FIG. 2D. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of Compound A upon glucose levels in rats.
[0229] FIG. 3A. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of Compound B upon body weight in rats.
[0230] FIG. 3B. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of
[0231] Compound B upon cumulative food intake in rats.
[0232] FIG. 3C. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of Compound B upon insulin levels in rats.
[0233] FIG. 3D. Effect of subcutaneous administration of 75, 300 or
1200 nmole/kg/day of Compound B upon glucose levels in rats.
[0234] FIG. 4. Effect of subcutaneous administration of 200, 600 or
1800 nmole/kg/day of Compound A upon blood glucose levels in
mice.
[0235] FIG. 5. Effect of intraperitoneal administration of 6.4
.mu.mole/kg of Compound A upon blood glucose levels in obese
mice.
DETAILED DESCRIPTION OF THE INVENTION
[0236] Recent studies have reported that staggering numbers of
people world wide are overweight and suffering a wide variety of
serious and expensive health problems. According the World Health
Organization (as reported in Kouris-Blazos et al., Asia Pac. J.
Clin. Nutr., 2007, 16:329-338), an estimated 1 billion people
throughout the world are overweight and an estimated 300 million of
these are obese. An estimated 22 million children under the age of
5 are severely overweight and in the European Union alone, the
number of children who are overweight is expected to rise by 1.3
million children per year (Kosti et al., 2006, Cent. Eur. J. Public
Health, 14:151-159). Obesity, as defined by the Statistical
Bulletin provided by the Metropolitan Life Insurance Co., (1959,
40:1), is a condition in which a person is approximately 20-25%
over normal body weight. Alternatively, an individual is considered
obese if the person has a body mass index of greater than 25% over
normal or greater than 30% over normal with risk factors (see Bray
et al., Diabetes/Metabolism Review, 1988, 4:653-679 or Flynn et
al., Proc. Nutritional Society, 1991, 50:413). One of the main
causes for obesity is the consumption of a high caloric diet
(Riccardi et al., Clin. Nutr., 2004, 23:447-456).
[0237] Diabetes is a chronic, debilitating disease afflicting many
overweight and obese people. It is estimated that 20.8 million
people in the United States alone have diabetes and more than 6
million more additional cases remain undiagnosed (Cornell, Manag.
Care Pharm., 2007, 13:S11-5). Type 2 diabetes (also referred to
herein as type II diabetes) is a chronic disease characterized by
insulin resistance, impaired insulin secretion and hyperglycemia.
Worldwide, type II diabetes is believed to affect approximately 171
million people, imparting numerous microvascular and macrovascular
complications resulting in morbidity and mortality (Mudaliar,
Indian J. Med. Res., 2007, 125:275-296). Mudaliar further notes
that despite the availability of anti-hyperglycaemic agents
available, control of glucose remains elusive in many patients.
[0238] Insulin resistance, also referred to as reduced insulin
sensitivity, is a condition in which the amount of insulin needed
to clear glucose from the blood of a subject is increased as
compared to the amount of insulin needed to clear the same amount
of glucose from the blood of a normal, non-insulin sensitive
subject. Insulin resistance is regarded as the main link between
obesity and type II diabetes (see Obici et al., J. Clin. Inv.,
2001, 108:1079-1085 and references therein). It is known that rats
fed a high fat diet show an increase in body weight (diet-induced
obesity or DIO) and a decrease in insulin sensitivity. Such DIO
rats provide an animal model in which to study the mechanisms of
insulin resistance due to obesity (see for example Banno et al.,
FEBS letters, 2007, 581:1131-1136). The size and weight of adipose
tissues are increased in DIO rats and it is thought that the
accompanying hypertrophy of adipocytes leads to changes in the
release of adipocytokines such as leptin and adiponectin which are
known to regulate insulin sensitivity; it is thought that
morphological changes in adipose tissue as well as changes in
plasma levels of adipocytokines are among the causes of insulin
resistance in DIO rats (summarized in Banno, et al., FEBS letters,
2007, 581:1131-1136 and references therein).
[0239] Melanocortins are proposed to play a large role in energy
metabolism and homeostasis. Melanocortins cleaved from the POMC
precursor exert their effects by binding to members of the
melanocortin receptor family located in the brain. The major effect
of melanocortin in the brain is to reduce food intake however, it
has also been shown that melanocortin agonists or antagonists
injected directly into the cerebral ventricle affect insulin
actions in the periphery while food was withdrawn or while food
intake was kept constant (see Schwartz et al., Nature, 2000,
404:661-671; Seeley et al., Ann. Rev. Nutr., 2004, 24:133-149; Cone
et al., Recent Prog. Horm. Res., 1996, 51:287-317; Heijbor et al.,
Diabetologia, 2005, 48:1621-1626; Obici et al., J. Clin. Inv.,
2001, 108:1079-1085). Taken together, these data suggest that
central administration of melanocortins affects insulin sensitivity
and may do so independently of energy balance. Banno et al., (FEBS
letters, 2007, 581:1131-1136) demonstrated that intracerebral
injections of a melanocortin agonist to DIO rats ameliorated
insulin sensitivity in the periphery, decreased the size of and
increased the number of adipocytes in white adipose tissue and
decreased triglycerides content in the liver.
[0240] Considering the large numbers of overweight and/or insulin
resistant subjects in need of treatment, intracerebral
administration is an unlikely means to disperse medicaments to
patients. There is a need in the art, therefore, to identify
melanocortin agonists and antagonists suitable for peripheral
administration to affect parameters of insulin action and energy
metabolism such as insulin sensitivity, cellular characteristics of
white adipose tissue, triglyceride levels and the like.
Nomenclature and Abbreviations
[0241] As used herein, an "obese subject" or mammal is
characterized as having a body weight approximately 20% or greater
than the normal body weight for said subject. Normal body weight
may be determined by a comparison of the weight of the subject at a
prior point in time, such as when insulin metabolism was normal, or
by a comparison of the weight of the subject as compared to
averages of other subjects of a similar age and/or condition.
[0242] As used herein, an "overweight subject" or mammal is
characterized as having a body weight approximately 5% greater to
approximately 20% greater than the normal body weight for said
subject. Normal body weight may be determined by a comparison of
the weight of the subject at a prior point in time, such as when
insulin metabolism was normal, or by a comparison of the weight of
the subject as compared to averages of other subjects of a similar
age and/or condition.
[0243] As used herein, a "normal subject" or mammal is
characterized as having a body weight up to approximately 5%
greater than to approximately 5% less than the normal body weight
for said subject. Normal body weight may be determined by a
comparison of the weight of the subject at a prior point in time,
such as when insulin metabolism was normal, or by a comparison of
the weight of the subject as compared to averages of other subjects
of a similar age and/or condition.
[0244] As used herein, a "lean subject" or mammal is characterized
as having a body weight approximately 5% to 30% or even to 50% less
than the normal body weight for said subject. Normal body weight
may be determined by a comparison of the weight of the subject at a
prior point in time, such as when insulin metabolism was normal, or
by a comparison of the weight of the subject as compared to
averages of other subjects of a similar age and/or condition.
[0245] As used herein, the terms "treat", "treating" and
"treatment" include palliative, curative and prophylactic
treatment.
[0246] As used herein, "measurable" means the biologic effect is
both reproducible and significantly different from the baseline
variability of the assay.
[0247] As used herein, peripherial administration includes all
forms of administration of a compound or a composition comprising a
compound of the instant invention which excludes intracranial
administration. Examples of peripheral administration include, but
are not limited to, oral, parenteral (e.g., intramuscular,
intraperitoneal, intravenous or subcutaneous injection, implant and
the like), nasal, vaginal, rectal, sublingual or topical routes of
administration, including transdermal patch applications and the
like.
[0248] A "subject", as used herein and throughout this application,
refers to a mammalian or non-mammalian animal including, for
example and without limitation, a human, a rat, a mouse or farm
animal. Reference to a subject does not necessarily indicate the
presence of a disease or disorder. The term "subject" includes, for
example, a mammalian or non-mammalian animal being dosed with a
melanocortin analog as part of an experiment, a mammalian or
non-mammalian animal being treated to help alleviate a disease or
disorder, and a mammalian or non-mammalian animal being treated
prophylactically to retard or prevent the onset of a disease or
disorder. Subject mammals may be human subjects of any age, such as
an infant, a child, an adult or an elderly adult.
[0249] A "therapeutically acceptable amount" of a compound or
composition of the invention, regardless of the formulation or
route of administration, is that amount which elicits a desired
biological response in a subject. The biological effect of the
therapeutic amount may occur at and be measured at many levels in
an organism. For example, the biological effect of the therapeutic
amount may occur at and be measured at the cellular level by
measuring the response at a receptor which binds melanocortin
and/or a melanocortin analog, or the biological effect of the
therapeutic amount may occur at and be measured at the system
level, such as effecting an increase/decrease in the levels of
insulin. The biological effect of the therapeutic amount may occur
at and be measured at the organism level, such as the alleviation
of a symptom(s) or progression of a disease or condition in a
subject. A therapeutically acceptable amount of a compound or
composition of the invention, regardless of the formulation or
route of administration, may result in one or more biological
responses in a subject. In the event that the compound or
composition of the invention is subject to testing in an in vitro
system, a therapeutically acceptable amount of the compound or
composition may be viewed as that amount which gives a measurable
response in the in vitro system of choice.
[0250] The nomenclature used to define the peptides is that
typically used in the art wherein the amino group at the N-terminus
appears to the left and the carboxyl group at the C-terminus
appears to the right. Where the amino acid has D and L isomeric
forms, it is the L form of the amino acid that is represented
unless otherwise explicitly indicated.
[0251] The compounds of the invention useful for the treatment of
insulin resistance, with or without weight loss, may possess one or
more chiral centers and so exist in a number of stereoisomeric
forms. All stereoisomers and mixtures thereof are included in the
scope of the present invention. Racemic compounds may either be
separated using preparative HPLC and a column with a chiral
stationary phase or resolved to yield individual enantiomers
utilizing methods known to those skilled in the art. In addition,
chiral intermediate compounds may be resolved and used to prepare
chiral compounds of the invention.
[0252] The compounds of the invention useful for the treatment of
insulin resistance, with or without weight loss, may exist in one
or more tautomeric forms. All tautomers and mixtures thereof are
included in the scope of the present invention. For example, a
claim to 2-hydroxypyridinyl would also cover its tautomeric form,
.alpha.-pyridonyl.
[0253] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Also,
all publications, patent applications, patents and other references
mentioned herein are incorporated by reference in their
entirety.
TABLE-US-00010 Symbol Meaning Abu .alpha.-aminobutyric acid Ac acyl
group Acc 1-amino-1-cyclo(C.sub.3-C.sub.9)alkyl carboxylic acid A3c
1-amino-1-cyclopropanecarboxylic acid A4c
1-amino-1-cyclobutanecarboxylic acid A5c
1-amino-1-cyclopentanecarboxylic acid A6c
1-amino-1-cyclohexanecarboxylic acid Aha 7-aminoheptanoic acid Ahx
6-aminohexanoic acid Aib .alpha.-aminoisobutyric acid Aic
2-aminoindan-2-carboxylic acid Ala or A alanine .beta.-Ala
.beta.-alanine Apc denotes the structure: ##STR00008## Apn
5-aminopentanoic acid (HN--(CH.sub.2).sub.4--C(O) Arg or R arginine
hArg homoarginine Asn or N asparagine Asp or D aspartic acid Bal
3-benzothienylalanine Bip 4,4'-biphenylalanine, represented by the
structure ##STR00009## Bpa 4-benzoylphenylalanine 4-Br--Phe
4-bromo-phenylalanine Cha .beta.-cydohexylalanine hCha
homo-cyclohexylalanine Chg cydohexylglycine Cys or C cysteine hCys
homocysteine Dab 2,4-diaminobutyric acid Dap 2,3-diaminopropionic
acid Dip .beta.,.beta.-diphenylalanine Doc
8-amino-3,6-dioxaoctanoic acid with the structure of: ##STR00010##
2-Fua .beta.-(2-furyl)-alanine Gaba 4-aminobutyric acid Gln or Q
glutamine Glu or E glutamic acid Gly or G glycine His or H
histidine 3-Hyp trans-3-hydroxy-L-proline, i.e., (2S, 3S)-
3-hydroxypyrrolidine-2-carboxylic acid 4-Hyp 4-hydroxyproline,
i.e., (2S, 4R)- 4-hydroxypyrrolidine-2-carboxylic acid Ile or I
isoleucine Leu or L leucine hLeu homoleucine Lys or K lysine Met or
M methionine .beta.-hMet .beta.-homomethionine 1-Nal
.beta.-(1-naphthyl)alanine: 2-Nal .beta.-(2-naphthyl)alanine Nip
nipecotic acid Nle norleucine Oic octahydroindole-2-carboxylic acid
Orn ornithine 2-Pal .beta.-(2-pyridiyl)alanine 3-Pal
.beta.-(3-pyridiyl)alanine 4-Pal .beta.-(4-pyridiyl)alanine Pen
penicillamine Pff (S)-pentafluorophenylalanine Phe or F
phenylalanine hPhe homophenylalanine Pro or P proline hPro
homoproline Ser or S serine Tle tert-Leucine Taz
.beta.-(4-thiazolyl)alanine 2-TN .beta.-(2-thienyl)alanine 3-TN
.beta.-(3-thienyl)alanine Thr or T threonine Trp or W tryptophan
Tyr or Y tyrosine D-(Et)Tyr has a structure of ##STR00011## Val or
V valine Certain other abbreviations used herein are defined as
follows: Boc: tert-butyloxycarbonyl Bzl: benzyl DCM:
dichloromethane DIC: N, N-diisopropylcarbodiimide DIEA:
diisopropylethyl amine Dmab:
4-{N-(1-(4,4-dimethy1-2,6-dioxocyclohexylidene)-
3-methylbutyl)-amino}benzyl DMAP: 4-(dimethylamino)pyridine DMF
dimethylformamide DNP: 2,4-dinitrophenyl Fm: fluorenylmethyl Fmoc:
fluorenylmethyloxycarbonyl For: formyl HBTU:
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate cHex cyclohexyl HOAT:
O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate HOBt: 1-hydroxy-benzotriazole MBHA
4-methylbenzhydrylamine Mmt: 4-methoxytrityl NMP:
N-methylpyrrolidone O-tBu oxy-tert-butyl Pbf:
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl PyBroP
bromo-tris-pyrrolidino-phosphonium hexafluorophosphate tBu:
tert-butyl TIS: triisopropylsilane TOS: tosyl Trt trityl TFA:
trifluoro acetic acid TFFH: tetramethylfluoroforamidinium
hexafluorophosphate Z: benzyloxycarbonyl
[0254] Unless otherwise indicated, with the exception of the
N-terminal amino acid, all abbreviations (e.g. Ala) of amino acids
in this disclosure stand for the structure of --NH--C(R)(R')--CO--,
wherein R and R' each is, independently, hydrogen or the side chain
of an amino acid (e.g., R=CH.sub.3 and R'=H for Ala), or R and R'
may be joined to form a ring system.
[0255] For the N-terminal amino acid, the abbreviation stands for
the structure of:
##STR00012##
[0256] The designation "NH.sub.2" in e.g.,
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO:7),
indicates that the C-terminus of the peptide is amidated.
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) (SEQ ID NO:36), or
alternatively Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH (SEQ ID
NO:36), indicates that the C-terminus is the free acid.
[0257] "-c(Cys-Cys)-" or "-cyclo(Cys-Cys)-" denotes the
structure:
##STR00013##
[0258] "-c(Cys-Pen)-" or "-cyclo(Cys-Pen)-" denotes the
structure:
##STR00014##
[0259] "-c(Asp-Lys)-" or "-cyclo(Asp-Lys)-" denotes the
structure:
##STR00015##
[0260] Applicants have devised the following shorthand used in
naming the specific embodiments and/or species:
[0261] "Hydantoin(C(O)-(A.sup.a-A.sup.b)" denotes the
structure:
##STR00016##
[0262] wherein amino acid "A.sup.a" has the structure:
##STR00017##
and
[0263] amino acid "A.sup.b" the structure:
##STR00018##
For example, a compound represented as
"c[Hydantoin(C(O)-(Cys-A.sup.b))-A.sup.1-A.sup.2-A.sup.3-A.sup.4-Cys]-"
would have the following the structure:
##STR00019##
whereas a compound represented as
"c[Hydantoin(C(O)-(A.sup.b-Cys))-A.sup.1-A.sup.2-A.sup.3-A.sup.4-Cys]-"
would have the structure:
##STR00020##
For further guidance,
"c[Hydantoin(C(O)-(Asp-A.sup.b))-A.sup.1-A.sup.2-A.sup.3-A.sup.4-Lys]-"
represents the following compound:
##STR00021##
whereas
"c[Hydantoin(C(O)-(Dap-A.sup.b))-A.sup.1-A.sup.2-A.sup.3-A.sup.4--
Asp]-" has the following formula:
##STR00022##
[0264] "Acyl" refers to R''--C(O)--, where R'' is H, alkyl,
substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl,
substituted alkenyl, aryl, alkylaryl, or substituted alklyaryl, and
is indicated in the general formula of a particular embodiment as
"Ac".
[0265] "Alkyl" refers to a hydrocarbon group containing one or more
carbon atoms, where multiple carbon atoms if present are joined by
single bonds. The alkyl hydrocarbon group may be straight-chain or
contain one or more branches or cyclic groups.
[0266] "Hydroxyalkyl" refers to an alkyl group wherein one or more
hydrogen atoms of the hydrocarbon group are substituted with one or
more hydroxy radicals, such as hydroxymethyl, hydroxyethyl,
hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl and the
like.
[0267] "Substituted alkyl" refers to an alkyl wherein one or more
hydrogen atoms of the hydrocarbon group are replaced with one or
more substituents selected from the group consisting of halogen,
(i.e., fluorine, chlorine, bromine, and iodine), --OH, --CN, --SH,
--NH.sub.2, --NHCH.sub.3, --NO.sub.2, and --C.sub.1-20 alkyl,
wherein said --C.sub.1-20 alkyl optionally may be substituted with
one or more substituents selected, independently for each
occurrence, from the group consisting of halogens, --CF.sub.3,
--OCH.sub.3, --OCF.sub.3, and --(CH.sub.2).sub.0-20--COOH. In
different embodiments 1, 2, 3 or 4 substituents are present. The
presence of --(CH.sub.2).sub.0-20--COOH results in the production
of an alkyl acid. Non-limiting examples of alkyl acids containing,
or consisting of, --(CH.sub.2).sub.0-20--COOH include 2-norbornane
acetic acid, tert-butyric acid, 3-cyclopentyl propionic acid, and
the like.
[0268] The term "halo" encompasses fluoro, chloro, bromo and
iodo.
[0269] "Heteroalkyl" refers to an alkyl wherein one of more of the
carbon atoms in the hydrocarbon group is replaced with one or more
of the following groups: amino, amido, --O--, --S-- or carbonyl. In
different embodiments 1 or 2 heteroatoms are present.
[0270] "Substituted heteroalkyl" refers to a heteroalkyl wherein
one or more hydrogen atoms of the hydrocarbon group are replaced
with one or more substituents selected from the group consisting of
halogen, (i.e., fluorine, chlorine, bromine, and iodine), --OH,
--CN, --SH, --NH.sub.2, --NHCH.sub.3, --NO.sub.2, and --C.sub.1-20
alkyl, wherein said --C.sub.1-20 alkyl optionally may be
substituted with one or more substituents selected, independently
for each occurrence, from the group consisting of halogens,
--CF.sub.3, --OCH.sub.3, --OCF.sub.3, and
--(CH.sub.2).sub.0-20--COOH. In different embodiments 1, 2, 3 or 4
substituents are present.
[0271] "Alkenyl" refers to a hydrocarbon group made up of two or
more carbons where one or more carbon-carbon double bonds are
present. The alkenyl hydrocarbon group may be straight-chain or
contain one or more branches or cyclic groups.
[0272] "Substituted alkenyl" refers to an alkenyl wherein one or
more hydrogens are replaced with one or more substituents selected
from the group consisting of halogen (i.e., fluorine, chlorine,
bromine, and iodine), --OH, --CN, --SH, --NH.sub.2, --NHCH.sub.3,
--NO.sub.2, and --C.sub.1-20 alkyl, wherein said --C.sub.1-20 alkyl
optionally may be substituted with one or more substituents
selected, independently for each occurrence, from the group
consisting of halogens, --CF.sub.3, --OCH.sub.3, --OCF.sub.3, and
--(CH.sub.2).sub.0-20--COOH. In different embodiments 1, 2, 3 or 4
substituents are present.
[0273] "Aryl" refers to an optionally substituted aromatic group
with at least one ring having a conjugated pi-electron system,
containing up to three conjugated or fused ring systems. Aryl
includes carbocylic aryl, heterocyclic aryl and biaryl groups.
Preferably, the aryl is a 5- or 6-membered ring. Preferred atoms
for a heterocyclic aryl are one or more sulfur, oxygen, and/or
nitrogen. Non-limiting examples of aryl include phenyl, 1-naphthyl,
2-naphthyl, indole, quinoline, 2-imidazole, 9-anthracene, and the
like. Aryl substituents are selected from the group consisting of
--C.sub.1-20 alkyl, --C.sub.1-20 alkoxy, halogen (i.e., fluorine,
chlorine, bromine, and iodine), --OH, --CN, --SH, --NH.sub.2,
--NO.sub.2, --C.sub.1-20 alkyl substituted with halogens,
--CF.sub.3, --OCF.sub.3, and --(CH.sub.2).sub.0-20--COOH. In
different embodiments the aryl contains 0, 1, 2, 3, or 4
substituents.
[0274] "Alkylaryl" refers to an "alkyl" joined to an "aryl".
[0275] The term "(C.sub.1-C.sub.12)hydrocarbon moiety" encompasses
alkyl, alkenyl and alkynyl and in the case of alkenyl and alkynyl
there is C.sub.2-C.sub.12.
[0276] For the avoidance of doubt, unless otherwise indicated, the
term substituted means substituted by one or more defined groups.
In the case where groups may be selected from a number of
alternative groups, the selected groups may be the same or
different. For the avoidance of doubt, the term independently means
that where more than one substituent is selected from a number of
possible substituents, those substituents may be the same or
different.
[0277] The pharmaceutically acceptable salts of the compounds of
the invention which contain a basic centre are, for example,
non-toxic acid addition salts formed with inorganic acids such as
hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric
acid, with carboxylic acids or with organo-sulfonic acids. Examples
include the HCl, HBr, HI, sulfate or bisulfate, nitrate, phosphate
or hydrogen phosphate, acetate, benzoate, succinate, saccharate,
fumarate, maleate, lactate, citrate, tartrate, gluconate,
camsylate, methanesulfonate, ethanesulfonate, benzenesulfonate,
p-toluenesulfonate and pamoate salts. Compounds of the invention
can also provide pharmaceutically acceptable metal salts, in
particular non-toxic alkali and alkaline earth metal salts, with
bases. Examples include the sodium, potassium, aluminum, calcium,
magnesium, zinc and diethanolamine salts (Berge, S. M. et al., J.
Pharm. Sci., 66:1-19 (1977); Gould, P. L., Int'l J. Pharmaceutics,
33:201-17 (1986); and Bighley, L. D. et al., Encyclo. Pharma.
Tech., Marcel Dekker Inc, New York, 13:453-97 (1996).
[0278] The pharmaceutically acceptable solvates of the compounds of
the invention include the hydrates thereof. Also included within
the scope of the invention and various salts of the invention are
polymorphs thereof. Hereinafter, compounds their pharmaceutically
acceptable salts, their solvates or polymorphs, defined in any
aspect of the invention (except intermediate compounds in chemical
processes) are referred to as "compounds of the invention".
In Vitro Studies
[0279] Compounds of the present invention can be and were tested
for activity as ligands of one or more of the melanocortin
receptors according to the following procedures. One skilled in the
art would know that procedures similar to those described herein
may be used to assay the binding activities of the compounds of the
invention to melanocortin receptor molecules.
Radioligand Binding Assays
[0280] Cellular membranes used for the in vitro receptor binding
assays were obtained from transgenic CHO-K1 cells stably expressing
hMC-R receptor subtypes 1, 3, 4 or 5. The CHO-K1 cells expressing
the desired hMC-R receptor type were sonicated (Branson.RTM.
setting 7, approximately 30 sec) in ice-cold 50 mM Tris-HCl at pH
7.4 and then centrifuged at 39,000 g for 10 minutes at
approximately 4.degree. C. The pellets were resuspended in the same
buffer and centrifuged at 50,000 g for 10 minutes at approximately
4.degree. C. The washed pellets containing the cellular membranes
were stored at approximately -80.degree. C.
[0281] Competitive inhibition of
[.sup.125I](Tyr.sup.2)-(Nle.sup.4-D-Phe.sup.7).alpha.-MSH
([.sup.125I]-NDP-.alpha.-MSH, Amersham Biosciences.RTM.) binding
was carried out in polypropylene 96 well plates. Cell membranes
(1-10 .mu.g protein/well) prepared as described above were
incubated in 50 mM Tris-HCl at pH 7.4 containing 0.2% bovine serum
albumin (BSA), 5 mM MgCl.sub.2, 1 mM CaCl.sub.2 and 0.1 mg/mL
bacitracin, with increasing concentrations of the test compound and
0.1-0.3 nM [.sup.125I]-NDP-.alpha.-MSH for approximately 90-120
minutes at approximately 37.degree. C. Bound
[.sup.125I]-NDP-.alpha.-MSH ligand was separated from free
[.sup.125I]-NDP-.alpha.-MSH by filtration through GF/C glass fiber
filter plates (Unifilter.RTM.; Packard) presoaked with 0.1% (w/v)
polyethylenimine (PEI), using a Packard Filtermate.RTM. harvester.
Filters were washed three times with 50 mM Tris-HCl at pH 7.4 at a
temperature of approximately 0-4.degree. C. and then assayed for
radioactivity using a Packard Topcount.RTM. scintillation counter.
Binding data were analyzed by computer-assisted non-linear
regression analysis (XL fit; IDBS). A selection of the preferred
embodiments was tested using the above-discussed assay and the
binding constants (Ki in nM) are reported in Tables 5, 6, 7 and
8.
TABLE-US-00011 TABLE 5 Radioligand Binding Assay Data for Selected
Compounds Ki Ki Ki Ki Ki hMC1-R/ SEQ ID Compound hMC1-R hMC3-R
hMC4-R hMC5-R MC4-R NO: Ac-Arg-c(Cys-D-Ala-His-D- 3.87 10.1 2.09
430 1.9 SEQ ID Phe-Arg-Trp-Cys)-NH.sub.2 NO: 50
Ac-D-Arg-c(Cys-D-Ala-His- 4.01 12.1 1.76 352 2.3 SEQ ID
D-Phe-Arg-Trp-Cys)-NH.sub.2 NO: 50 Ac-D-Arg-c(Cys-D-Ala-His- 8.29
13.3 2.78 816 3.0 SEQ ID D-Phe-Arg-Trp-Pen)-NH.sub.2 NO: 51
Ac-D-Arg-c(Cys-His-D-Phe- 3.93 172 11.0 538 0.36 SEQ ID
Arg-Trp-Gaba-Pen)-NH.sub.2 NO: 52 Ac-Arg-c(Cys-His-D-Phe- 1.81 20.5
4.57 502 0.4 SEQ ID Arg-Trp-Gaba-Pen)-NH.sub.2 NO: 52
Ac-Arg-c(Cys-D-Ala-His-D- 9.67 22.0 4.2 1900 2.3 SEQ ID
Phe-Arg-Trp-Pen)-NH.sub.2 NO: 51 Ac-D-Arg-c(Asp-His-D- 0.79 45.5
1.21 493 0.6 SEQ ID Phe-Arg-Trp-Ala-Lys)-NH.sub.2 NO: 53
Ac-Arg-c(Asp-His-D-Phe- 0.68 20.7 1.01 783 0.7 SEQ ID
Arg-Trp-Ala-Lys)-NH.sub.2 NO: 53 Ac-Nle-c(Cys-D-Ala-His-D- 114 63.9
3.07 1657 37.1 SEQ ID 2-Nal-Arg-1-Nal-Cys)-NH.sub.2 NO: 16
Ac-Nle-c(Cys-D-Ala-His-D- 11 26 7.6 1800 1.4 SEQ ID
Phe-Arg-Trp-Cys)-NH.sub.2 NO: 7 D-Phe-c(Cys-His-D-(Et)Tyr- 0.05 9.3
1.1 2.9 0.0 SEQ ID Arg-Trp-.beta.-Ala-D-Cys)-Thr- NO: 24 NH.sub.2
Nle-c(Cys-His-D-Phe-Arg- 0.07 4.1 0.85 8.8 0.1 SEQ ID
Trp-Apn-Cys)-NH.sub.2 NO: 27 Ac-Nle-c(Cys-His-D-Phe- 0.12 10 0.43
0.42 0.3 SEQ ID Arg-Trp-Gaba-Pen)-NH.sub.2 NO: 32
Nle-c(Cys-His-D-Phe-Arg- 0.05 1.3 0.47 0.2 0.1 SEQ ID
Trp-Gaba-Cys)-NH.sub.2 NO: 34 Ac-Nle-c(Asp-His-D-Phe- 0.0996 9318
0.617 10.9 0.16 SEQ ID Arg-Trp-.beta.-Ala-Lys)-NH.sub.2 NO: 1
Ac-Nle-c(Cys-His-D-Phe- .0132 16.1 1.23 0.359 0.11 SEQ ID
Arg-Trp-Ahx-Cys)-NH.sub.2 NO: 2 D-Phe-c(Cys-His-D-Phe- 0.207 43.2
2.58 344 0.08 SEQ ID Arg-Trp-.beta.-Ala-D-Cys)-Thr- NO: 3 NH.sub.2
D-Phe-c(Cys-His-D-Phe- 0.420 106 4.75 1260 0.09 SEQ ID
Arg-Trp-Gaba-D-Cys)-Thr- NO: 3 NH.sub.2 Ac-Nle-c(Cys-His-D-Phe-
0.0951 9.33 0.894 13.4 0.11 SEQ ID Arg-Trp-Apn-Cys)-NH.sub.2 NO: 2
Ac-Nle-c(Asp-His-D-Phe- 0.999 300 11.1 431 0.09 SEQ ID
Arg-Trp-Apn-Lys)-NH.sub.2 NO: 4 Ac-Cha-c(Asp-His-D-Phe- 0.106 11.8
1.49 110 0.07 SEQ ID Arg-Trp-Gaba-Lys)-NH.sub.2 NO: 6
Ac-Nle-c(Asp-His-D-Phe- 0.0506 9.89 1.04 16.3 0.05 SEQ ID
Arg-Trp-Gaba-Lys)-NH.sub.2 NO: 6 Ac-Chg-c(Asp-His-D-Phe- 0.884 223
22.5 609 0.04 SEQ ID Arg-Trp-Gaba-Lys)-NH.sub.2 NO: 11
Ac-hCha-c(Asp-His-D-Phe- 0.721 93.5 56.0 747 0.01 SEQ ID
Arg-Trp-Gaba-Lys)-NH.sub.2 NO: 11 Ac-D-Chg-c(Asp-His-D- 0.227 14.5
2.99 164 0.08 SEQ ID Phe-Arg-Trp-Gaba-Lys)- NO: 11 NH.sub.2
Ac-hPhe-c(Asp-His-D-Phe- 0.277 25.2 3.37 203 0.08 SEQ ID
Arg-Trp-Gaba-Lys)-NH.sub.2 NO: 11 Ac-Nle-c(Cys-His-D-Phe- 0.323
14.1 1.96 24.0 0.16 SEQ ID Arg-D-Trp-.beta.-Ala-Cys)-NH.sub.2 NO:
15 Ac-Nle-c(Pen-D-Ala-His-D- 34.1 118 17.0 5560 2.01 SEQ ID
Phe-Arg-Trp-Cys)-NH.sub.2 NO: 21 Ac-Nle-c(Cys-D-Ala-His-D- 29.1
22.8 3.84 2550 7.58 SEQ ID Phe-Arg-Trp-Pen)-NH.sub.2 NO: 22
D-Phe-c(Cys-His-D-Phe- 0.442 123 10.3 521 0.04 SEQ ID
hArg-Trp-.beta.-Ala-D-Cys)- NO: 23 Thr-NH.sub.2
D-Phe-c(Cys-His-D-Phe- 5.80 3370 583 1130 0.01 SEQ ID
Arg-Bip-.beta.-Ala-D-Cys)-Thr- NO: 25 NH.sub.2
D-Phe-c(Cys-His-D-(Et)Tyr- 0.0567 31.4 14.7 9.27 0 SEQ ID
hArg-Trp-.beta.-Ala-D-Cys)- NO: 24 Thr-NH.sub.2
D-Phe-c(Cys-His-D-Phe- 1.68 1260 172 1220 0.01 SEQ ID
hArg-Bip-.beta.-Ala-D-Cys)- NO: 26 Thr-NH.sub.2
D-Phe-c(Cys-His-D-(Et)Tyr- 0.128 85.6 36.9 38.0 0 SEQ ID
hArg-Bip-.beta.-Ala-D-Cys)- NO: 26 Thr-NH.sub.2
Ac-Nle-c(Cys-D-Ala-His-D- 0.352 149 3.01 339 0.12 SEQ ID
Phe-Arg-Trp-Gly-Cys)-NH.sub.2 NO: 54 Ac-Nle-c(Cys-D-Ala-His-D- 3.93
876 48.0 4940 0.08 SEQ ID Phe-Arg-Trp-D-Ala-Cys)- NO: 54 NH.sub.2
Ac-Nle-c(Cys-D-Ala-His-D- 0.995 287 4.80 766 0.21 SEQ ID
Phe-Arg-Trp-.beta.-Ala-Cys)- NO: 54 NH.sub.2
Ac-Nle-c(Cys-D-Ala-His-D- 0.848 184 3.76 956 0.23 SEQ ID
Phe-Arg-Trp-Gaba-Cys)- NO: 54 NH.sub.2 Ac-Nle-c(Cys-D-Ala-His-D-
1.10 228 7.58 859 0.15 SEQ ID Phe-Arg-Trp-Apn-Cys)- NO: 54 NH.sub.2
Ac-Nle-c(Asp-D-Ala-His-D- 0.659 98.9 2.55 4.19 0.26 SEQ ID
Phe-Arg-Trp-Lys)-NH.sub.2 NO: 28 Ac-Nle-c(Asp-D-Ala-His-D- 4.12 445
50.6 4300 0.08 SEQ ID Phe-Arg-Bal-Lys)-NH.sub.2 NO: 28
Ac-c(Cys-Glu-His-D-Phe- 111 1710 47.7 694 2.33 SEQ ID
Arg-Trp-Ala-Cys)-NH.sub.2 NO: 55 Ac-c(Cys-Glu-His-D-Phe- 262 2500
96.4 1460 2.72 SEQ ID Arg-2-Nal-Ala-Cys)-NH.sub.2 NO: 55
Ac-c(Cys-D-Ala-His-D-Phe- 199 5990 96.7 >10000 2.06 SEQ ID
Arg-Trp-Ala-Cys)-NH.sub.2 NO: 56 Ac-c(Cys-D-Ala-His-D-Phe- 132 4560
40.7 8810 3.24 SEQ ID Arg-2-Nal-Ala-Cys)-NH.sub.2 NO: 56
Ac-Nle-c(Cys-D-Ala-His-D- 9.12 1130 22.1 2860 0.41 SEQ ID
Phe-Arg-Trp-Ala-Cys)-NH.sub.2 NO: 57 Ac-Nle-c(Cys-D-Ala-His-D- 1.00
227 5.55 496 0.18 SEQ ID Phe-Arg-Trp-.beta.-Ala-Cys)- NO: 57
NH.sub.2 Ac-Nle-c(Cys-D-Ala-His-D- 0.536 169 3.12 358 0.17 SEQ ID
Phe-Arg-Trp-Gaba-Cys)- NO: 57 NH.sub.2 Ac-Nle-c(Cys-D-Ala-His-D-
32.1 330 17.4 165 1.84 SEQ ID Phe-Arg-Trp-Pen)-OH NO: 29
Ac-Nle-c(Cys-D-Abu-His- 10.6 41.1 7.69 54.9 1.38 SEQ ID
D-Phe-Arg-Trp-Cys)-NH.sub.2 NO: 30 Ac-Nle-c(Cys-D-Val-His-D- 13.0
104 10.1 40 1.29 SEQ ID Phe-Arg-Trp-Cys)-NH.sub.2 NO: 30
Ac-Nle-c(Cys-D-Ile-His-D- 4.28 38.5 9.0 12.5 0.48 SEQ ID
Phe-Arg-Trp-Cys)-NH.sub.2 NO: 30 Ac-Nle-c(Cys-D-Leu-His-D- 1.60
6.82 4.13 5.57 0.39 SEQ ID Phe-Arg-Trp-Cys)-NH.sub.2 NO: 30
Ac-Nle-c(Cys-D-Tle-His-D- 12.0 85.8 11.2 40 1.07 SEQ ID
Phe-Arg-Trp-Cys)-NH.sub.2 NO: 30 Ac-Nle-c(Cys-D-Cha-His-D- 0.353
2.08 1.41 0.857 0.25 SEQ ID Phe-Arg-Trp-Cys)-NH.sub.2 NO: 30
Ac-Nle-c(Pen-His-D-Phe- 0.537 86.1 5.89 2.56 0.09 SEQ ID
Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 31 Ac-Nle-c(Pen-His-D-Phe- 0.744 178
3.51 2.69 0.21 SEQ ID Arg-Trp-Gaba-Pen)-NH.sub.2 NO: 32
Ac-Leu-c(Cys-His-D-Phe- 0.216 17.4 0.995 0.486 0.22 SEQ ID
Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 33 Ac-Cha-c(Cys-His-D-Phe- 0.107
9.11 0.884 0.354 0.12 SEQ ID Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 33
Ac-Ile-c(Cys-His-D-Phe- 0.148 13.9 1.06 0.423 0.14 SEQ ID
Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 33 Ac-Phe-c(Cys-His-D-Phe- 0.254
18.5 2.13 0.714 0.12 SEQ ID Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 33
Ac-Val-c(Cys-His-D-Phe- 0.256 29.9 1.98 0.864 0.13 SEQ ID
Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 33 Ac-2-Nal-c(Cys-His-D-Phe- 0.560
39.2 2.94 2.73 0.19 SEQ ID Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 33
Phe-c(Cys-His-D-Phe-Arg- 0.186 15.2 4.93 0.537 0.04 SEQ ID
Trp-Gaba-Cys)-NH.sub.2 NO: 34 Ac-Nle-c(Cys-3-Pal-D-Phe- 21.1 151
10.4 92.6 2.03 SEQ ID Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 35
Ac-Nle-c(Cys-D-Ala-His-D- 30.7 152 15.6 114 1.97 SEQ ID
Phe-Arg-Trp-Cys)-OH NO: 36 Ac-Nle-c(Cys-His-Phe-Arg- 5.20 150 138
20.3 0.04 SEQ ID D-Trp-Gaba-Cys)-NH.sub.2 NO: 37
Ac-Nle-c(Asp-D-Ala-His-D- 4.89 290 21.3 11.1 0.23 SEQ ID
Phe-Arg-Bal-Ala-Lys)-NH.sub.2 NO: 58 Ac-Nle-c(Cys-D-Ala-His-D- 25.5
3.82 7.61 102 3.35 SEQ ID 2-Nal-Arg-Trp-Cys)-NH.sub.2 NO: 16
Ac-Nle-c(Cys-D-Ala-His-D- 32.5 5.85 2.53 94.6 12.85 SEQ ID
2-Nal-Arg-2-Nal-Cys)-NH.sub.2 NO: 16 Ac-Nle-c(Cys-D-Ala-His-D- 22.2
12.7 16.6 125 1.34 SEQ ID 2-Nal-Arg-Bal-Cys)-NH.sub.2 NO: 20
Ac-Nle-c(Asp-His-D-2-Nal- 1.17 1.56 0.277 3.24 4.22 SEQ ID
Arg-Trp-Ala-Lys)-NH.sub.2 NO: 38 Ac-Nle-c(Asp-His-D-2-Nal- 0.648
2.78 0.329 1.4 1.97 SEQ ID Arg-Trp-.beta.-Ala-Lys)-NH.sub.2 NO: 38
Ac-Nle-c(Cys-His-D-2-Nal- 0.393 1.86 0.375 1.11 1.05 SEQ ID
Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 39 Ac-Nle-c(Cys-His-D-2-Nal- 0.333
2.91 0.998 0.366 0.33 SEQ ID Arg-Trp-Ahx-Cys)-NH.sub.2 NO: 39
Ac-hPhe-c(Asp-His-D-2- 0.461 2.45 0.931 1.37 0.50 SEQ ID
Nal-Arg-Trp-Gaba-Lys)- NO: 40 NH.sub.2
Ac-Cha-c(Asp-His-D-2-Nal- 0.576 3.98 2.82 3.91 0.20 SEQ ID
Arg-Trp-Gaba-Lys)-NH.sub.2 NO: 40 Ac-Arg-c(Cys-D-Ala-His-D- 17.9
1.68 0.256 23.4 69.9 SEQ ID 2-Nal-Arg-Trp-Cys)-NH.sub.2 NO: 49
TABLE-US-00012 TABLE 6 Radioligand Binding Assay Data for Selected
Compounds Ki Ki Ki Ki Compound hMC1-R hMC3-R hMC4-R hMC5-R
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 49.9 9.00 0.569 218
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269)
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg- 11.9 38.1 5.70 11.8
Arg-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- NH.sub.2 (SEQ ID NO: 60)
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg- 3.46 16.6 6.65 4.88
Arg-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp- Lys)-NH.sub.2 (SEQ ID NO:
61) Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.-Ala- 0.614 5.09 2.31
3.23 Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg- Arg-NH.sub.2 (SEQ ID
NO: 62) Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.- 1.56 14.1
5.17 7.12 Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg- Arg-Arg-NH.sub.2
(SEQ ID NO: 62) H-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-Doc- 1.10 1.58
6.00 0.629 Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-
Arg-Arg-NH.sub.2 (SEQ ID NO: 63)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- 0.0868 0.751 0.0944 0.147
Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-Lys-Arg-
Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 64)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly- 1.66 4.80 0.250 9.62
Cys)-Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 65)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.- 0.0452 0.298 0.169
0.386 Ala-.beta.-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 66)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- 0.0808 0.396 0.0747 0.311
Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 67)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly- 4.41 4.23 0.455 12.9
Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 68)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 1.25 0.661 0.292 5.94
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 1.89 0.546 0.166 6.06
Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 87.8 9.08 1.20 359
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 124 17.8 1.11 348
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 163 23.0 0.586 844
Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- 0.144 0.352 0.0845 0.415
Doc-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln- Arg-Arg-Arg-NH.sub.2 (SEQ
ID NO: 701) Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 1.74 0.590
0.170 4.38 Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 3.86 4.97 0.192 38.3
Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-Arg-
Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 12.8 15.9 0.950 165
Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 73)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 3.07 4.05 0.498 31.1
Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 74)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 0.792 0.570 0.162 4.18
Cys)-Pro-Pro-Lys-Asp-.beta.Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Gln-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 75)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 0.726 0.474 0.209 5.12
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Gln-Arg-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 76)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 0.857 0.580 0.209 4.42
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Gln-Lys-Arg-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 77)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 0.813 0.675 0.269 4.20
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Arg-Arg-Gln-Arg-NH.sub.2 (SEQ ID NO: 78)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 7.84 10.2 0.783 91.8
Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Aib-Arg-Lys-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 79)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 2.93 9.07 0.293 59.0
Cys)-Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 2.42 6.56 0.238 41.7
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 6.66 19.3 0.819 88.8
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 2.63 2.09 0.0737 11.6
Cys)-Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 2.48 1.21 0.209 9.17
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 3.65 2.26 0.261 12.1
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 7.32 11.0 0.659 78.0
Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2(SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 4.11 7.26 0.302 48.3
Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-Arg-
Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 84)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 6.77 14.3 0.781 84.0
Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2(SEQ ID NO: 283)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 3.04 3.22 0.230 3.85
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Arg-Gln-Arg-Arg-NH.sub.2 (SEQ ID NO: 2685)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 3.24 2.66 0.208 5.96
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Gln-Lys-Lys-Arg-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 86)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 1.58 1.43 0.275 2.97
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Arg-Arg-Arg-Gln-NH.sub.2 (SEQ ID NO: 87)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 4.59 6.28 0.588 22.6
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 6.46 5.22 0.380 15.3
Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-Lys-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 4.62 5.68 0.505 45.3
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 2.12 3.99 0.352 27.5
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Lys-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 89)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 3.41 0.975 0.549 11.3
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 4.18 1.12 0.223 15.3
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 90)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 2.71 0.732 0.202 5.53
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 91)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 5.66 1.40 0.446 6.23
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Lys-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 92)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.211 0.665 0.635 118
Cys)-(Doc)2-Tyr-Gly-Arg-Lys-Lys-Arg-Arg- Gln-Arg-Arg-Arg-NH.sub.2
(SEQ ID NO: 136) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.351 0.891
0.503 102 Cys)-.beta.-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-
Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 137)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.209 0.699 0.596 137
Cys)-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg- Gln-Arg-Arg-Arg-NH.sub.2(SEQ
ID NO: 136) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.439 1.52 0.476
115 Cys)-.beta.-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln-
Arg-Arg-Arg-NH.sub.2(SEQ ID NO: 138)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.821 2.50 0.700 148
Cys)-.beta.-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg- Arg-Arg-NH.sub.2(SEQ
ID NO: 138) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.406 1.11 0.602
131 Cys)-.beta.-Ala-Tyr-Gly-Arg-Arg-Arg-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 139)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 1.27 4.63 1.51 220
Cys)-.beta.-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln-
Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 139)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-.beta.-Ala- 2058 113 10.7 239
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib- 1818 306 5.87 979
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 1.75 1.74 0.15 16.8
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 95)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 1.50 1.61 0.301 10.4
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 96)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 1.81 2.08 0.305 19.3
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 97)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 2.69 2.59 0.243 19.2
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Lys-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 2.25 0.62 0.303 2.77
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Lys-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 99)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 1.49 0.604 0.865 3.13
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg- NH.sub.2(SEQ ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 3.28 1.95 0.575 15.5
Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Lys-Arg-Arg-
Arg-Gln-Arg-Arg-Arg-NH.sub.2(SEQ ID NO: 105)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 2.24 1.57 0.437 16.4
Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-Arg-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 2.14 1.12 0.624 11.9
Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-Lys-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 2.50 1.59 0.573 15.7
Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 3.00 1.70 0.442 15.5
Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Lys-Arg-
Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 104)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)- 4.29 2.15 0.425 15.5
Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Lys-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 103)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.410 0.837 0.246 56.3
Cys)-.beta.-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.572 1.07 0.210 63.6
Cys)-.beta.-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.475 0.800 0.196 53.8
Cys)-.beta.-Ala-Gly-Arg-Arg-Lys-Arg-Arg-Gln- Arg-Arg-Arg-NH.sub.2
(SEQ ID NO: 141) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.779 1.21
0.293 56.0 Cys)-.beta.-Ala-Gly-Arg-Lys-Arg-Arg-Arg-Gln-
Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.212 1.23 0.484 58.5
Cys)-.beta.-Ala-Arg-Arg-Lys-Arg-Arg-Gln-Arg- Arg-Arg-NH.sub.2 (SEQ
ID NO: 143) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.778 1.22 0.468
47.0 Cys)-.beta.-Ala-Arg-Lys-Arg-Arg-Arg-Gln-Arg- Arg-Arg-NH.sub.2
(SEQ ID NO: 144)
TABLE-US-00013 TABLE 7 Binding Constants for Formula (V) Examples
Ki Ki Ki Ki Formula (V) Compounds hMC1 hMC3 hMC4 hMC5
c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-Phe- 230 7590 126 7020
Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 271)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe- 72.6 1920 45.2 >10000
Arg-Trp-Lys]-NH.sub.2 (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe- 60.4 2840 52.4 >10000
Arg-Trp-Orn]-NH.sub.2 (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe- 28 90.5 12.7 877
Arg-Trp-Dab]-NH.sub.2 (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe- 16.4 863 4.97 >10000
Arg-Trp-Dap]-NH.sub.2 (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe- 37.7 576 7.81 6400
Arg-Trp-Orn]-NH.sub.2 (SEQ ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D-Phe- 66.6 1820 19.9 >10000
Arg-Trp-Dap]-NH.sub.2 (SEQ ID NO: 273)
c[Hydantoin(C(O)-(Asp-His))-D-2-Nal-Arg- 200 68.8 6.63 142
Trp-Lys]-NH.sub.2 (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-Aic))-D-2-Nal-Arg- 9028 2628 35.8 1156
Trp-Lys]-NH.sub.2 (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-A5c))-D-2-Nal-Arg- 9938 2390 44.6 1103
Trp-Lys]-NH.sub.2 (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-A6c))-D-2-Nal-Arg- 2170 1479 16.5 451
Trp-Lys]-NH.sub.2 (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-Apc))-D-2-Nal-Arg- 1276 2756 266 1096
Trp-Lys]-NH.sub.2 (SEQ ID NO: 275)
c[Hydantoin(C(O)-(Asp-A3c))-D-2-Nal-Arg- 7567 1922 420 2879
Trp-Lys]-NH.sub.2 (SEQ ID NO: 275) Formula (V) Compounds hMC1 hMC3
hMC4 hMC5 Binding Constants for Formula (VI) Examples Ki Ki Ki Ki
Formula (VI) Compounds hMC1 hMC3 hMC4 hMC5
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His-D- 14.3 198 5.76 67.8
Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His-D- 11.9 311 5.41 73.9
Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(A6c-Nle))-c(Cys-D-Ala-His- 31.6 224 19.6 2500
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(D-Ala-Nle))-c(Cys-D-Ala- 16.0 63.9 8.64 1820
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Val-Nle))-c(Cys-D-Ala-His- 33.7 132 40.2 3210
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Leu-Nle))-c(Cys-D-Ala-His- 48.3 534 74.1 3290
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Cha-Nle))-c(Cys-D-Ala-His- 40.8 870 137 3560
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Aib-Nle))-c(Cys-D-Ala-His- 17.7 73.6 8.40 2120
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His- 7.92 46.4 6.70 21.3
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His- 20.9 69.7 8.32 50.0
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala-His- 12.9 38.5 3.53 27.1
D-Phe-Arg-Trp-Pen)-NH.sub.2 (SEQ ID NO: 280)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala-His- 127 811 10.4 381
D-Phe-Arg-Trp-Pen)-NH.sub.2 (SEQ ID NO: 280)
Hydantoin(C(O)-(Ala-Gly))-c(Cys-D-Ala-His- 13.9 38.4 5.73 18.9
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(D-Ala-Gly))-c(Cys-D-Ala- 11.7 73.1 4.28 34.7
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Aib-Gly))-c(Cys-D-Ala-His- 36.8 290 13.7 133
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Val-Gly))-c(Cys-D-Ala-His- 15.3 160 8.66 33.4
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Ile-Gly))-c(Cys-D-Ala-His- 11.6 194 11.5 28.9
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Leu-Gly))-c(Cys-D-Ala-His- 19.3 331 26.7 44.6
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-Glu-His- 9.49 124 2.95 2260
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-Glu-His- 4.30 78.0 1.77 4540
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 287)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D- 8.59 94.1 2.44 7760
Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His-D- 5.68 55.5 2.44 4220
Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 285)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His- 2.65 41.3 4.17 650
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D-Ala- 3.52 48.7 5.78 872
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D-Ala- 3.51 29.2 6.04 914
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO288)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala-His- 1.14 01.7 4.53 783
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 286)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala-His- 11.9 7.43 0.195 14.6
D-2-Nal-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 282) Binding Constants
for Formula (VII) Examples Ki Ki Ki Ki Formula (VII) Compounds hMC1
hMC3 hMC4 hMC5 c[Hydantoin(C(O)-(Aib-Cys))-D-Ala-His-D- 47.6 1100
47.1 >10000 Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Val-Cys))-D-Ala-His-D- 21.2 730 34.5 >10000
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Leu-Cys))-D-Ala-His-D- 47.4 1550 27.9 >10000
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Ile-Cys))-D-Ala-His-D-Phe- 53.4 1760 41.6
>10000 Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(A6c-Cys))-D-Ala-His-D- 38.5 1760 53.2 9270
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Gly-Cys))-Glu-His-D-Phe- 15.6 305 8.92 3070
Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 291)
TABLE-US-00014 TABLE 8 Radioligand Binding Assay Data for Selected
Compounds Ki Ki Ki Ki Compound hMC1-R hMC3-R hMC4-R hMC5-R
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe- 8.53 21.2 3.72 714
Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 292)
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe- 6.09 34.9 2.02 864
Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 292)
Ac-1-Nal-Arg-c(Cys-D-Ala-His-D-Phe- 6.27 36.4 1.53 888
Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 292)
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe- 1.48 14.8 2.34 491
Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 292)
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe- 4.7 42 2.25 1470
Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 292)
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe- 0.323 1.33 1.95 786
Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 292)
Melanocortin Functional Activity and Selectivity
[0282] The compounds of the present invention will interact
preferentially (i.e., selectively) to MC-4 relative to the other
melanocortin receptors. Selectivity is particularly important when
the compounds are administered to humans or other animals to
minimize the number of side effects associated with their
administration. MC-4 selectivity of a compound is defined herein as
the ratio of the EC.sub.50 of the compound for an MC-1 receptor
(EC.sub.50-MC-1) over the EC.sub.50 of the compound for the MC-3
(EC.sub.50-MC-3)/MC-4 (EC.sub.50-MC-4) receptor, the EC.sub.50
values being measured as described above. The formulas are as
follows:
MC-3 selectivity=[EC.sub.50-MC-1]/[EC.sub.50-MC-3]
MC-4 selectivity=[EC.sub.50-MC-1]/[EC.sub.50-MC-4]
A compound is defined herein as being "selective for the MC-3
receptor" when the above mentioned ratio "MC-3-selectivity" is at
least about 10, preferably at least about 100, and more preferably
at least about 500.
[0283] A compound is defined herein as being "selective for the
MC-4 receptor" when the above mentioned ratio "MC-4-selectivity" is
at least about 10, preferably at least about 100, and more
preferably at least about 500.
[0284] One skilled in the art would know that procedures similar to
those described herein may be used to assay the binding activities
of the compounds of the invention to melanocortin receptor
molecules.
Cyclic AMP Bioassay
[0285] Intracellular cyclic AMP (cAMP) levels were determined by an
electrochemiluminescence (ECL) assay (Meso Scale Discovery.RTM.,
Gaithersburg, Md.; referred to hereinafter as MSD). CHO-K1 cells
stably expressing the hMC receptor subtypes were suspended in RMPI
1640 .RTM. assay buffer (RMPI 1640 buffer contains 0.5 mM
isobutylmethylxanthine (IBMX), and 0.2% protein cocktail (MSD
blocker A)). Transgenic CHO-K1 cells stably expressing hMC receptor
subtypes 1, 3, 4 or 5 were dispensed at a density of approximately
7,000 cells/well in 384-well Multi-Array.RTM. plates (MSD)
containing integrated carbon electrodes and coated with anti-cAMP
antibody. Increasing concentrations of the test compounds were
added and the cells were incubated for approximately 40 minutes at
approximately 37.degree. C. Following this incubation, lysis buffer
(HEPES-buffered saline solution with MgCl.sub.2 and Triton
X-100.RTM. at ph 7.3) containing 0.2% protein cocktail and 2.5 nM
TAG.TM. ruthenium-labeled cAMP (MSD) was added and the cells were
incubated for approximately 90 minutes at room temperature. At the
end of the second incubation period read buffer (Tris-buffered
solution containing an ECL co-reactant and Triton X-100 at ph 7.8)
was added and the cAMP levels in the cell lysates were immediately
determined by ECL detection with a Sector Imager 6000 Reader.RTM.
(MSD). Data were analyzed using a computer-assisted non-linear
regression analysis (XL fit; IDBS) and reported as either an
EC.sub.50 value or a Kb value.
[0286] EC.sub.50 represents the concentration of an agonist
compound needed to obtain 50% of the maximum reaction response,
e.g., 50% of the maximum level of cAMP as determined using the
assay described above. The Kb value reflects the potency of an
antagonist and is determined by Schild analysis. In brief,
concentration-response curves of an agonist are carried out in the
presence of increasing concentrations of an antagonist. The Kb
value is the concentration of antagonist which would produce a
2-fold shift in the concentration-response curve for an agonist. It
is calculated by extrapolating the line on a Schild plot to zero on
the y-axis.
[0287] A selection of compounds was tested using the
above-discussed assays and the results are reported in Tables 9,
10, 11, and 12.
TABLE-US-00015 TABLE 9 cAMP Bioassay Data for Selected Compounds
EC.sub.50 EC.sub.50 EC.sub.50 EC.sub.50 EC.sub.50 hMC1-R/ SEQ ID
Compound hMC1-R hMC3-R hMC4-R hMC5-R MC4-R NO: Ac-Arg-c(Cys-D- 5.79
5.25 0.313 1630 18.0 SEQ ID Ala-His-D-Phe- NO: 50
Arg-Trp-Cys)-NH.sub.2 Ac-D-Arg-c(Cys-D- 6.17 5.6 0.397 1020 16.0
SEQ ID Ala-His-D-Phe- NO: 50 Arg-Trp-Cys)-NH.sub.2
Ac-D-Arg-c(Cys-D- 26.5 10.5 0.493 2440 54.0 SEQ ID Ala-His-D-Phe-
NO: 51 Arg-Trp-Pen)-NH.sub.2 Ac-D-Arg-c(Cys- 8.43 32.4 0.959 2140
9.0 SEQ ID His-D-Phe-Arg- NO: 52 Trp-Gaba-Pen)-NH.sub.2
Ac-Arg-c(Cys-His- 4.23 8.09 0.719 23.2 6.0 SEQ ID D-Phe-Arg-Trp-
NO: 52 Gaba-Pen)-NH.sub.2 Ac-Arg-c(Cys-D- 48.3 13.3 0.79 10000 61.0
SEQ ID Ala-His-D-Phe- NO: 51 Arg-Trp-Pen)-NH.sub.2 Ac-D-Arg-c(Asp-
1.48 5.76 0.078 297 19.0 SEQ ID His-D-Phe-Arg- NO: 53
Trp-Ala-Lys)-NH.sub.2 Ac-Arg-c(Asp-His- 1.39 2.89 0.055 467 25.0
SEQ ID D-Phe-Arg-Trp- NO: 53 Ala-Lys)-NH.sub.2 EC.sub.50 EC.sub.50
EC.sub.50 EC.sub.50 EC.sub.50 hMC1-R/ SEQ ID Compound hMC1-R hMC3-R
hMC4-R hMC5-R MC4-R NO: Ac-Nle-c(Cys-D-Ala-His- 2.4 0.33 0.078 420
31 SEQ ID D-Phe-Arg-Trp-Cys)- NO: 7 NH.sub.2 D-Phe-c(Cys-His-D-
0.35 1.1 0.11 0.37 3 SEQ ID (Et)Tyr-Arg-Trp-.beta.-Ala- NO: 24
D-Cys)-Thr-NH.sub.2 Nle-c(Cys-His-D-Phe- 0.31 0.27 0.018 3.1 17 SEQ
ID Arg-Trp-Apn-Cys)-NH.sub.2 NO: 27 Ac-Nle-c(Cys-His-D-Phe- 0.28
0.24 0.028 3.9 10 SEQ ID Arg-Trp-Gaba-Pen)-NH.sub.2 NO: 32
Nle-c(Cys-His-D-Phe- 0.37 0.1 0.021 1.7 18 SEQ ID
Arg-Trp-Gaba-Cys)-NH.sub.2 NO: 34 Ac-Nle-c(Asp-His-D- 0.834 0.145
0.128 2.79 6.52 SEQ ID Phe-Arg-Trp-.beta.-Ala-Lys)- NO: 1 NH.sub.2
Ac-Nle-c(Cys-His-D-Phe- 0.76 0.199 0.0492 1.73 15.45 SEQ ID
Arg-Trp-Apn-Cys)-NH.sub.2 NO: 2 Ac-Cha-c(Asp-His-D- 3.26 0.189
0.0949 30.2 34.35 SEQ ID Phe-Arg-Trp-Gaba-Lys)- NO: 6 NH.sub.2
Ac-Nle-c(Asp-His-D- 1.37 0.628 0.131 3.48 10.46 SEQ ID
Phe-Arg-Trp-Gaba-Lys)- NO: 6 NH.sub.2 Ac-hCha-c(Asp-His-D- 2.27
3.32 7.24 415 0.31 SEQ ID Phe-Arg-Trp-Gaba-Lys)- NO: 11 NH.sub.2
Ac-Nle-c(Pen-D-Ala-His- ND 1.89 0.531 ND ND SEQ ID
D-Phe-Arg-Trp-Cys)- NO: 21 NH.sub.2 Ac-Nle-c(Cys-D-Ala-His- 14.3
2.03 0.183 2240 78.14 SEQ ID D-Phe-Arg-Trp-Pen)- NO: 22 NH.sub.2
D-Phe-c(Cys-His-D- 0.345 2.71 5376 2.38 0.06 SEQ ID
(Et)Tyr-hArg-Trp-.beta.-Ala- NO: 24 D-Cys)-Thr-NH.sub.2
D-Phe-c(Cys-His-D- 0.685 81.8 86.9 31.8 0.01 SEQ ID
(Et)Tyr-hArg-Bip-.beta.-Ala- NO: 26 D-Cys)-Thr-NH.sub.2
Ac-Nle-c(Asp-D-Ala-His- 0.931 3.22 1.65 >10000 0.56 SEQ ID
D-Phe-Arg-Bal-Lys)-NH.sub.2 NO: 28 Ac-Nle-c(Cys-D-Leu-His- 3.24
0.465 0.0915 78.5 35.41 SEQ ID D-Phe-Arg-Trp-Cys)- NO: 30 NH.sub.2
Ac-Nle-c(Cys-D-Cha- 0.819 0.541 0.453 45.3 1.81 SEQ ID
His-D-Phe-Arg-Trp-Cys)- NO: 30 NH.sub.2 EC50 Kb Kb EC50 SEQ ID
Compound hMC1-R hMC3-R MC4-R hMC5-R NO: Ac-Nle-c(Cys-D-Ala-His-D-2-
17.6 12.4 38.8 11.8 SEQ ID Nal-Arg-Trp-Cys)-NH.sub.2 NO: 16
Ac-Nle-c(Asp-His-D-2-Nal-Arg- 0.619 2.98 0.109 0.189 SEQ ID
Trp-Ala-Lys)-NH.sub.2 NO: 38 Ac-Nle-c(Asp-His-D-2-Nal-Arg- 0.913
0.536 0.346 0.489 SEQ ID Trp-.beta.-Ala-Lys)-NH.sub.2 NO: 38
Ac-Nle-c(Cys-His-D-2-Nal-Arg- 0.231 18.4 0.782 0.153 SEQ ID
Trp-Gaba-Cys)-NH.sub.2 NO: 39 Ac-Nle-c(Cys-His-D-2-Nal-Arg- 0.581
10.8 0.967 0.126 SEQ ID Trp-Ahx-Cys)-NH.sub.2 NO: 39
Ac-hPhe-c(Asp-His-D-2-Nal-Arg- 0.413 9.32 0.824 0.307 SEQ ID
Trp-Gaba-Lys)-NH.sub.2 NO: 40 Ac-Cha-c(Asp-His-D-2-Nal-Arg- 1.27
3.02 0.442 0.736 SEQ ID Trp-Gaba-Lys)-NH.sub.2 NO: 40
Ac-Nle-c(Cys-D-Ala-His-D-2- 383 61.5 53.6 2842 SEQ ID
Nal-Arg-1-Nal-Cys)-NH.sub.2 NO: 16 EC50 Kb Kb EC50 SEQ ID Compound
hMC1-R hMC3-R MC4-R hMC5-R NO: Ac-Arg-c(Cys-D-Ala-His-D-2- 193 5.72
1.58 1111 SEQ ID Nal-Arg-Trp-Cys)-NH.sub.2 NO: 49 ND = not
determined
TABLE-US-00016 TABLE 10A EC.sub.50 Kb Kb EC.sub.50 Compound hMC1-R
hMC3-R hMC4-R hMC5-R Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 66.1
33.4 0.687 6.84 Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269)
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg- ND 4500 105 ND
Arg-Arg-Nle-c(Asp-His-D-2-Nal-Arg-Trp- Lys)-NH.sub.2 (SEQ ID NO:
60) Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg- ND 395 16.8 ND
Arg-Arg-Doc-Nle-c(Asp-His-D-2-Nal-Arg- Trp-Lys)-NH.sub.2 (SEQ ID
NO: 61) Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.- ND 207 18.5 ND
Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln- Arg-Arg-Arg-NH.sub.2 (SEQ ID
NO: 62) Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.- ND 220 4.07
ND Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln- Arg-Arg-Arg-NH.sub.2 (SEQ
ID NO: 62) H-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- ND 261 3.11 ND
Doc-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg- Gln-Arg-Arg-Arg-NH.sub.2 (SEQ
ID NO: 63) Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- ND 14.1 22.8 ND
Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 64)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly- ND 233 26.0 ND
Cys)-Pro-Pro-Lys-Asp-Tyr-Gly-Arg-Lys-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 65)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-.beta.- 1.39 16.2 7.94 0.839
Ala-.beta.-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 66)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- 3.65 19.4 3.73 1.61
Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-Lys-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 67)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly- ND 17.7 1.49 ND
Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 68)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 6.3 70.0 1.66 38.2
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg- NH.sub.2 (SEQ ID NO: 69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 12.1 30.3 1.81 70.0
Cys)-Pro-Pro-Lys-Asp-Doc-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 69)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 33.6 140 12.2 66.9
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 269 105 5.92 104
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269) Ac-c
Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 690 70.7 4.56 177
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 269)
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)- 3.23 8.97 4.61 2.86
Doc-Doc-Tyr-Gly-Arg-Lys-Lys-Arg-Arg- Gln-Arg-Arg-Arg-NH.sub.2 (SEQ
ID NO: 70) Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 52.0 170 6.14 328
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 72)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 146 104 32.0 1400
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 73)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 114 44.6 28.4 879
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Arg-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 74)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 67.1 439 46.5 582
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Aib-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 79)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 144 116 8.93 819
Cys)-Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 36.0 46.5 11.4 56.1
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 80)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 93.0 71 15.9 >10000
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 39.7 30.9 6.66 501
Cys)-Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 35.2 22.9 12.6 199
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 82)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 29.1 13.6 13.4 204
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 81)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 86.1 41.7 19.4 2360
Cys)-Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 38.3 20.2 21.2 >10000
Cys)-Pro-Pro-Arg-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 84)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 68.6 153 33.2 >10000
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Arg-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 83)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 70.4 286 18.6 >10000
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 33.1 65.1 15.3 1720
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Lys-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 89)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 88.2 10.6 17.4 514
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 88)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 58.7 39.3 10.3 460
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 90)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 45.4 12.7 12.7 162
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 91)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 309 22.8 17.1 570
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Lys-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 92)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 7.86 10.5 0.843 4900
Cys)-.beta.-Ala-Tyr-Gly-Arg-Arg-Arg-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 139)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 29.7 25.6 7.37 82.9
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 15.2 14.6 4.52 36.8
Cys)-Pro-Pro-Lys-Asp-.beta.Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Gln-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 75)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 6.7 9.38 11.7 46.2
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Gln-Arg-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 76)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 7.9 41.7 10.9 62.4
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Gln-Lys-Arg-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 77)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 16.9 36.0 7.12 58.9
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Arg-Arg-Gln-Arg-NH.sub.2 (SEQ ID NO: 78)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 16.4 20.8 7.31 44.2
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Arg-Gln-Arg-Arg-NH.sub.2 (SEQ ID NO: 85)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 12.0 13.7 9.38 54.2
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Gln-Lys-Lys-Arg-Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 86)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala- 7.5 12.2 7.61 51.7
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Arg-Arg-Arg-Gln- NH.sub.2 (SEQ ID NO: 87)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 43.3 215 5.87 1286
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 37.9 112 41.1 1798
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 71) EC50 EC50
EC50 EC50 Compound hMC1-R hMC3-R hMC4-R hMC5-R
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 4.70 4.56 0.634 147
Cys)-(Doc)2-Tyr-Gly-Arg-Lys-Lys-Arg- Arg-Gln-Arg-Arg-Arg-NH.sub.2
(SEQ ID NO: 136) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 5.90 7.73
1.02 2890 Cys)-.beta.-Ala-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-
Arg-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 137)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 0.481 7.32 0.964 2010
Cys)-.beta.-Ala-Gly-Arg-Arg-Arg-Arg-Arg-Gln- Arg-Arg-Arg-NH.sub.2
(SEQ ID NO: 136) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 7.15 9.37
1.25 1570 Cys)-.beta.-Ala-Arg-Arg-Arg-Arg-Arg-Gln-Arg-
Arg-Arg-NH.sub.2 (SEQ ID NO: 138) EC.sub.50 Kb Kb EC.sub.50
Compound hMC1-R hMC3-R hMC4-R hMC5-R
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-.beta.- ND ND ND ND
Ala-Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib- 770 221 4.52 869
Cys)-Pro-Pro-Lys-Asp-NH.sub.2 (SEQ ID NO: 270)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 29 22.6 16.7 173
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 95)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 102 26.3 14.6 261
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 96)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 26.6 101 9.34 351
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 97)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala- 45.5 181 6.35 149
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Lys-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 92)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 23.7 9.22 5.87 39.7
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Lys-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 99)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala- 34.7 15.0 8.68 28.2
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 19.1 106 4.59 100
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Lys-Arg-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 105)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 19.8 37.8 8.43 158
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Arg-Lys-Arg-Arg-Gln-Arg-Arg-Arg- NH.sub.2 (SEQ ID NO: 100)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 11.2 52.1 9.45 95.7
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Tyr-Gly-Arg-
Lys-Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 101)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 33.8 93.6 4.42 89.5
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Arg-
Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 102)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 232 68.8 10.0 250
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Arg-Arg-Lys-
Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 104)
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala- 32.2 98.3 5.23 194
Cys)-Pro-Pro-Lys-Asp-.beta.-Ala-Gly-Arg-Lys-
Arg-Arg-Arg-Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 103) EC50 EC50
EC50 EC50 Compound hMC1-R hMC3-R hMC4-R hMC5-R
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 5.66 4.70 0.422 1551
Cys)-.beta.-Ala-Tyr-Gly-Arg-Arg-Lys-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 141)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 7.57 4.18 0.600 1792
Cys)-.beta.-Ala-Tyr-Gly-Arg-Lys-Arg-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 2.36 2.74 0.260 500
Cys)-.beta.-Ala-Gly-Arg-Arg-Lys-Arg-Arg- Gln-Arg-Arg-Arg-NH.sub.2
(SEQ ID NO: 141) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 2.81 3.29
0.298 566 Cys)-.beta.-Ala-Gly-Arg-Lys-Arg-Arg-Arg-
Gln-Arg-Arg-Arg-NH.sub.2 (SEQ ID NO: 142)
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 1.86 1.39 0.367 165
Cys)-.beta.-Ala-Arg-Arg-Lys-Arg-Arg-Gln- Arg-Arg-Arg-NH.sub.2 (SEQ
ID NO: 143) Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- 2.06 1.61 0.394
199 Cys)-.beta.-Ala-Arg-Lys-Arg-Arg-Arg-Gln- Arg-Arg-Arg-NH.sub.2
(SEQ ID NO: 144) ND = not determined
TABLE-US-00017 TABLE 11 Intracellular Cyclic AMP (cAMP) Levels for
Formula (I) Examples EC.sub.50 EC.sub.50 EC.sub.50 EC.sub.50 hMC1
hMC3 hMC4 hMC5 Formula (V) Compounds
c[Hydantoin(C(O)-(Cys-D-Ala))-His-D-Phe- -- 218 5.42 --
Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 271)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe- -- 22.3 3.62 --
Arg-Trp-Lys]-NH.sub.2 (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe- -- 39.2 4.94 --
Arg-Trp-Orn]-NH.sub.2 (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Glu-D-Ala))-His-D-Phe- 56.7 18.2 0.182 >10000
Arg-Trp-Dap]-NH.sub.2 (SEQ ID NO: 276)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D- 56.6 88.6 4.50 9300
Phe-Arg-Trp-Orn]-NH.sub.2 (SEQ ID NO: 273)
c[Hydantoin(C(O)-(Asp-D-Ala))-His-D- -- 49.3 2.12 --
Phe-Arg-Trp-Dap]-NH.sub.2 (SEQ ID NO: 273) Formula (VI) Compounds
Hydantoin(C(O)-(Nle-Gly))-c(Cys-Glu-His- 54.3 12.2 0.177 >10000
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-Glu-His- 124 8.05 0.214 >10000
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(A6c-Nle))-c(Cys-D-Ala- -- 4.89 1.80 --
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(D-Ala-Nle))-c(Cys-D-Ala- -- 2.56 1.47 --
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Val-Nle))-c(Cys-D-Ala- -- 4.61 0.977 --
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Leu-Nle))-c(Cys-D-Ala- -- 9.68 1.83 --
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Cha-Nle))-c(Cys-D-Ala- -- 9.97 13.9 --
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 284)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala- 14.2 2.46 0.336 201
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Nle-Gly))-c(Cys-D-Ala- 17.0 21.5 0.584 352
His-D-Phe-Arg-Trp-Pen)-NH.sub.2 (SEQ ID NO: 280)
Hydantoin(C(O)-(Gly-Gly))-c(Cys-D-Ala- 40.2 8.90 0.495 8300
His-D-Phe-Arg-Trp-Pen)-NH.sub.2 (SEQ ID NO: 280)
Hydantoin(C(O)-(Ala-Gly))-c(Cys-D-Ala- 17.6 2.23 0.241 516
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(D-Ala-Gly))-c(Cys-D-Ala- 4.70 2.22 0.309 355
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-Glu- 18.0 17.1 0.160 2710
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-Glu- 12.9 10.3 0.125 7440
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 287)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His- 8.83 7.86 0.0979 4010
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-Glu-His- 9.97 3.63 0.0687 335
D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 285)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala- 8.81 18.2 0.503 3560
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(D-Arg-Gly))-c(Cys-D- 11.5 23.2 0.513 3950
Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 279)
Hydantoin(C(O)-(Gly-D-Arg))-c(Cys-D- 7.53 11.6 0.435 9840
Ala-His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 288)
Hydantoin(C(O)-(Gly-Arg))-c(Cys-D-Ala- 8.85 5.17 0.599 3610
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 286)
Hydantoin(C(O)-(Arg-Gly))-c(Cys-D-Ala- 96.6 13.1 21.2 103
His-D-2-Nal-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 282) Formula (VII)
Compounds c[Hydantoin(C(O)-(Aib-Cys))-D-Ala-His-D- -- 6.28 0.407 --
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Val-Cys))-D-Ala-His-D- -- 3.77 0.214 --
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Leu-Cys))-D-Ala-His-D- -- 4.72 0.428 --
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Ile-Cys))-D-Ala-His-D- -- 8.51 1.85 --
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(A6c-Cys))-D-Ala-His-D- -- 5.66 1.72 --
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 290)
c[Hydantoin(C(O)-(Gly-Cys))-Glu-His-D- 14.5 21.8 0.576 1780
Phe-Arg-Trp-Cys]-NH.sub.2 (SEQ ID NO: 291)
TABLE-US-00018 TABLE 12 cAMP Bioassay Data for Selected Compounds
EC.sub.50 EC.sub.50 EC.sub.50 EC.sub.50 Compound hMC1-R hMC3-R
hMC4-R hMC5-R Ac-Tyr-Arg-c(Cys-D-Ala- 6.42 2.39 0.194 1540
His-D-Phe-Arg-Trp-Cys)- NH.sub.2 (SEQ ID NO: 292)
Ac-2-Nal-Arg-c(Cys-D- 9.66 6.11 0.275 1730 Ala-His-D-Phe-Arg-Trp-
Cys)-NH.sub.2 (SEQ ID NO: 292) Ac-1-Nal-Arg-c(Cys-D- 8.67 4.21
0.363 1320 Ala-His-D-Phe-Arg-Trp- Cys)-NH.sub.2 (SEQ ID NO: 292)
Ac-Trp-Arg-c(Cys-D-Ala- 5.78 3.95 0.219 2580
His-D-Phe-Arg-Trp-Cys)- NH.sub.2 (SEQ ID NO: 292)
In Vivo Studies
[0288] Compounds of the present invention can be and were tested
for an effect upon insulin resistance and/or body weight according
to the following procedures. One skilled in the art would know that
procedures similar to those described herein may be used to assay
the effect of the compounds of the invention upon insulin
resistance and/or body weight.
[0289] Ligand compounds activating melanocortin receptors tested in
the in vivo studies were as follows (Table 13):
TABLE-US-00019 TABLE 13 Ligand Code Structure Compound A
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp- Cys)-NH.sub.2 SEQ ID NO: 50
Compound B Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-
His-D-Phe-Arg-Trp-Cys)-NH.sub.2 (SEQ ID NO: 278)
Acute Feeding Experiments (Fasting)
[0290] Male Sprague Dawley rats (250 g) were housed in individual
cages and maintained under 12:12 hour light:dark conditions. The
rats were fasted for 18 hours prior to the start of the experiment
with water available ad libitum. At time 0, the rats were injected
subcutaneously (sc) with selected compounds at doses of 100
nmole/kg, or with vehicle, and were provided with food. Individual
food consumption was measured at about 2, 4 and 6 hours after
injection. Data for selected compounds of the invention are
reported in FIG. 1.
Chronic Feeding Experiments
[0291] Male, Sprague Dawley rats that had been fed either a normal
diet (300 g; Research Diets 12450) or a high fat diet (400 g;
Research Diets 12451) for 10 weeks prior to the start of the
experiment were housed in individual cages and maintained under
12:12 hour light:dark conditions with both food and water available
ad libitum. The rats were anesthetized and implanted subcutaneously
with an osmotic mini pump (Alzet, Cupertino, Calif.). The pumps
delivered either Compound A or Compound B at doses of 75, 300 or
1200 nmole/kg/day, or vehicle for 7 days. Individual body weight
and food consumption were measured daily.
[0292] On day 7 rats were anesthetized and fit with a jugular-right
atrial cannula. On day 8 an iv glucose tolerance test was performed
and blood samples were withdrawn into heparinized syringes at time
-10 and 0. Immediately after the time 0 blood sample, the rats were
injected with glucose (1 g/kg) via the indwelling cannula.
Subsequent blood samples were withdrawn at 2.5, 5, 10, 20 and 40
minutes later. Plasma levels of glucose (Diagnostic Chemicals
Limited) and insulin (Alpco) were determined by commercially
available kits. Results are shown in FIGS. 2A-D and 3A-D.
Glucose Tolerance Tests
[0293] Male, C57BL/6 mice that had been fed either a normal diet
(30 g; Research Diets 12450) or a high fat diet (45 g; Research
Diets 12452) for 12 weeks prior to the start of the experiment were
housed in individual cages and maintained under 12:12 hour
light:dark conditions with both food and water available ad
libitum. The mice were anesthetized and implanted subcutaneously
with an osmotic mini pump (Alzet, Cupertino, Calif.). The pumps
delivered Compound A at doses of 200, 600 or 1800 nmole/kg/day, or
vehicle for 14 days. On day 14 the mice were fasted for 18 hours or
overnight. On day 15 an glucose tolerance test was performed by
injecting the mice with glucose (2 g/kg) ip. Blood samples were
taken by tail stick at 0, 15, 30, 60 and 180 minutes after the
glucose injection and blood glucose level was measured using an
Accu-Chek glucometer. Results are shown in FIG. 4.
[0294] Male, Lep.sup.ob/Lep.sup.ob mice (50 g) were group housed
maintained under 12:12 hour light:dark conditions with both food
and water available ad libitum. The mice were fasted for 18 hours
or overnight and an ip glucose tolerance test was performed. Mice
were injected with Compound A ip at a dose of 6.4 .mu.mole/kg at
-15 minutes and a blood sample was taken by tail stick. At time 0
mice were injected ip with glucose (1 g/kg) and blood samples were
taken by tail stick at 0, 15, 30, 60 and 90 minutes later and blood
glucose level was measured using Glucometer Elite XL (Bayer
Corporation). Results are shown in FIG. 5.
ADMINISTRATION AND USE
[0295] The peptides of this invention can be provided in the form
of pharmaceutically acceptable salts. Examples of such salts
include, but are not limited to, those formed with organic acids
(e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic,
benzoic, methanesulfonic, toluenesulfonic, or pamoic acid),
inorganic acids (e.g., hydrochloric acid, sulfuric acid, or
phosphoric acid), and polymeric acids (e.g., tannic acid,
carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of
polylactic-glycolic acids). A typical method of making a salt of a
peptide of the present invention is well known in the art and can
be accomplished by standard methods of salt exchange. Accordingly,
the TFA salt of a peptide of the present invention (the TFA salt
results from the purification of the peptide by using preparative
HPLC, eluting with TFA containing buffer solutions) can be
converted into another salt, such as an acetate salt, by dissolving
the peptide in a small amount of 0.25 N acetic acid aqueous
solution. The resulting solution is applied to a semi-prep HPLC
column (Zorbax.RTM., 300 SB, C-8). The column is eluted with: (1)
0.1N ammonium acetate aqueous solution for 0.5 hours; (2) 0.25N
acetic acid aqueous solution for 0.5 hours; and (3) a linear
gradient (20% to 100% of solution B over 30 minutes) at a flow rate
of 4 ml/min (solution A is 0.25N acetic acid aqueous solution;
solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The
fractions containing the peptide are collected and lyophilized to
dryness.
[0296] As is well known to those skilled in the art, the known and
potential uses of peptides with melanocortin receptor (MC-R)
agonist or antagonist activity is varied and multitudinous, thus
the administration of the compounds of this invention for purposes
of eliciting an agonist effect can have the same effects and uses
as melanocortin itself.
[0297] Accordingly, the present invention includes within its scope
pharmaceutical compositions comprising, as an active ingredient, at
least one of the compounds of formula (I) in association with a
pharmaceutically acceptable carrier.
[0298] The dosage of active ingredient in the compositions of this
invention may be varied; however, it is necessary that the amount
of the active ingredient be such that a suitable dosage form is
obtained. The selected dosage depends upon the desired therapeutic
effect, on the route of administration, and on the duration of the
treatment. In general, an effective dosage for the activities of
this invention is in the range of 1.times.10.sup.-7 to 200
mg/kg/day, preferably 1.times.10.sup.4 to 100 mg/kg/day which can
be administered as a single dose or divided into multiple
doses.
[0299] The compounds of this invention can be administered by oral,
parenteral (e.g., intramuscular, intraperitoneal, intravenous or
subcutaneous injection, or implant), nasal, vaginal, rectal,
sublingual or topical routes of administration and can be
formulated with pharmaceutically acceptable carriers to provide
dosage forms appropriate for each route of administration.
[0300] Solid dosage forms for oral administration include capsules,
tablets, pills, powders and granules. In such solid dosage forms,
the active compound is admixed with at least one inert
pharmaceutically acceptable carrier such as sucrose, lactose, or
starch. Such dosage forms can also comprise, as is normal practice,
additional substances other than such inert diluents, e.g.,
lubricating agents such as magnesium stearate. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents. Tablets and pills can additionally be prepared
with enteric coatings.
[0301] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups, the elixirs containing inert diluents commonly used in the
art, such as water. Besides such inert diluents, compositions can
also include adjuvants, such as wetting agents, emulsifying and
suspending agents, and sweetening, flavoring and perfuming
agents.
[0302] Preparations according to this invention for parenteral
administration include sterile aqueous or non-aqueous solutions,
suspensions, or emulsions. Examples of non-aqueous solvents or
vehicles are propylene glycol, polyethylene glycol, vegetable oils,
such as olive oil and corn oil, gelatin, and injectable organic
esters such as ethyl oleate. Such dosage forms may also contain
adjuvants such as preserving, wetting, emulsifying, and dispersing
agents. Preparations may be sterilized by, for example, filtration
through a bacteria-retaining filter, by incorporating sterilizing
agents into the compositions, by irradiating the compositions, or
by heating the compositions. Preparations can also be manufactured
in the form of sterile solid compositions which can be dissolved in
sterile water or some other sterile injectable medium immediately
before use.
[0303] Compositions for rectal or vaginal administration are
preferably suppositories which may contain, in addition to the
active substance, excipients such as cocoa butter or a suppository
wax.
[0304] Compositions for nasal or sublingual administration are also
prepared with standard excipients well known in the art.
[0305] Further, a compound of this invention can be administered in
a sustained release composition such as those described in the
following patents and patent applications. U.S. Pat. No. 5,672,659
teaches sustained release compositions comprising a bioactive agent
and a polyester. U.S. Pat. No. 5,595,760 teaches sustained release
compositions comprising a bioactive agent in a gelable form. U.S.
Pat. No. 5,821,221 teaches polymeric sustained release compositions
comprising a bioactive agent and chitosan. U.S. Pat. No. 5,916,883
teaches sustained release compositions comprising a bioactive agent
and cyclodextrin. The teachings of the foregoing patents and
applications are incorporated herein by reference.
Sequence CWU 1
1
33518PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = beta-Ala or
1-amino-1-cyclohexanecarboxylic acid (A6c)MOD_RES(8)..(8)AMIDATION
1Xaa Asp His Xaa Arg Trp Xaa Lys 1 5 28PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 6-aminohexanoic acid (Ahx) or
5-aminopentanoic acid (Apn)MOD_RES(8)..(8)AMIDATION 2Xaa Cys His
Xaa Arg Trp Xaa Cys 1 5 39PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= D-PheDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = Ala, beta-Ala or 4-aminobutyric acid
(Gaba)MISC_FEATURE(8)..(8)Xaa = D-CysMOD_RES(9)..(9)AMIDATION 3Xaa
Cys His Xaa Arg Trp Xaa Xaa Thr 1 5 48PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MOD_RES(8)..(8)AMIDATION 4Xaa Asp His Xaa Arg Trp Xaa Lys 1 5
58PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
1-amino-1-cyclohexanecarboxylic acid (A6c) modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 5Xaa Asp His Xaa Arg Trp Xaa Lys 1 5
68PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal), beta-cyclohexylAla (Cha) or Nle, all modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 6Xaa Asp His Xaa Arg Trp Xaa Lys 1 5
78PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa = D-Ala, beta-Ala,
4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or
GlyMISC_FEATURE(5)..(5)Xaa = D-PheMOD_RES(8)..(8)AMIDATION 7Xaa Cys
Xaa His Xaa Arg Trp Cys 1 5 88PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(2)..(2)Xaa =
D-CysMISC_FEATURE(3)..(3)Xaa = Ala, D-Ala, beta-Ala, 4-aminobutyric
acid (Gaba), alpha-aminoisobutyric acid (Aib) or
GlyMISC_FEATURE(5)..(5)Xaa = D-PheMOD_RES(8)..(8)AMIDATION 8Xaa Xaa
Xaa His Xaa Arg Trp Cys 1 5 98PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa = D-Ala, beta-Ala,
4-aminobutyric acid (Gaba), alpha-aminoisobutyric acid (Aib) or
GlyMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
D-CysMOD_RES(8)..(8)AMIDATION 9Xaa Cys Xaa His Xaa Arg Trp Xaa 1 5
108PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(2)..(2)Xaa =
D-CysMISC_FEATURE(3)..(3)Xaa = Ala, D-Ala, beta-Ala, 4-aminobutyric
acid (Gaba) or alpha-aminoisobutyric acid
(Aib)MISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
D-CysMOD_RES(8)..(8)AMIDATION 10Xaa Xaa Xaa His Xaa Arg Trp Xaa 1 5
118PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
octahydroindole-2-carboxylic acid (Oic), cyclohexylGly (Chg),
homo-cyclohexylAla (hCha), D-Cha,nipecotic acid (Nip), hPro, hLeu,
Phe, D-Phe, D-Chg, hPhe, beta-homoMet, or 4-aminobutyric acid
(Gaba), all modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 11Xaa Asp His Xaa Arg Trp Xaa Lys 1
5 128PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = beta-cyclohexylAla
(Cha) modified with
n-butanoylDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 12Xaa Asp His Xaa Arg Trp Xaa Lys 1
5 138PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = beta-cyclohexylAla
(Cha), homo-cyclohexylAla (hCha), Leu, homo-Leu (hLeu) or Phe, all
modified with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMOD_RES(8)..(8)AMIDATION
13Xaa Asp His Xaa Arg Xaa Ala Lys 1 5 148PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMISC_FEATURE(7)..(7)Xaa =
D-Ala, beta-Ala, 4-aminobutyric acid (Gaba), 7-aminoheptanoic acid
(Aha) or 5-aminopentanoic acid (Apn)MOD_RES(8)..(8)AMIDATION 14Xaa
Asp His Xaa Arg Xaa Xaa Lys 1 5 158PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMISC_FEATURE(7)..(7)Xaa =
5-aminopentanoic acid (Apn), 4-aminobutyric acid (Gaba),
6-aminohexanoic acid (Ahx), beta-Ala, or
D-AlaMOD_RES(8)..(8)AMIDATION 15Xaa Cys His Xaa Arg Xaa Xaa Cys 1 5
168PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(7)..(7)Xaa = Trp, beta-(2-naphthyl)Ala
(2-Nal) or beta-(1-naphthyl)Ala (1-Nal)MOD_RES(8)..(8)AMIDATION
16Xaa Cys Xaa His Xaa Arg Xaa Cys 1 5 178PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with
n-butanoylDOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(7)..(7)Xaa =
beta-(2-naphthyl)Ala (2-Nal) or TrpMOD_RES(8)..(8)AMIDATION 17Xaa
Cys Xaa His Xaa Arg Xaa Cys 1 5 188PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(7)..(7)Xaa =
beta-(2-naphthyl)Ala (2-Nal), beta-(1-naphthyl)Ala (1-Nal) or
3-benzothienylAla (Bal)MOD_RES(8)..(8)AMIDATION 18Xaa Cys Xaa His
Xaa Arg Xaa Cys 1 5 198PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(7)..(7)Xaa = D-AlaMOD_RES(8)..(8)AMIDATION
19Xaa Asp His Xaa Arg Trp Xaa Lys 1 5 208PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-beta-2-naphthylAla
(D-2-Nal)MISC_FEATURE(7)..(7)Xaa = 3-benzothienylAla
(Bal)MOD_RES(8)..(8)AMIDATION 20Xaa Cys Xaa His Xaa Arg Xaa Cys 1 5
218PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(2)..(2)Xaa = penicillamine
(Pen)MISC_FEATURE(3)..(3)Xaa = D-AlaMISC_FEATURE(5)..(5)Xaa =
D-PheMOD_RES(8)..(8)AMIDATION 21Xaa Xaa Xaa His Xaa Arg Trp Cys 1 5
228PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(2)..(2)Xaa = Cys or
penicillamine (Pen)MISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MOD_RES(8)..(8)AMIDATION 22Xaa Xaa Xaa His Xaa
Arg Trp Xaa 1 5 239PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMOD_RES(9)..(9)AMIDATION 23Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr
1 5 249PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = Arg or homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMOD_RES(9)..(9)AMIDATION 24Xaa Cys His Xaa Xaa Trp Xaa Xaa Thr
1 5 259PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMOD_RES(9)..(9)AMIDATION 25Xaa Cys His Xaa Arg Xaa Xaa Xaa Thr
1 5 269PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa = D-Phe or
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMOD_RES(9)..(9)AMIDATION 26Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr
1 5 278PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MOD_RES(8)..(8)AMIDATION 27Xaa Cys His Xaa Arg Trp Xaa Cys 1 5
288PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(7)..(7)Xaa = Trp
or 3-benzothienylAla (Bal)MOD_RES(8)..(8)AMIDATION 28Xaa Asp Xaa
His Xaa Arg Xaa Lys 1 5 298PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen) or CysMOD_RES(8)..(8)C-terminus is the free
acid 29Xaa Cys Xaa His Xaa Arg Trp Xaa 1 5 308PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-alpha-aminobutyric acid (D-Abu), D-Val, D-Ile, D-Leu, D-tert-Leu
(D-Tle) or D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMOD_RES(8)..(8)AMIDATION 30Xaa Cys Xaa His Xaa Arg Trp Cys 1 5
318PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(2)..(2)Xaa = penicillamine
(Pen)MISC_FEATURE(4)..(4)Xaa = D-PheMISC_FEATURE(7)..(7)Xaa =
4-aminobutyric acid (Gaba)MOD_RES(8)..(8)AMIDATION 31Xaa Xaa His
Xaa Arg Trp Xaa Cys 1 5 328PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(2)..(2)Xaa = Cys or
penicillamine (Pen)MISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(8)..(8)Xaa = penicillamine
(Pen)MOD_RES(8)..(8)AMIDATION 32Xaa Xaa His Xaa Arg Trp Xaa Xaa 1 5
338PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Leu,
beta-cyclohexylAla (Cha), Ile, Phe, Val or beta-(2-naphthyl)Ala
(2-Nal), all modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 33Xaa Cys His Xaa Arg Trp Xaa Cys 1
5 348PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle or
PheDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 34Xaa Cys His Xaa Arg Trp Xaa Cys 1
5 358PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
beta-(3-pyridiyl)Ala (3-Pal)MISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 35Xaa Cys Xaa Xaa Arg Trp Xaa Cys 1
5 368PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMOD_RES(8)..(8)C-terminus is
the free acid 36Xaa Cys Xaa His Xaa Arg Trp Cys 1 5
378PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(6)..(6)Xaa =
D-TrpMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)AMIDATION 37Xaa Cys His Phe Arg Xaa Xaa Cys 1
5 388PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(7)..(7)Xaa = Ala or
beta-AlaMOD_RES(8)..(8)AMIDATION 38Xaa Asp His Xaa Arg Trp Xaa Lys
1 5 398PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(7)..(7)Xaa =
4-aminobutyric acid (Gaba) or 6-aminohexanoic acid
(Ahx)MOD_RES(8)..(8)AMIDATION 39Xaa Cys His Xaa Arg Trp Xaa Cys 1 5
408PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = homo-Phe (hPhe) or
beta-cyclohexylAla (Cha), both modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(7)..(7)Xaa =
4-aminobutyric acid (Gaba)MOD_RES(8)..(8)AMIDATION 40Xaa Asp His
Xaa Arg Trp Xaa Lys 1 5 418PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = beta-Ala or 5-aminopentanoic acid
(Apn)MOD_RES(8)..(8)C-terminus is the free acid 41Xaa Asp His Xaa
Arg Trp Xaa Lys 1 5 428PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 6-aminohexanoic acid (Ahx) or
5-aminopentanoic acid (Apn)MOD_RES(8)..(8)C-terminus is the free
acid 42Xaa Cys His Xaa Arg Trp Xaa Cys 1 5 439PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = Ala, beta-Ala or 4-aminobutyric acid
(Gaba)MISC_FEATURE(8)..(8)Xaa = D-CysMOD_RES(9)..(9)C-terminus is
the free acid 43Xaa Cys His Xaa Arg Trp Xaa Xaa Thr 1 5
448PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = beta-cyclohexylAla
(Cha), Nle, cyclohexylGly (Chg), D-Cha, homo-cyclohexylAla (hCha),
D-Chg or homo-Phe (hPhe), all modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MOD_RES(8)..(8)C-terminus is the free acid 44Xaa Asp His Xaa
Arg Trp Xaa Lys 1 5 458PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMISC_FEATURE(7)..(7)Xaa =
4-aminobutyric acid (Gaba), 6-aminohexanoic acid (Ahx), beta-Ala or
D-AlaMOD_RES(8)..(8)C-terminus is the free acid 45Xaa Cys His Xaa
Arg Xaa Xaa Cys 1 5 468PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa
= D-AlaMISC_FEATURE(5)..(5)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(7)..(7)Xaa = Trp, beta-(2-naphthyl)Ala
(2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylalanine
(Bal)MOD_RES(8)..(8)C-terminus is the free acid 46Xaa Cys Xaa His
Xaa Arg Xaa Cys 1 5 478PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(2)..(2)Xaa
= penicillamine (Pen)MISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMOD_RES(8)..(8)C-terminus is
the free acid 47Xaa Xaa Xaa His Xaa Arg Trp Cys 1 5
488PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(8)..(8)Xaa = penicillamine
(Pen)MOD_RES(8)..(8)C-terminus is the free acid 48Xaa Cys His Xaa
Arg Trp Xaa Xaa 1 5 498PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MOD_RES(8)..(8)AMIDATION 49Arg Cys Xaa His Xaa Arg Trp Cys
1 5 508PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Arg or D-Arg, both
modified with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa
= D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMOD_RES(8)..(8)AMIDATION
50Xaa Cys Xaa His Xaa Arg Trp Cys 1 5 518PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = D-Arg or Arg, both modified
with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MOD_RES(8)..(8)AMIDATION 51Xaa Cys Xaa His Xaa
Arg Trp Xaa 1 5 528PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = D-Arg
or Arg, both modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(8)..(8)Xaa = penicillamine
(Pen)MOD_RES(8)..(8)AMIDATION 52Xaa Cys His Xaa Arg Trp Xaa Xaa 1 5
538PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = D-Arg or Arg, both
modified with acyl (Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMOD_RES(8)..(8)AMIDATION 53Xaa Asp His Xaa Arg Trp Ala Lys 1
5 549PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(9)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa = Gly,
D-Ala, beta-Ala, 4-aminobutyric acid (Gaba) or 5-aminopentanoic
acid (Apn)MOD_RES(9)..(9)AMIDATION 54Xaa Cys Xaa His Xaa Arg Trp
Xaa Cys 1 5 558PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)CyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(6)..(6)Xaa = Trp or beta-(2-naphthyl)alanine
(2-Nal)MOD_RES(8)..(8)AMIDATION 55Cys Glu His Xaa Arg Xaa Ala Cys 1
5 568PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)CyclicMISC_FEATURE(2)..(2)Xaa =
D-AlaMISC_FEATURE(4)..(4)Xaa = D-PheMISC_FEATURE(6)..(6)Xaa = Trp
or beta-(2-naphthyl)Ala (2-Nal)MOD_RES(8)..(8)AMIDATION 56Cys Xaa
His Xaa Arg Xaa Ala Cys 1 5 579PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(9)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa = Ala,
beta-Ala or 4-aminobutyric acid (Gaba)MOD_RES(9)..(9)AMIDATION
57Xaa Cys Xaa His Xaa Arg Trp Xaa Cys 1 5 589PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(9)CyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(7)..(7)Xaa =
3-benzothienylAla (Bal)MOD_RES(9)..(9)AMIDATION 58Xaa Asp Xaa His
Xaa Arg Xaa Ala Lys 1 5 598PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(8)CyclicMISC_FEATURE(3)..(3)Xaa =
D-GluMISC_FEATURE(5)..(5)Xaa = D-PheMOD_RES(8)..(8)AMIDATION 59Xaa
Cys Xaa His Xaa Arg Trp Cys 1 5 6018PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(12)..(12)Xaa =
NleDOMAIN(13)..(18)cyclicMISC_FEATURE(15)..(15)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MOD_RES(18)..(18)AMIDATION 60Tyr
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Xaa Asp His Xaa Arg 1 5 10
15 Trp Lys 6119PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(12)..(12)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(13)..(13)Xaa =
NleDOMAIN(14)..(19)cyclicMISC_FEATURE(16)..(16)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MOD_RES(19)..(19)AMIDATION 61Tyr
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Xaa Xaa Asp His Xaa 1 5 10
15 Arg Trp Lys 6219PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle or
Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(8)..(8)Xaa =
beta-AlaMOD_RES(19)..(19)AMIDATION 62Xaa Asp His Xaa Arg Trp Lys
Xaa Tyr Gly Arg Lys Lys Arg Arg Gln 1 5 10 15 Arg Arg Arg
6320PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(8)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MOD_RES(20)..(20)AMIDATION
63Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Lys Lys Arg Arg 1
5 10 15 Gln Arg Arg Arg 20 6422PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MOD_RES(22)..(22)AMIDATION 64Xaa
Asp His Xaa Arg Trp Lys Pro Pro Lys Asp Tyr Gly Arg Lys Lys 1 5 10
15 Arg Arg Gln Arg Arg Arg 20 6523PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MOD_RES(23)..(23)AMIDATION 65Cys Glu His Xaa Arg Trp Gly
Cys Pro Pro Lys Asp Tyr Gly Arg Lys 1 5 10 15 Lys Arg Arg Gln Arg
Arg Arg 20 6620PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(8)..(9)Xaa =
beta-AlaMOD_RES(20)..(20)AMIDATION 66Xaa Asp His Xaa Arg Trp Lys
Xaa Xaa Tyr Gly Arg Lys Lys Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
6723PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(12)..(12)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MOD_RES(23)..(23)AMIDATION
67Xaa Asp His Xaa Arg Trp Lys Pro Pro Lys Asp Xaa Tyr Gly Arg Lys 1
5 10 15 Lys Arg Arg Gln Arg Arg Arg 20 6824PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MOD_RES(24)..(24)AMIDATION 68Cys Glu His Xaa Arg Trp Gly Cys
Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Arg Gln Arg
Arg Arg 20 6924PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa = beta-Ala or
8-amino-3,6-dioxaoctanoic acid (Doc)MOD_RES(24)..(24)AMIDATION
69Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1
5 10 15 Lys Lys Arg Arg Gln Arg Arg Arg 20 7020PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(8)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MOD_RES(20)..(20)AMIDATION
70Xaa Asp His Xaa Arg Trp Lys Xaa Xaa Tyr Gly Arg Lys Lys Arg Arg 1
5 10 15 Gln Arg Arg Arg 20 7124PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(2-naphthyl)Ala (2-Nal),
beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
71Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1
5 10 15 Lys Lys Arg Arg Gln Arg Arg Arg 20 7222PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
72Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Arg Arg Arg 1
5 10 15 Arg Arg Gln Arg Arg Arg 20 7323PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
73Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Arg 1
5 10 15 Arg Arg Arg Gln Arg Arg Arg 20 7424PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
74Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1
5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg 20 7524PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 75Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Gln Arg
Arg Arg Arg 20 7624PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 76Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Gln Arg Arg
Arg Arg Arg 20 7724PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 77Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Gln Lys Arg Arg
Arg Arg Arg 20 7824PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 78Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Arg Arg
Arg Gln Arg 20 7924PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMISC_FEATURE(15)..(15)Xaa
= alpha-aminoisobutyric acid (Aib)MOD_RES(24)..(24)AMIDATION 79Cys
Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Xaa Arg 1 5 10
15 Lys Lys Arg Arg Gln Arg Arg Arg
20 8022PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with
acyl (Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(1-naphthyl)Ala
(1-Nal)MISC_FEATURE(11)..(11)Xaa = Arg or
LysMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
80Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg 1
5 10 15 Arg Arg Gln Arg Arg Arg 20 8123PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(1-naphthyl)Ala (1-Nal) or
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(23)..(23)AMIDATION 81Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Arg Arg 1 5 10 15 Arg Arg Arg Gln Arg
Arg Arg 20 8222PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(2-naphthyl)Ala
(2-Nal)MISC_FEATURE(11)..(11)Xaa = Arg or
LysMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
82Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg 1
5 10 15 Arg Arg Gln Arg Arg Arg 20 8323PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = 3-benzothienylAla
(Bal)MISC_FEATURE(11)..(11)Xaa = Arg or
LysMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
83Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg 1
5 10 15 Arg Arg Arg Gln Arg Arg Arg 20 8422PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
84Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Arg Asp Xaa Arg Arg Arg 1
5 10 15 Arg Arg Gln Arg Arg Arg 20 8524PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 85Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Arg Arg
Gln Arg Arg 20 8624PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 86Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Gln Lys Lys Arg Arg
Arg Arg Arg 20 8724PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 87Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Arg Arg
Arg Arg Gln 20 8822PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(1-naphthyl)Ala (1-Nal) or
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 88Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Arg Lys 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 8922PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(1-naphthyl)Ala
(1-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 89Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Lys Arg 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 9024PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(2-naphthyl)Ala
(2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 90Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Arg Lys Arg Arg Gln
Arg Arg Arg 20 9123PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(2-naphthyl)Ala
(2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(23)..(23)AMIDATION 91Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Gly Arg Arg 1 5 10 15 Lys Arg Arg Gln Arg
Arg Arg 20 9223PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(2-naphthyl)Ala (2-Nal) or
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(23)..(23)AMIDATION 92Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Gly Arg Lys 1 5 10 15 Arg Arg Arg Gln Arg
Arg Arg 20 9322PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 93Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Arg Lys 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 9422PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 94Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Lys Arg 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 9524PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(1-naphthyl)Ala
(1-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 95Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Arg Lys Arg Arg Gln
Arg Arg Arg 20 9624PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 96Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Arg Arg Arg Gln
Arg Arg Arg 20 9723PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(1-naphthyl)Ala
(1-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(23)..(23)AMIDATION 97Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Gly Arg Arg 1 5 10 15 Lys Arg Arg Gln Arg
Arg Arg 20 9822PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(2-naphthyl)Ala
(2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 98Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Arg Lys 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 9922PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 99Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Lys Arg 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 10024PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
100Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Lys Arg Arg Gln Arg Arg Arg 20 10124PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
101Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Tyr Gly Arg
1 5 10 15 Lys Arg Arg Arg Gln Arg Arg Arg 20 10223PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
102Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Arg
1 5 10 15 Lys Arg Arg Gln Arg Arg Arg 20 10323PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal) or 3-benzothienylAla
(Bal)MISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
103Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Lys Asp Xaa Gly Arg Lys
1 5 10 15 Arg Arg Arg Gln Arg Arg Arg 20 10422PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 104Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Arg Lys 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 10522PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(22)..(22)AMIDATION 105Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Arg Lys Arg 1 5 10 15 Arg Arg Gln Arg Arg
Arg 20 10624PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 106Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Gln Arg
Arg Arg Arg 20 10724PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 107Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Gln Arg Arg
Arg Arg Arg 20 10824PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 108Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Gln Lys Arg Arg
Arg Arg Arg 20 10924PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 109Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Gln Lys Lys Arg Arg
Arg Arg Arg 20 11024PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 110Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Arg Arg
Gln Arg Arg 20 11124PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 111Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Arg Arg
Arg Gln Arg 20 11224PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(24)..(24)AMIDATION 112Cys Glu His Xaa Arg Trp Ala
Cys Pro Pro Lys Asp Xaa Tyr Gly Arg 1 5 10 15 Lys Lys Arg Arg
Arg Arg Arg Gln 20 11322PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMOD_RES(1)..(1)modified with
acyl (Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
113Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg 20 11424PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
114Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg 20 11523PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
115Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg Arg 20 11625PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(25)..(25)AMIDATION
116Cys Glu His Xaa Arg Trp Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg Arg 20 25
11722PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
117Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg 20 11823PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
118Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg Arg 20 11923PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
119Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Arg Gln Arg Arg Arg 20 12024PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with
acylDOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
120Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg 20 12125PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(25)..(25)AMIDATION
121Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg Arg 20 25
12225PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(1-naphthyl)Ala (1-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(25)..(25)AMIDATION
122Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Arg Gln Arg Arg Arg 20 25
12322PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
123Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg 20 12423PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
124Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Arg Gln Arg Arg Arg 20 12523PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
125Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg Arg 20 12624PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
126Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg 20 12725PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(25)..(25)AMIDATION
127Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Arg Gln Arg Arg Arg 20 25
12825PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
beta-(2-naphthyl)Ala (2-Nal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(25)..(25)AMIDATION
128Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg Arg 20 25
12922PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
129Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg 20 13023PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
130Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Gln Arg Arg Arg Arg 20 13123PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(23)..(23)AMIDATION
131Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Arg Arg Arg
1 5 10 15 Arg Arg Arg Gln Arg Arg Arg 20 13223PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(13)..(13)Xaa =
beta-AlaMOD_RES(23)..(23)AMIDATION 132Cys Glu His Xaa Arg Xaa Ala
Cys Pro Pro Lys Asp Xaa Gly Arg Arg 1 5 10 15 Arg Arg Arg Gln Arg
Arg Arg 20 13324PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(24)..(24)AMIDATION
133Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg 20 13425PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(25)..(25)AMIDATION
134Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Gln Arg Arg Arg Arg 20 25
13525PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with acyl
(Ac)DOMAIN(1)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphthyl)Ala (D-2-Nal)MISC_FEATURE(6)..(6)Xaa =
3-benzothienylAla (Bal)MISC_FEATURE(11)..(11)Xaa = Lys or
ArgMISC_FEATURE(13)..(13)Xaa = beta-AlaMOD_RES(25)..(25)AMIDATION
135Cys Glu His Xaa Arg Xaa Ala Cys Pro Pro Xaa Asp Xaa Tyr Gly Arg
1 5 10 15 Arg Arg Arg Arg Arg Gln Arg Arg Arg 20 25
13621PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(21)..(21)AMIDATION 136Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Tyr Gly Arg Lys Lys Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
13720PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(20)..(20)AMIDATION 137Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Tyr Gly Arg Lys Lys Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
13819PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = Gly or
absentMOD_RES(19)..(19)AMIDATION 138Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
13920PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(20)..(20)AMIDATION 139Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
14020PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(20)..(20)AMIDATION 140Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Gly Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
14120PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(20)..(20)AMIDATION 141Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Gly Arg Arg Lys Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
14220PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(20)..(20)AMIDATION 142Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Gly Arg Lys Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
14318PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(18)..(18)AMIDATION 143Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Arg Arg Lys Arg Arg Gln Arg 1 5 10 15 Arg Arg
14418PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(18)..(18)AMIDATION 144Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Arg Lys Arg Arg Arg Gln Arg 1 5 10 15 Arg Arg
14520PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(20)..(20)AMIDATION 145Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Tyr Gly Arg Lys Lys Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
14620PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MOD_RES(20)..(20)AMIDATION
146Xaa Cys Xaa His Xaa Arg Trp Cys Xaa Tyr Gly Arg Lys Lys Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 14720PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(20)..(20)AMIDATION 147Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
14819PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = beta-Ala or
absentMOD_RES(19)..(19)AMIDATION 148Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
14921PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(10)Xaa =
beta-AlaMISC_FEATURE(11)..(11)Xaa = Tyr or
absentMOD_RES(21)..(21)AMIDATION 149Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Xaa Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
15020PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa = Tyr
or absentMOD_RES(20)..(20)AMIDATION 150Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
15119PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(19)..(19)AMIDATION 151Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
15221PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(11)..(11)Xaa = Tyr
or absentMOD_RES(21)..(21)AMIDATION 152Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Xaa Xaa Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg
20 15321PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(21)..(21)AMIDATION 153Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg Arg 20
15420PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = beta-Ala or
absentMOD_RES(20)..(20)AMIDATION 154Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
15522PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(10)Xaa =
beta-AlaMISC_FEATURE(11)..(11)Xaa = Tyr or
absentMOD_RES(22)..(22)AMIDATION 155Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Xaa Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg Arg
20 15621PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa = Tyr
or absentMOD_RES(21)..(21)AMIDATION 156Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg Arg
20 15720PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(20)..(20)AMIDATION 157Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
15822PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(11)..(11)Xaa = Tyr
or absentMOD_RES(22)..(22)AMIDATION 158Xaa Cys Xaa His Xaa Arg Trp
Cys Xaa Xaa Xaa Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg
Arg 20 15920PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
159Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 16018PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
160Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 16120PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
161Xaa Asp His Xaa Arg Trp Ala Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 16218PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
162Xaa Asp His Xaa Arg Trp Ala Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 16318PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(8)..(8)Xaa = beta-AlaMISC_FEATURE(9)..(9)Xaa =
Gly or absentMOD_RES(18)..(18)AMIDATION 163Xaa Asp His Xaa Arg Trp
Lys Xaa Xaa Arg Arg Arg Arg Arg Gln Arg 1 5 10 15 Arg Arg
16420PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(8)Xaa = beta-AlaMISC_FEATURE(9)..(9)Xaa =
beta-Ala or absentMOD_RES(20)..(20)AMIDATION 164Xaa Asp His Xaa Arg
Trp Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg
Arg 20 16519PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(10)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
Gly or absentMOD_RES(19)..(19)AMIDATION 165Xaa Asp His Xaa Arg Trp
Lys Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
16619PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(8)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(9)..(9)Xaa = Tyr or
absentMOD_RES(19)..(19)AMIDATION 166Xaa Asp His Xaa Arg Trp Lys Xaa
Xaa Gly Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
16720PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(20)..(20)AMIDATION 167Xaa Asp His Xaa Arg Trp Lys Xaa
Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
16818PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(8)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
or absentMOD_RES(18)..(18)AMIDATION 168Xaa Asp His Xaa Arg Trp Lys
Xaa Xaa Arg Arg Arg Arg Arg Gln Arg 1 5 10 15 Arg Arg
16919PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(8)Xaa = beta-AlaMISC_FEATURE(9)..(9)Xaa =
Gly or absentMOD_RES(19)..(19)AMIDATION 169Xaa Asp His Xaa Arg Trp
Lys Xaa Xaa Arg Arg Arg Arg Arg Gln Arg 1 5 10 15 Arg Arg Arg
17021PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(8)Xaa = beta-AlaMISC_FEATURE(9)..(9)Xaa =
beta-Ala or absentMOD_RES(21)..(21)AMIDATION 170Xaa Asp His Xaa Arg
Trp Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg
Arg Arg 20 17120PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
Gly or absentMOD_RES(20)..(20)AMIDATION 171Xaa Asp His Xaa Arg Trp
Lys Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg
20 17219PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(8)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(9)..(9)Xaa = Gly or
absentMOD_RES(19)..(19)AMIDATION 172Xaa Asp His Xaa Arg Trp Lys Xaa
Xaa Arg Arg Arg Arg Arg Gln Arg 1 5 10 15 Arg Arg Arg
17321PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(8)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid (Doc)
or absentMOD_RES(21)..(21)AMIDATION 173Xaa Asp His Xaa Arg Trp Lys
Xaa Xaa Tyr Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg Arg
20 17420PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(7)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(8)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = Gly or
absentMOD_RES(20)..(20)AMIDATION 174Xaa Asp His Xaa Arg Trp Lys Xaa
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
17520PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(20)..(20)AMIDATION 175Xaa Asp His Xaa Arg Trp Xaa
Lys Xaa Tyr Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
17618PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(18)..(18)AMIDATION 176Xaa Asp His Xaa Arg Trp Xaa
Lys Xaa Arg Arg Arg Arg Arg Gln Arg 1 5 10 15 Arg Arg
17720PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 6-aminohexanoic acid
(Ahx)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
177Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 17818PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 6-aminohexanoic acid
(Ahx)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
178Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 17921PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMOD_RES(21)..(21)AMIDATION
179Xaa Cys His Xaa Arg Trp Xaa Xaa Thr Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15 Arg Gln Arg Arg Arg 20 18019PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMOD_RES(19)..(19)AMIDATION
180Xaa Cys His Xaa Arg Trp Xaa Xaa Thr Xaa Arg Arg Arg Arg Arg Gln
1 5 10 15 Arg Arg Arg 18120PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
181Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 18218PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
182Xaa Cys His Xaa Arg Trp Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 18320PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
beta-cyclohexylAla (Cha), homo-cyclohexylAla (hCha), or Nle, all
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
183Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 18418PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = beta-cyclohexylAla (Cha) or
homo-cyclohexylAla (hCha), both modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
184Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 18518PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle or
cyclohexylGly (Chg), both modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
185Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 18620PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
cyclohexylGly (Chg) or homo-cyclohexylAla (hCha), both modified
with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
186Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 18721PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = homo-cyclohexylAla (hCha)
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(10)Xaa = beta-AlaMOD_RES(21)..(21)AMIDATION
187Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15 Arg Gln Arg Arg Arg 20 18819PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = homo-cyclohexylAla (hCha)
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(19)..(19)AMIDATION 188Xaa Asp His Xaa Arg
Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
18921PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = homo-cyclohexylAla
(hCha) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(21)..(21)AMIDATION 189Xaa Asp His Xaa Arg
Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg 20 19019PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
homo-cyclohexylAla (hCha) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(19)..(19)AMIDATION 190Xaa Asp His Xaa Arg
Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
19122PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = homo-cyclohexylAla
(hCha) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(22)..(22)AMIDATION 191Xaa Asp His Xaa Arg
Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 19220PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
homo-cyclohexylAla (hCha) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(20)..(20)AMIDATION 192Xaa Asp His Xaa Arg
Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 19322PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
homo-cyclohexylAla (hCha) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(22)..(22)AMIDATION 193Xaa Asp His Xaa Arg
Trp Xaa Lys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 19420PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
homo-cyclohexylAla (hCha) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(20)..(20)AMIDATION 194Xaa Asp His Xaa Arg
Trp Xaa Lys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 19520PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = D-cyclohexylGly
(D-Chg) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
195Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 19618PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = D-cyclohexylGly (D-Chg)
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
196Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 19720PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
homo-phenylAla (hPhe) modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
197Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 19818PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = homo-phenylAla (hPhe) modified
with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
198Xaa Asp His Xaa Arg Trp Xaa Lys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 19920PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMISC_FEATURE(7)..(7)Xaa =
5-aminopentanoic acid (Apn) or 6-aminohexanoic acid
(Ahx)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(20)..(20)AMIDATION
199Xaa Cys His Xaa Arg Xaa Xaa Cys Xaa Tyr Gly Arg Arg Arg Arg Arg
1 5 10 15 Gln Arg Arg Arg 20 20018PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMISC_FEATURE(7)..(7)Xaa =
5-aminopentanoic acid (Apn) or 6-aminohexanoic acid
(Ahx)MISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
200Xaa Cys His Xaa Arg Xaa Xaa Cys Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 20120PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMISC_FEATURE(7)..(7)Xaa =
beta-AlaMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(20)..(20)AMIDATION 201Xaa Cys His Xaa Arg Xaa Xaa
Cys Xaa Tyr Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
20218PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(6)..(6)Xaa = D-TrpMISC_FEATURE(7)..(7)Xaa =
beta-AlaMISC_FEATURE(9)..(9)Xaa =
beta-AlaMOD_RES(18)..(18)AMIDATION 202Xaa Cys His Xaa Arg Xaa Xaa
Cys Xaa Arg Arg Arg Arg Arg Gln Arg 1 5 10 15 Arg Arg
20320PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(20)..(20)AMIDATION 203Xaa Cys Xaa His Xaa Arg Trp Xaa
Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
20421PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MISC_FEATURE(9)..(10)Xaa =
beta-AlaMISC_FEATURE(11)..(11)Xaa = Tyr or
absentMOD_RES(21)..(21)AMIDATION 204Xaa Cys Xaa His Xaa Arg Trp Xaa
Xaa Xaa Xaa Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
20519PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = beta-Ala or
absentMOD_RES(19)..(19)AMIDATION 205Xaa Cys Xaa His Xaa Arg Trp Xaa
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
20619PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa = Gly
or absentMOD_RES(19)..(19)AMIDATION 206Xaa Cys Xaa His Xaa Arg Trp
Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
20721PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(21)..(21)AMIDATION 207Xaa Cys Xaa His Xaa Arg Trp Xaa
Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
20820PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(8)..(8)Xaa =
penicillamine (Pen)MISC_FEATURE(9)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(11)..(11)Xaa = Gly
or absentMOD_RES(20)..(20)AMIDATION 208Xaa Cys Xaa His Xaa Arg Trp
Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
20920PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa
= Tyr or absentMOD_RES(20)..(20)AMIDATION 209Xaa Cys His Xaa Arg
Trp Xaa Xaa Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg
Arg 20 21018PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(18)..(18)AMIDATION
210Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg 21119PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(9)Xaa = beta-AlaMOD_RES(19)..(19)AMIDATION
211Xaa Cys His Xaa Arg Trp Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln Arg
1 5 10 15 Arg Arg Arg
21221PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(10)Xaa =
beta-AlaMOD_RES(21)..(21)AMIDATION 212Xaa Cys His Xaa Arg Trp Xaa
Xaa Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg
20 21320PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(10)Xaa = beta-AlaMISC_FEATURE(11)..(11)Xaa
= Gly or absentMOD_RES(20)..(20)AMIDATION 213Xaa Cys His Xaa Arg
Trp Xaa Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg
Arg 20 21420PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = Tyr or
absentMOD_RES(20)..(20)AMIDATION 214Xaa Cys His Xaa Arg Trp Xaa Xaa
Xaa Xaa Gly Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg Arg 20
21521PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(11)..(11)Xaa = Tyr or
absentMOD_RES(21)..(21)AMIDATION 215Xaa Cys His Xaa Arg Trp Xaa Xaa
Xaa Xaa Xaa Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
21619PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(19)..(19)AMIDATION 216Xaa Cys His Xaa Arg
Trp Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
21720PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(20)..(20)AMIDATION 217Xaa Cys His Xaa Arg
Trp Xaa Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 21822PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMISC_FEATURE(11)..(11)Xaa
= beta-Ala or absentMOD_RES(22)..(22)AMIDATION 218Xaa Cys His Xaa
Xaa Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg 1 5 10 15 Arg Arg
Gln Arg Arg Arg 20 21920PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMISC_FEATURE(11)..(11)Xaa
= beta-Ala or absentMOD_RES(20)..(20)AMIDATION 219Xaa Cys His Xaa
Xaa Trp Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg
Arg Arg 20 22019PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MOD_RES(19)..(19)AMIDATION 220Xaa Cys His Xaa Xaa Trp Xaa Xaa
Thr Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
22122PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(11)..(11)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(22)..(22)AMIDATION 221Xaa Cys His Xaa Xaa
Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg 1 5 10 15 Arg Arg Gln
Arg Arg Arg 20 22223PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMISC_FEATURE(11)..(11)Xaa
= beta-Ala or absentMOD_RES(23)..(23)AMIDATION 222Xaa Cys His Xaa
Xaa Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg 1 5 10 15 Arg Arg
Gln Arg Arg Arg Arg 20 22321PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa
= D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMISC_FEATURE(11)..(11)Xaa
= beta-Ala or absentMOD_RES(21)..(21)AMIDATION 223Xaa Cys His Xaa
Xaa Trp Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg
Arg Arg Arg 20 22423PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(11)..(11)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(23)..(23)AMIDATION 224Xaa Cys His Xaa Xaa
Trp Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg 1 5 10 15 Arg Arg Gln
Arg Arg Arg Arg 20 22521PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(11)..(11)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(21)..(21)AMIDATION 225Xaa Cys His Xaa Xaa
Trp Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg
Arg Arg 20 22622PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMOD_RES(22)..(22)AMIDATION
226Xaa Cys His Xaa Xaa Xaa Xaa Xaa Thr Xaa Tyr Gly Arg Arg Arg Arg
1 5 10 15 Arg Gln Arg Arg Arg Arg 20 22722PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMISC_FEATURE(11)..(11)Xaa
= beta-Ala or absentMOD_RES(22)..(22)AMIDATION 227Xaa Cys His Xaa
Xaa Xaa Xaa Xaa Thr Xaa Xaa Tyr Gly Arg Arg Arg 1 5 10 15 Arg Arg
Gln Arg Arg Arg 20 22820PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = beta-AlaMISC_FEATURE(11)..(11)Xaa
= beta-Ala or absentMOD_RES(20)..(20)AMIDATION 228Xaa Cys His Xaa
Xaa Xaa Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg
Arg Arg 20 22921PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(5)..(5)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MOD_RES(21)..(21)AMIDATION 229Xaa Cys His Xaa Xaa Xaa Xaa Xaa
Thr Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
23022PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MOD_RES(22)..(22)AMIDATION 230Xaa Cys His Xaa Xaa Xaa Xaa Xaa
Thr Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg Arg
20 23122PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(11)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MOD_RES(22)..(22)AMIDATION 231Xaa Cys His Xaa Xaa Xaa Xaa Xaa
Thr Xaa Xaa Tyr Gly Arg Arg Arg 1 5 10 15 Arg Arg Gln Arg Arg Arg
20 23220PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(5)..(5)Xaa = homo-Arg
(hArg)MISC_FEATURE(6)..(6)Xaa = 4,4'-biphenylAla
(Bip)MISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa =
D-CysMISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(11)..(11)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(20)..(20)AMIDATION 232Xaa Cys His Xaa Xaa
Xaa Xaa Xaa Thr Xaa Xaa Arg Arg Arg Arg Arg 1 5 10 15 Gln Arg Arg
Arg 20 23321PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(9)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(10)..(10)Xaa =
beta-AlaMOD_RES(21)..(21)AMIDATION 233Xaa Cys Xaa His Xaa Arg Trp
Gly Cys Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg
20 23419PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(9)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(10)..(10)Xaa =
beta-AlaMOD_RES(19)..(19)AMIDATION 234Xaa Cys Xaa His Xaa Arg Trp
Gly Cys Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
23521PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(21)..(21)AMIDATION 235Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg 20 23619PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(19)..(19)AMIDATION 236Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
23722PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(22)..(22)AMIDATION 237Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 23820PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(20)..(20)AMIDATION 238Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 23921PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(21)..(21)AMIDATION 239Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg 20 24019PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(19)..(19)AMIDATION 240Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10
15 Arg Arg Arg 24122PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(22)..(22)AMIDATION 241Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 24220PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 5-aminopentanoic acid
(Apn)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(20)..(20)AMIDATION 242Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 24321PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = beta-Ala or
absentMOD_RES(21)..(21)AMIDATION 243Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
24419PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = beta-Ala or
absentMOD_RES(19)..(19)AMIDATION 244Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
24521PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(21)..(21)AMIDATION 245Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg 20
24619PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(19)..(19)AMIDATION 246Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
24722PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = beta-Ala or
absentMOD_RES(22)..(22)AMIDATION 247Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg Arg
20 24820PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
beta-AlaMISC_FEATURE(10)..(10)Xaa = beta-Ala or
absentMOD_RES(20)..(20)AMIDATION 248Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
24922PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(22)..(22)AMIDATION 249Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg Arg Arg Arg
20 25020PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-LeuMISC_FEATURE(5)..(5)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(10)..(10)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) or
absentMOD_RES(20)..(20)AMIDATION 250Xaa Cys Xaa His Xaa Arg Trp Cys
Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
25121PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(21)..(21)AMIDATION 251Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg 20 25219PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(19)..(19)AMIDATION 252Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
25321PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(21)..(21)AMIDATION 253Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg 20 25419PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(19)..(19)AMIDATION 254Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
25522PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified with acyl
(Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(22)..(22)AMIDATION 255Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 25620PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa
= D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(20)..(20)AMIDATION 256Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 25722PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle modified
with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(22)..(22)AMIDATION 257Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 25820PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Nle
modified with acyl (Ac)DOMAIN(2)..(8)cyclicMISC_FEATURE(3)..(3)Xaa
= D-beta-cyclohexylAla (D-Cha)MISC_FEATURE(5)..(5)Xaa =
D-PheMISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(20)..(20)AMIDATION 258Xaa Cys Xaa His Xaa
Arg Trp Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 25921PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(21)..(21)AMIDATION 259Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg 20 26019PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(19)..(19)AMIDATION 260Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
26122PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(22)..(22)AMIDATION 261Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 26220PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = beta-AlaMISC_FEATURE(10)..(10)Xaa =
beta-Ala or absentMOD_RES(20)..(20)AMIDATION 262Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 26321PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(21)..(21)AMIDATION 263Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg 20 26419PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(19)..(19)AMIDATION 264Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
26522PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(22)..(22)AMIDATION 265Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Tyr Gly Arg Arg Arg Arg 1 5 10 15 Arg Gln Arg
Arg Arg Arg 20 26620PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
NleDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-PheMISC_FEATURE(7)..(7)Xaa = 4-aminobutyric acid
(Gaba)MISC_FEATURE(9)..(9)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc)MISC_FEATURE(10)..(10)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) or absentMOD_RES(20)..(20)AMIDATION 266Xaa Cys His Xaa Arg
Trp Xaa Cys Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg
Arg 20 26720PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
D-PheDOMAIN(2)..(8)cyclicMISC_FEATURE(4)..(4)Xaa =
D-(Et)TyrMISC_FEATURE(7)..(7)Xaa = beta-AlaMISC_FEATURE(8)..(8)Xaa
= D-CysMISC_FEATURE(9)..(10)Xaa =
beta-AlaMOD_RES(20)..(20)AMIDATION 267Xaa Cys His Xaa Arg Trp Xaa
Xaa Xaa Xaa Arg Arg Arg Arg Arg Gln 1 5 10 15 Arg Arg Arg Arg 20
26812PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with
acyl (Ac)MISC_FEATURE(4)..(4)Xaa = D-4-bromo-phenylAla
(D-4-Br-Phe)MOD_RES(12)..(12)AMIDATION 268Cys Glu His Xaa Arg Trp
Gly Cys Pro Pro Lys Asp 1 5 10 26912PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = Trp, beta-(2-naphthyl)Ala
(2-Nal), beta-(1-naphthyl)Ala (1-Nal) or 3-benzothienylAla
(Bal)MOD_RES(12)..(12)AMIDATION 269Cys Glu His Xaa Arg Xaa Ala Cys
Pro Pro Lys Asp 1 5 10 27012PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with acyl
(Ac)MISC_FEATURE(4)..(4)Xaa = D-beta-(2-naphthyl)Ala
(D-2-Nal)MISC_FEATURE(6)..(6)Xaa = beta-(2-naphthyl)Ala
(2-Nal)MISC_FEATURE(7)..(7)Xaa = beta-Ala or alpha-aminoisobutyric
acid (Aib)MOD_RES(12)..(12)AMIDATION 270Cys Glu His Xaa Arg Xaa Xaa
Cys Pro Pro Lys Asp 1 5 10 2717PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin
sensitivityDOMAIN(1)..(7)cyclicMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(1)..(1)Xaa = Cys or homocyteine
(hCys)MISC_FEATURE(2)..(2)Xaa = D-AlaMISC_FEATURE(4)..(4)Xaa =
D-PheMOD_RES(7)..(7)AMIDATION 271Xaa Xaa His Xaa Arg Trp Cys 1 5
2727PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityDOMAIN(1)..(7)CyclicMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(1)..(1)Xaa = Cys or homocysteine
(hCys)MISC_FEATURE(2)..(2)Xaa = D-AlaMISC_FEATURE(4)..(4)Xaa =
D-beta-(2-naphythyl)alanine (D-2-Nal)MOD_RES(7)..(7)AMIDATION
272Xaa Xaa His Xaa Arg Trp Cys 1 5 2737PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(7)cyclicMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(2)..(2)Xaa = D-AlaMISC_FEATURE(4)..(4)Xaa
= D-PheMISC_FEATURE(7)..(7)Xaa = Lys, ornithine (Orn),
2,4-diaminobutyric acid (Dab), or 2,3-diaminopropionic acid
(Dap)MOD_RES(7)..(7)AMIDATION 273Asp Xaa His Xaa Arg Trp Xaa 1 5
2746PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(1)..(6)cyclicMISC_FEATURE(2)..(2)Xaa = His,
1-amino-1-cyclopropanecarboxylic acid (A3c),
1-amino-1cyclopentanecarboxylic acid (A5c),
1-amino-1-cyclohexanecarboxylic acid (A6c),
2-aminoindan-2-carboxylic acid (Aic), or ApcMISC_FEATURE(3)..(3)Xaa
= D-PheMOD_RES(6)..(6)AMIDATION 274Asp Xaa Xaa Arg Trp Lys 1 5
2756PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityDOMAIN(1)..(6)cyclicMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(2)..(2)Xaa = His,
1-amino-1-cyclopropanecarboxylic acid (A3c),
1-amino-1cyclopentanecarboxylic acid (A5c),
1-amino-1-cyclohexanecarboxylic acid (A6c),
2-aminoindan-2-carboxylic acid (Aic), or ApcMISC_FEATURE(3)..(3)Xaa
= D-beta-(2-naphythyl)alanine (D-2-Nal)MOD_RES(6)..(6)AMIDATION
275Asp Xaa Xaa Arg Trp Lys 1 5 2767PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(1)..(7)cyclicMISC_FEATURE(2)..(2)Xaa =
D-AlaMISC_FEATURE(4)..(4)Xaa = D-PheMISC_FEATURE(7)..(7)Xaa = Lys,
ornithine (Orn), 2,4-diaminobutyric acid (Dab), or
2,3-diaminopropionic acid (Dap)MOD_RES(7)..(7)AMIDATION 276Glu Xaa
His Xaa Arg Trp Xaa 1 5 2776PRTArtificial SequenceMelanocortin
receptor ligand to treat insulin
sensitivityDOMAIN(1)..(6)cyclicMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(3)..(3)Xaa =
D-PheMOD_RES(6)..(6)AMIDATIONMISC_FEATURE(6)..(6)Xaa = Lys or
2,3-diaminopropionic acid (Dap) 277Glu His Xaa Arg Trp Xaa 1 5
2789PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Arg, norleucine (Nle),
Gly, or D-ArgMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(3)..(9)cyclicMISC_FEATURE(6)..(6)Xaa =
D-PheMOD_RES(9)..(9)AMIDATION 278Xaa Gly Cys Glu His Xaa Arg Trp
Cys 1 5 2799PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = norleucine
(Nle), Gly, Ala, D-Ala, alpha-aminoisobutyric acid (Aib), Val, Ile,
Leu, D-Arg, or ArgMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(3)..(9)cyclicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-PheMOD_RES(9)..(9)AMIDATION 279Xaa
Gly Cys Xaa His Xaa Arg Trp Cys 1 5 2809PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = norleucine (Nle) or
GlyMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(3)..(9)cyclicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-PheMISC_FEATURE(9)..(9)Xaa =
penicillamine (Pen)MOD_RES(9)..(9)AMIDATION 280Xaa Gly Cys Xaa His
Xaa Arg Trp Xaa 1 5 2819PRTArtificial SequenceMelanocortin receptor
ligand to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa =
norleucine (Nle) or GlyMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(3)..(9)cyclicMISC_FEATURE(6)..(6)Xaa =
D-beta-(2-naphythyl)alanine (D-2-Nal)MOD_RES(9)..(9)AMIDATION
281Xaa Gly Cys Glu His Xaa Arg Trp Cys 1 5 2829PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMISC_FEATURE(1)..(1)Xaa = D-Arg or
ArgMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(3)..(9)cyclicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-beta-(2-naphythyl)alanine
(D-2-Nal)MOD_RES(9)..(9)AMIDATION 282Xaa Gly Cys Xaa His Xaa Arg
Trp Cys 1 5 2839PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Ala, Val, or
GlyMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(2)..(2)Xaa = norleucine
(Nle)DOMAIN(3)..(9)cyclicMISC_FEATURE(6)..(6)Xaa =
D-PheMOD_RES(9)..(9)AMIDATION 283Xaa Xaa Cys Glu His Xaa Arg Trp
Cys 1 5 2849PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(1)..(1)Xaa =
1-amino-1-cyclohexanecarboxylic acid (A6c), Gly, Ala, D-Ala, Val,
Leu, beta-cyclohexylalanine (Cha), or alpha-aminoisobutyric acid
(Aib)MISC_FEATURE(2)..(2)Xaa = norleucine
(Nle)DOMAIN(3)..(9)cyclicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-PheMOD_RES(9)..(9)AMIDATION 284Xaa
Xaa Cys Xaa His Xaa Arg Trp Cys 1 5 2859PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(3)..(9)cyclicMISC_FEATURE(6)..(6)Xaa = D-Phe or
D-beta-(2-naphythyl)alanine (D-2-Nal)MOD_RES(9)..(9)AMIDATION
285Gly Arg Cys Glu His Xaa Arg Trp Cys 1 5 2869PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)DOMAIN(3)..(9)cyclicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-Phe or D-beta-(2-naphythyl)alanine
(D-2-Nal)MOD_RES(9)..(9)AMIDATION 286Gly Arg Cys Xaa His Xaa Arg
Trp Cys 1 5 2879PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(2)..(2)Xaa =
D-ArgDOMAIN(3)..(9)cyclicMISC_FEATURE(6)..(6)Xaa =
D-PheMOD_RES(9)..(9)AMIDATION 287Gly Xaa Cys Glu His Xaa Arg Trp
Cys 1 5 2889PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(2)..(2)Xaa =
D-ArgDOMAIN(3)..(9)cyclicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-Phe or D-beta-(2-naphythyl)alanine
(D-2-Nal)MOD_RES(9)..(9)AMIDATION 288Gly Xaa Cys Xaa His Xaa Arg
Trp Cys 1 5 2899PRTArtificial SequenceMelanocortin receptor ligand
to treat insulin sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(1)..(1)Xaa = norleucine
(Nle)DOMAIN(3)..(9)cyclicMISC_FEATURE(6)..(6)Xaa =
D-PheMOD_RES(9)..(9)AMIDATION 289Xaa Ala Cys Glu His Xaa Arg Trp
Cys 1 5 2908PRTArtificial SequenceMelanocortin receptor ligand to
treat insulin sensitivityMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(1)..(1)Xaa = norleucine (Nle), Ala,
D-Ala, alpha-aminoisobutyric acid (Aib), Val, alpha-aminobutyric
acid (Abu), Leu, Ile, beta-cyclohexylalanine (Cha),
1-amino-1-cyclohexanecarboxylic acid (A6c), Phe, or
GlyDOMAIN(1)..(8)cyclicMISC_FEATURE(3)..(3)Xaa =
D-AlaMISC_FEATURE(5)..(5)Xaa = D-PheMOD_RES(8)..(8)AMIDATION 290Xaa
Cys Xaa His Xaa Arg Trp Cys 1 5 2918PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(1)..(8)cyclicMOD_RES(1)..(1)modified with
hydantoin(CO)MISC_FEATURE(5)..(5)Xaa =
D-PheMOD_RES(8)..(8)AMIDATION 291Gly Cys Glu His Xaa Arg Trp Cys 1
5 2929PRTArtificial SequenceMelanocortin receptor ligand to treat
insulin sensitivityMISC_FEATURE(1)..(1)Xaa = Tyr,
beta-(2-naphthyl)alanine (2-Nal), beta-(1-naphthyl)alanine (1-Nal),
Phe, Trp, (S)-pentafluorophenylalanine (Pff), or His, all modified
with acyl group (Ac)DOMAIN(3)..(9)cylicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-PheMOD_RES(9)..(9)AMIDATION 292Xaa
Arg Cys Xaa His Xaa Arg Trp Cys 1 5 2939PRTArtificial
SequenceMelanocortin receptor ligand to treat insulin
sensitivityDOMAIN(3)..(9)cyclicMISC_FEATURE(4)..(4)Xaa =
D-AlaMISC_FEATURE(6)..(6)Xaa = D-PheMOD_RES(9)..(9)AMIDATION 293His
Arg Cys Xaa His Xaa Arg Trp Cys 1 5 2949PRTArtificial Sequenceamino
acid moiety of synthetic melanocortin peptide ligand 294Arg Lys Lys
Arg Arg Gln Arg Arg Arg 1 5 29511PRTArtificial Sequenceamino acid
moiety of synthetic melanocortin peptide ligand 295Tyr Ala Arg Lys
Ala Arg Arg Gln Ala Arg Arg 1 5 10 29611PRTArtificial Sequenceamino
acid moiety of synthetic melanocortin peptide ligand 296Tyr Ala Arg
Ala Ala Arg Arg Ala Ala Arg Arg 1 5 10 29711PRTArtificial
Sequenceamino acid moiety of synthetic melanocortin peptide ligand
297Tyr Ala Arg Arg Arg Arg Arg Arg Arg Arg Arg 1 5 10
29811PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 298Tyr Ala Ala Ala Arg Arg Arg Arg Arg
Arg Arg 1 5 10 29911PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 299Tyr Ala Arg Ala Pro Arg
Arg Ala Arg Arg Arg 1 5 10 30010PRTArtificial Sequenceamino acid
moiety of synthetic melanocortin peptide ligand 300Tyr Ala Arg Ala
Pro Arg Arg Pro Arg Arg 1 5 10 3019PRTArtificial Sequenceamino acid
moiety of synthetic melanocortin peptide ligand 301Arg Lys Gln Lys
Arg Arg Arg Arg Arg 1 5 3029PRTArtificial Sequenceamino acid moiety
of synthetic melanocortin peptide ligand 302Arg Lys Lys Arg Gln Arg
Arg Arg Arg 1 5 3039PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 303Arg Lys Lys Arg Arg Arg
Gln Arg Arg 1 5 3049PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 304Arg Lys Lys Arg Arg Arg
Arg Gln Arg 1 5 3059PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 305Arg Lys Lys Arg Arg Arg
Arg Arg Gln 1 5 3069PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 306Arg Lys Lys Gln Arg Arg
Arg Arg Arg 1 5 3079PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 307Arg Gln Lys Lys Arg Arg
Arg Arg Arg 1 5 3089PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 308Arg Gln Arg Arg Arg Arg
Arg Arg Arg 1 5 30910PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 309Arg Gln Arg Arg Arg Arg
Arg Arg Arg Arg 1 5 10 3109PRTArtificial Sequenceamino acid moiety
of synthetic melanocortin peptide ligand 310Arg Arg Gln Arg Arg Arg
Arg Arg Arg 1 5 31110PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 311Arg Arg Gln Arg Arg Arg
Arg Arg Arg Arg 1 5 10 3129PRTArtificial Sequenceamino acid moiety
of synthetic melanocortin peptide ligand 312Arg Arg Arg Gln Arg Arg
Arg Arg Arg 1 5 31310PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 313Arg Arg Arg Gln Arg Arg
Arg Arg Arg Arg 1 5 10 3149PRTArtificial Sequenceamino acid moiety
of synthetic melanocortin peptide ligand 314Arg Arg Arg Arg Gln Arg
Arg Arg Arg 1 5 31510PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 315Arg Arg Arg Arg Gln Arg
Arg Arg Arg Arg 1 5 10 3165PRTArtificial Sequenceamino acid moiety
of synthetic melanocortin peptide ligand 316Arg Arg Arg Arg Arg 1 5
3179PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 317Arg Arg Arg Arg Arg Gln Arg Arg Arg
1 5 31810PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 318Arg Arg Arg Arg Arg Gln Arg Arg Arg
Arg 1 5 10 3196PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 319Arg Arg Arg Arg Arg Arg 1 5
32010PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 320Arg Arg Arg Arg Arg Arg Gln Arg Arg
Arg 1 5 10 3217PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 321Arg Arg Arg Arg Arg Arg Arg 1 5
32210PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 322Arg Arg Arg Arg Arg Arg Arg Gln Arg
Arg 1 5 10 3238PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 323Arg Arg Arg Arg Arg Arg Arg Arg 1 5
32410PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 324Arg Arg Arg Arg Arg Arg Arg Arg Gln
Arg 1 5 10 3259PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 325Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 32610PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 326Arg Arg Arg Arg Arg Arg Arg Arg Arg
Gln 1 5 10 3279PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 327Gln Arg Lys Lys Arg Arg Arg Arg Arg
1 5 3289PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 328Gln Arg Arg Arg Arg Arg Arg Arg Arg
1 5 32910PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 329Gln Arg Arg Arg Arg Arg Arg Arg Arg
Arg 1 5 10 33011PRTArtificial Sequenceamino acid moiety of
synthetic melanocortin peptide ligand 330Tyr Gly Arg Lys Lys Arg
Arg Gln Arg Arg Arg 1 5 10 33112PRTArtificial Sequenceamino acid
moiety of synthetic melanocortin peptide
ligandMISC_FEATURE(12)..(12)Xaa = 8-amino-3,6-dioxaoctanoic acid
(Doc) 331Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Xaa 1 5 10
3324PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligandMISC_FEATURE(1)..(1)Xaa = beta-alanine
(B-Ala)MISC_FEATURE(2)..(2)Xaa = beta-alanine (B-Ala) 332Xaa Xaa
Tyr Gly 1 3334PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligandMISC_FEATURE(1)..(1)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc)MISC_FEATURE(2)..(2)Xaa =
8-amino-3,6-dioxaoctanoic acid (Doc) 333Xaa Xaa Tyr Gly 1
3349PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 334Arg Lys Arg Arg Arg Gln Arg Arg Arg
1 5 3359PRTArtificial Sequenceamino acid moiety of synthetic
melanocortin peptide ligand 335Arg Arg Lys Arg Arg Gln Arg Arg Arg
1 5
* * * * *